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SUMMARY 
Patient transition across care settings represent a high-risk period for the occurrence of drug-related 
problems (DRP), such as discrepancies. These DRPs often result in patient readmission, resulting in 
higher costs of care in public health. A DRP is commonly defined as an event or circumstance involving 
drug therapy that actually, or potentially, interferes with the desired health outcomes. In both 
community and hospital settings, there is evidence that interventions initiated by pharmacists can 
reduce the occurrence of DRPs. For this thesis, we defined a ‘‘pharmaceutical intervention’’ as a 
recommendation initiated by a pharmacist in response to a DRP occurring in an individual patient in 
any phase of the medication process. The pharmaceutical intervention aims at optimising 
pharmacotherapy, in terms of efficacy, safety, economic, and humanistic aspects. 
The exchange of information (e.g. on pharmaceutical interventions) between primary and secondary 
care remains, however, a major challenge. The access to complete and accurate patient medical 
information and good communication is essential for the healthcare professionals to ensure safe and 
efficient care to the patients. In the current practice, the medication management at the time of 
admission and discharge from hospital is not seamlessly guaranteed through complete documentation 
and communication of clinical pharmaceutical interventions between inpatient and outpatient care. 
Seamless care is defined as any process which optimises efficiency, quality, and safety of medication 
management at transitions to establish a continuum of care. 
These pharmaceutical interventions should no longer be loose fragments, but should be brought 
together like a mosaic in an overall concept and documented in a form that enables the most 
seamlessly possible exchange of information at the hospital discharge of patient in the outpatient 
situation. To accomplish this task, the first step is to document the pharmaceutical interventions in 
their respective care setting by developing valid structured instruments in order to depict the practice. 
Such documentation of care represents the evidence of practice. It is therefore essential to be 
recorded in a standardised and structured manner. Classification, as essential part of documentation, 
enables a precise representation of what has been done (e.g. pharmaceutical interventions) by 
categorising key elements in a standardised manner, and as a consequence, facilitates the transfer of 
information. 
Once the pharmaceutical interventions are documented in the respective healthcare setting, the 
information exchange between the hospital and the community pharmacy and vice versa still remains 
challenging. Improving information exchange regarding pharmaceutical interventions could enable a 
more efficient and safer transfer of patients between inpatient and outpatient care. Thus as a second 
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step, an aligned classification system in both settings would facilitate a standardised documentation 
of pharmaceutical interventions. 
Hence, validated, structured, and standardised classification systems for pharmaceutical interventions, 
which fulfil both requirements of comprehensiveness and easy application with little time expenditure 
in daily clinical practice, are rare. Furthermore, there was no national consensus in Switzerland on how 
to record pharmaceutical interventions in a standardised manner to obtain data allowing 
epidemiological studies for research and political purposes. Therefore, we recognised the need of 
proper instruments able to depict the practice in their representative setting. 
 
The goal of this thesis was to create structured instruments for daily practice to improve the continuity 
of documentation and communication of pharmaceutical interventions during transitions of care. We 
approached this goal through  
a) developing and validating classification systems for pharmaceutical interventions (one for 
hospital and one for community setting) 
b) testing their feasibility in daily practice in observational studies 
c) exploring pharmacists’ satisfaction and opinions on documentation of pharmaceutical 
interventions 
d) analysing the documented pharmaceutical interventions 
e) investigating with an observation study the dispensing process of prescribed medicines in daily 
practice of community pharmacies, focusing on counselling activities 
f) assessing pharmacist’s opinions on patient counselling and on transfer of documented 
pharmaceutical interventions 
In the first project of this thesis (Project A), we developed together with the working group in clinical 
pharmacy of the Swiss Society of Public Health Administration and Hospital pharmacists (GSASA) an 
intervention oriented classification system for the hospital setting, the GSASA system. Study A1 aimed 
at validating the GSASA system. The GSASA system includes 5 categories (problem, type of problem, 
cause of intervention, intervention, and outcome of the intervention) and 41 subcategories. Total 
interrater reliability was moderate (Fleiss’ Kappa coefficient Κ=0.52). Interrater reliability and 
acceptability of the GSASA system were comparable to those of the well-established Pharmaceutical 
Care Network Europe (PCNE) system V6.2. 
In 2011, GSASA proposed the GSASA classification system of pharmaceutical interventions to all Swiss 
hospitals that are members of this society, and encouraged its application. One and a half years later, 
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the implementation of the GSASA system was evaluated to assess implementation outcome such as 
the number of hospital pharmacies using the system, to analyse the pooled data retrieved from Swiss 
hospitals, and to explore the user satisfaction (A2). Forty-four chief hospitals pharmacists responded 
by online questionnaire about the use and satisfaction with the classification system. Eleven of 12 
hospitals using the GSASA system provided us voluntary all classification data, covering an observation 
period of 121.5 months. Of a total of 9’543 recorded pharmaceutical interventions, 8.8% were not fully 
classifiable (n=840). In general, users were satisfied (3.8±0.9, Likert-scale 1-5) with the GSASA system, 
especially with its adequate time expenditure (4.1±1.0). Ten users (83.3%) reported to need less than 
two minutes and two (16.7%) up to four minutes to classify one intervention. The extent to which the 
system is used and the good acceptance within a short time after implementation are promising results 
to use it as basis for a further development. 
The aim of next study (A3) of the project was to design an innovative seamless concept of classification 
of pharmaceutical interventions in patient care. The basic structure of the GSASA classification system, 
currently used in hospitals, should be adopted as far as possible. As a first exploratory trial to test the 
suitability of the GSASA system in ambulatory settings, we analysed 65 protocols of medication reviews 
(Polymedication-Check, PMC) performed by community pharmacists, and all 190 interventions could 
be classified using the GSASA system (median of 3 per PMC). However, the system does not provide 
detailed information about certain interventions. We identified the need for a new classification 
system which allows high flexibility in documenting pharmaceutical interventions. According to the 
complexity of the case, the available information, the type of medication review, and the need for 
follow-up, different levels of classification may be indicated. This classification system should be 
suitable for both, community and hospital pharmacy practices to facilitate continuity of care. 
 
The second project of the thesis (Project B) reports the development process of the Pharmacists’ 
Documentation of Interventions in Seamless Care (PharmDISC) system which was split into two parts 
and four stages: Part 1 covered the development and piloting stages (B1), while Part 2 covered the 
evaluation and implementation stages (B2). 
The aim of Part 1 (B1) was to develop an intervention oriented classification system for community 
setting, the PharmDISC system, based on the GSASA system for the hospital setting (development 
stage), and to validate (interrater reliability, appropriateness, interpretability) it in an academic 
environment (piloting stage). In a prospective observational study in community pharmacies, 77 
master students in pharmacy consecutively collected each 10 first prescriptions requiring a 
pharmaceutical intervention and classified these interventions with the PharmDISC system. The 
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classification system includes 5 categories and 52 subcategories. Most of the 725 pharmaceutical 
interventions (n=686, 94.6%) were completely classified. The PharmDISC system reached an overall 
substantial users agreement (Κ=0.61). Additionally, with a focus group of nine pharmacists (six 
community and three hospital pharmacists), we assessed their opinions on the documentation of 
pharmaceutical interventions, and assessed face and content validity of the PharmDISC system. 
Despite some arising points for optimisation, the pharmacists were satisfied with the PharmDISC 
system. They recognised the importance of documentation of pharmaceutical interventions and 
believed that this may allow traceability, facilitate communication within the team and other 
healthcare professionals, and increase quality of care. Refinement based on the pharmacists’ 
suggestions resulted in a final version to be tested in an observational study with community 
pharmacists. 
In Part 2 of the PharmDISC development process (B2), the PharmDISC was tested on interrater 
reliability, appropriateness, interpretability, acceptability, feasibility, and validity in the daily life 
environment of community pharmacies (evaluation stage) and first implementation aspects were 
explored (implementation stage). In an observational study, 21 pharmacists each classified 30 
prescriptions requiring a pharmaceutical intervention with the PharmDISC system on 5 selected days 
within a 5-weeks period. The participating pharmacists were trained with an online training and could 
use a descriptive manual of the PharmDISC system to support them in the classification of 
pharmaceutical interventions. The PharmDISC system reached an average substantial user agreement 
(Κ=0.66). Of 519 documented pharmaceutical interventions, 430 (82.9%) were completely classified. 
Most users found the system comprehensive and practical. The PharmDISC system raised the 
awareness regarding drug-related problems for most users. To facilitate its implementation, an 
electronic version that automatically connects to the prescription together with a task manager for 
pharmaceutical interventions needing follow-up was suggested. Barriers could be time expenditure 
and lack of understanding the benefits. 
A subanalysis (B3) based on the data obtained from the validation results (B2) allowed characterising 
the pharmaceutical interventions performed during dispensing of prescribed medicines in community 
pharmacies, and identifying the frequent problems with the prescribed medicines. Pharmacists 
performed individualised pharmaceutical interventions to solve or prevent DRPs concerning 
prescribed medicines. Pharmacists mainly intervened to substitute a drug (n=132, 30.7%), adjust a 
dose (n=57, 13.3%), and clarify/complete information (n=48, 11.2%). In 138 (32.1%) cases, the 
pharmacists contacted the prescriber whereas in 292 cases (67.9%), only the pharmacist was involved 
(alone n=59, with the patient n=222, with the caregiver n=11). Direct patient-pharmacist interaction 
during the dispensing was essential to detect patient-reported problems with prescribed medicines. 
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In the third project of the thesis (Project C), we observed on site the whole dispensing process of 
prescribed medicines, focusing on counselling activities, in order to depict the current practice in 
community pharmacies (C1). One master student in pharmacy performed non-participant 
observations during one day at each of the 18 included community pharmacy. Within 556 prescription 
encounters, counselling was provided to 367 (66.0%) customer on 2.9 ±3.1 themes per prescription 
encounter (first 4.9±3.0; refill 1.0±1.7, p<0.001), predominantly about drug administration, use and 
dose. We identified factors influencing counselling provision at patient, prescription and pharmacy 
level. Significantly more counselling was provided by pharmacists, to customers with a first 
prescription, with a prescription requiring a pharmaceutical intervention, to carers who filled the 
prescription for a patient, to new customers, and to customers who did not refuse counselling. While 
pharmacists intervened frequently, only few additional activities and no further services were offered. 
Additionally, at the end of the observation day (C1), an interview (C2) was conducted with one 
pharmacist of each participating pharmacy to assess pharmacists’ opinions on patient counselling 
during dispensing of prescribed medicines in daily community pharmacy practice, and on 
documentation and transfer of pharmaceutical interventions. For the eighteen interviewed 
pharmacists, most important themes to be discussed at first prescription dispensing were indication, 
administration, and anamnesis and at refill prescription dispensing, adherence, therapy benefits, and 
adverse effects. The most frequently counselling triggers that pharmacists expressed were patient’s 
knowledge gap, patient’s motivation/interest, drug-drug interaction, polypharmacy/polymorbidity 
and special patient population. Barriers were refusal by patients, communication problems, lack of 
medical data, and lack of time. Pharmacists occasionally documented their pharmaceutical 
interventions, however almost always not in a standardised way. Pharmacists found important to 
transfer the performed pharmaceutical interventions to the other involved healthcare providers, but 
some barriers (e.g. too time-consuming, overwork) could hinder it. Therefore, a simple and fast in use 
computerised documentation system, with an additional intervention history option, could be a 
promising approach. 
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In summary, this thesis showed the following: 
 
The GSASA system 
• The GSASA classification system appeared to be reliable and promising for the documentation 
of pharmaceutical interventions in daily practice (practical and less time-consuming). Its 
validation was successful in terms of appropriateness, interpretability, validity, acceptability, 
feasibility, and reliability (A1). 
• After 18 months of introduction (2013), the GSASA classification system is already widely 
accepted in Swiss hospitals, suggesting to be suitable also to daily life settings. Most 
pharmaceutical interventions can be classified with adequate time effort and overall users’ 
satisfaction is good. The extent to which the system is used and the good acceptance within a 
short time after implementation are promising results to use it as basis for a further 
development (A2). 
• The GSASA classification system was tested in primary care and proved to be suitable also to 
classify interventions of medication reviews performed by community pharmacists in primary 
care; however, further refinements were necessary to improve the precision of the system. 
Thus, the development of one classification system suitable for both, primary and secondary 
care, flexible for addressing different levels of complexity, and easily integrable in daily 
practice and in electronic patient file was recognised as a promising approach (A3). 
 
The PharmDISC system 
• In a focus group interview, pharmacists recognised the importance of the documentation of 
pharmaceutical interventions and were convinced that this may allow traceability, facilitate 
communication within the team and other healthcare professionals, and eventually would 
increase quality of care (B1). 
• Substantial interrater reliability and high rating of acceptability and feasibility indicates that 
the new PharmDISC system is a valid system for the documentation of pharmaceutical 
interventions in daily practice of community pharmacies. The pharmacists were satisfied with 
the system and considered it helpful, easy to use, and practical for daily work. They appraised 
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the fact that by using an intervention oriented classification system, their awareness of DRPs 
and concurrently the intervention rate increased (B2). 
• The developed descriptive manual of the PharmDISC system and the online training were 
helpful elements for an accurate use of the PharmDISC system and are promising utilities to 
enhance its implementation (B2). 
 
Depicting real-life daily practice 
• The high number of pharmaceutical interventions following DRPs and patient-reported 
problems highlights the importance of a direct patient-pharmacist interaction when 
dispensing prescribed medicines (B3). 
• The observation of the dispensing process of prescribed medicines allowed to depict the 
community pharmacy practice from the customers’ perspective (at the counter). However, 
counselling was not equally provided, indicating that prescription encounters need different 
degrees of counselling. A more transparent practice and patient-centered counselling is 
necessary to better meet the patients’ needs on information. While pharmacists intervened 
frequently, only few additional activities and no further services were offered (C1). 
• Factors influencing counselling provision were identified at patient, prescription and pharmacy 
level. Significantly more counselling was provided by pharmacists, to customers with a first 
prescription, to customers with a prescription requiring a pharmaceutical intervention, to 
carers who filled the prescription for a patient, to new customers, and to customers who did 
not refuse counselling (C1). 
• A discrepancy in counselling content by observation compared to pharmacists’ opinions was 
revealed. Observations show a focus on product-centered themes (e.g. drug administration, 
dose), whereas pharmacists’ interviews highlight the importance of patient-centered themes 
(e.g. benefit, adherence). This might indicate that pharmacists are aware but hindered by 
barriers to practice according to good pharmacy practice guidelines (C2). 
• Pharmacists recognised the importance of the documentation of pharmaceutical interventions 
and their transfer to others healthcare providers, but reported also possible reasons of non-
transfer (e.g. minor relevant of pharmaceutical interventions, overwork) (C2). 
• A simple and fast in use computerised documentation system, with an additional intervention 
history option, could be a promising approach according to the positive reactions and the 
needs of the pharmacists. As stated by the pharmacists, its implementation should increase 
the appreciation and visibility of pharmacists’ work, facilitate data handling by saving time and 
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costs, ensure seamless care by improving collaboration among healthcare providers, and 
ultimately improve the therapy outcomes (C2).  
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GENERAL INTRODUCTION AND RATIONALE 
 
Drug-related problems and pharmaceutical interventions 
A drug-related problem (DRP) is commonly defined as an event or circumstance involving drug therapy 
that actually, or potentially, interferes with the desired health outcomes [1]. Many studies have shown 
that DRPs are very common in the hospital and community settings [2-4]. A DRP can be a risk to the 
patient (potential problem) or cause harm (manifest problem) as an adverse drug event (ADE) or an 
adverse drug reaction (ADR). Multiple causes for DRPs are known such as medication error, poor 
documentation, failures in communication, inappropriate processes in the healthcare setting or the 
patient’s behaviour. A systematic review analysing DRPs in hospitals showed that problems associated 
with pharmacotherapy lead to a prolonged hospital stay and increased healthcare costs. On average 
8% of hospitalised patients suffer from an ADE or ADR, and 5 to 10% of all prescriptions or drug 
administrations are incorrect [5]. 
In community setting, the pharmacists also frequently identify DRPs and consequently intervene to 
solve or prevent them. A Swiss study showed that in community pharmacies, more than half (53.4%) 
of the 616 prescriptions resulted in a DRP [4]. Common DRPs observed in community pharmacies are 
drug-drug interactions, inappropriate drug choice, and missing/unclear information regarding the 
prescription [4, 6]. Especially with initial prescriptions which also include hospital discharge 
prescriptions, it is of great importance that patients are properly instructed and that the right drug is 
used in the right dose at the right time during the right duration. It is also essential that no DRPs arise 
and that the drug therapy is not interrupted or conducted incorrectly. The introduction of a newly 
prescribed drug to the treatment plan is an unusual situation for a patient who may have only recently 
been confronted with a new diagnosis or the necessity for a new drug. The risk of DRPs may be 
increased in this situation [7, 8]. 
In both hospital and community settings, there is evidence that interventions initiated by pharmacists 
can reduce the occurrence of DRPs [5, 9, 10]. In this thesis, we defined a ‘‘pharmaceutical intervention’’ 
as a recommendation initiated by a pharmacist in response to a DRP occurring in an individual patient 
in any phase of the medication process. These intervention aims at optimising pharmacotherapy, in 
terms of efficacy, safety, economic, and humanistic aspects [11]. 
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Seamless care 
Patient transitions such as hospital admissions, hospital internal transitions, transfer to an external 
institution or transfer from inpatient to outpatient care are currently not appropriately organised in a 
seamless care approach, particularly concerning the medication management. Seamless care is 
defined as any process which optimises efficiency, quality, and safety of medication management at 
transitions to establish a continuum of care [12, 13]. Continuity of care is crucial to ensure safe and 
efficient care transitions [14], especially for high-risk and/or elderly patients [15]. Provision of 
pharmaceutical care and clinical pharmacy when present in the hospital focus their activities mainly 
on the processes during hospitalisation, making, however, an important contribution to the safe and 
efficient recovery of the patients. 
Patient transition across care settings represent a high-risk period for the occurrence of DRPs, such as 
discrepancies (medication omission, discontinuation and incomplete prescription requiring 
clarification) [16-22]. These DRPs often result in adverse drug events, ranging from minor symptoms 
to impairment or death, and in patient readmission [20, 22-24], resulting in higher costs of care in 
public health [25]. According to the literature, unintentional medication discrepancies were observed 
in 24-91% of the patients at hospital admission and/or discharge [16, 19]. Particularly in the case of 
high-risk patients, such as patients with polypharmacy, with four and more comorbidities, with 
impaired cognition, and who are non-adherent to the prescribed medicines, around half of the hospital 
admissions (46%) due to preventable DRPs could be avoided [26]. 
An observational study in 3 German hospitals revealed that almost two-thirds of the 300 recruited 
hospitalised patients are confronted with 3 or more medication changes during hospitalisation [27]. 
The patient knowledge and understanding of their hospital discharge medication, especially by 
medication changes, is a decisive factor for positive health outcome. A study reported that half of the 
long-term medication of 130 patients during the hospital stay has been modified by the healthcare 
providers with dose adjustment, drug discontinuation/restart, and/or substitution [28]. There is also a 
necessity on the part of the patients to better understand their drug therapy [29]. By educating 
patients, medication safety as well as patient satisfaction can be improved subsequently. According to 
the study by Williams et al. 60% of unplanned rehabilitation could be avoided by more efficient 
interventions during hospitalisation [30]. Various strategies such as development of services (e.g. 
medication reconciliation/review), education and implementation of guidelines for healthcare 
providers, development of information technologies to share data across settings of care, have been 
developed to improve the quality of care and to achieve better patient outcomes [16, 31-33]. 
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However, the exchange of information between primary and secondary care on the patient medication 
remains a major challenge. Improved information exchange can only be achieved through 
collaboration among the different healthcare providers [34], and especially through better networking 
of the pharmacists involved in the perihospital phase. 
The access to complete and accurate patient medical information and good communication between 
healthcare professionals is essential to ensure safe and efficient patient care [21, 22, 35, 36] and to 
coordinate effective medication management, particularly when several healthcare provider are 
involved [37]. In current practice, the medication management at the time of admission and discharge 
from the hospital is not seamlessly guaranteed through complete documentation and communication 
of clinical pharmaceutical interventions between inpatient and outpatient care. In addition, 
collaboration between hospital pharmacists, community pharmacists and the medical team is not 
sufficiently established at present. Gaps in transfer of information and communication between 
secondary and primary care could negatively influence patient safety and continuity of care [34]. 
Moreover, healthcare providers in primary care are often not informed about patient medical 
conditions and outcomes [38], and unaware of medication changes following hospital discharge [39]. 
The patient transfer from inpatient to outpatient care could be organised in a more efficient and safer 
way, if information about the performed pharmaceutical interventions would be exchanged. Currently, 
the reasons of clinically relevant changes in medication are rarely clearly communicated and the 
pharmaceutical interventions lose their value.  
An illustrative example 
During hospitalisation, a hospital pharmacist discovered a DRP in patient drug therapy and makes 
a recommendation, which is implemented in collaboration with the physician. This pharmaceutical 
intervention led to a change in the patient medication. After hospital discharge, the patient filled 
the hospital discharge prescription in the community pharmacy. The community pharmacist 
changed the prescribed medication back to the medication the patient took before hospitalisation, 
according to his/her medication history, prior prescriptions, and eventually by contacting the 
general practitioner. Because of insufficient documentation and communication, the results of the 
interprofessional work and the implemented pharmaceutical intervention during the hospital stay 
were lost. 
At hospital admission, DRPs already occur and these consequently lower the quality of the hospital 
stay and jeopardise the patient unnecessarily [22]. A standardised document allowing the assessment 
of the best possible medication history [40] could be helpful to assemble information merging from 
secondary and primary care. In Switzerland, as part of the national quality strategy of the Federal 
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Office, the Swiss Foundation of Patient Safety carries out a first pilot program of the project ‘progress! 
Safe Medication at Interfaces‘. 
At hospital discharge, patients often find themselves confronted with new drugs, new diagnoses, and 
new worries, as a result creating uncertainty. Both hospital and community pharmacists could 
contribute to medication safety and quality of life of the patients before, during and after the hospital 
stay. The seamless care approach currently developed in different PhD projects of the Pharmaceutical 
Care Research Group (PCRG) follows two strategies (Fig. 1): 
A) Hospital Setting: identification of drug-related risks in patients [26, 42], provision of intensive 
pharmaceutical care and prospective planning of hospital discharge and care for a safe transfer to 
the next involved healthcare providers [14]. 
B) Community setting: recording of the hospital discharge plan, processing of non-solved DRPs, 
check if there is a need for medication reconciliation/review and the prospective planning of care 
until the next visit to the physician, offer of follow-up services. 
These two strategies must be carried out in a complementary way and the community pharmacy 
should take on subsidiary responsibility in case of gaps in the discharge plan. Indeed, the readmission 
rate and number of adverse effects can be decreased by implementing a discharge order reconciliation 
[31], home medication review (e.g. follow-up at home of high-risk elderly patients after hospital 
discharge [43]) or others strategies including both predischarge and postdischarge interventions [32]. 
In this way, the quality of care and patient safety can be improved. According to current practice, this 
can be performed by a medication review, named Polymedication-check, in Swiss community 
pharmacies [44]. 
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Fig. 1: Field of pharmaceutical activities during and after hospitalisation to ensure continuity of care. 
At admission, the high-risk patients are identified with the Drug Associated Risk Tool (DART) [42, 45], 
and receive intensive pharmaceutical care during the hospital stay and a discharge plan for the 
community pharmacy, which perform a medication reconciliation and ensure the follow-up care. 
 
These strategies and pharmaceutical interventions should no longer be loose fragments, but should be 
brought together like a mosaic in an overall concept and documented in a form that enables the most 
seamlessly possible exchange of information at the hospital discharge of patient in the outpatient 
situation. To accomplish this task, the first step is to document the pharmaceutical interventions in 
their respective care setting by developing valid instruments in order to picture the practice. 
 
Documentation of pharmaceutical care 
Pharmaceutical care is commonly defined as the pharmacist’s contribution to the care of individuals 
to optimise medicines use and improve health outcomes (e.g. cure/prevention of the disease, 
elimination/reduction of patients’ symptomatology, stabilisation of the disease process) [46, 47]. 
Pharmaceutical care implies an effective cooperation with the patient and other involved healthcare 
providers to design a therapeutic plan together that improves treatment outcomes [47]. In order to 
support continuity of care, the pharmacists accept responsibility for the patients and the quality of 
their care, implicating the necessity of documentation and communication of the 
activities/interventions which have been done [47]. As Cipolle et al. said, “if you aren’t documenting 
the care you provide in comprehensive manner, then you don’t have a practice” [48]. Pharmacists are 
accustomed to record prescriptions, however many lack experience in documenting patient care 
 
GENERAL INTRODUCTION AND RATIONALE 
 
PhD Thesis Karen Maes 23 
 
activities [49]. Documentation is all the more important given that the current practice is changing 
towards an increasing provision of patient-centered care and cognitive pharmaceutical services [47, 
50]. Pharmacists acquired accordingly more responsibilities, and concurrently documentation has 
become central in daily pharmacy practice [37, 51].  
Already today, pharmacists participate actively in the medication management, and subsequently 
contribute to the improvement of patient care, whereas documentation and communication of these 
activities to patients and other healthcare providers is often lacking [34, 51]. Nevertheless, the joint 
International Pharmaceutical Federation and World Health Organization (FIP/WHO) published 
guidelines on Good Pharmacy Practice (GPP) [37]. GPP requires that each element of pharmacy 
activities is relevant to the patient and is effectively communicated to all involved persons. The 
common saying “if it wasn’t documented, it wasn’t done” applies for all healthcare providers, also for 
pharmacists if they want to be a full member of the healthcare system [51]. Therefore, documentation 
of pharmacists’ activities is and must be an essential part to the pharmaceutical care practice [47]. As 
an example, the American Society of Hospital Pharmacists (ASHP) has already published guidelines on 
documentation of pharmaceutical care in patient medical records [52]. 
In order to improve the treatment outcomes and reduce health costs, pharmaceutical care involves a 
broad range of activities such as detecting, preventing and solving DRPs, counselling, and medication 
review [46]. In fact, daily practice of pharmacists comprises a wide variety of interventions regarding 
DRPs. The documentation of these pharmaceutical interventions increases the pharmacists’ attention 
to the drug-related needs of patients, enhances counselling skills and improves pharmaceutical care in 
general [53]. It also highlights the pharmacists’ role in ensuring the safe use of medicines [54, 55]. 
Indeed, a prerequisite for high-quality pharmaceutical care is an effective documentation allowing the 
evaluation of the intervention outcome [56]. In other terms, the documentation of care represents the 
evidence of practice [57]. It is therefore essential to record activities/interventions in a concise, 
standardised and structured manner, and each documentation should contain similar key elements 
[51, 58]. To accomplish this task, the classification, as essential part of the documentation, enables a 
precise representation of what has been done (e.g. pharmaceutical interventions) by categorising key 
elements in a standardised manner, and as a consequence, facilitates the transfer of information. 
Once the pharmaceutical interventions are documented in the respective healthcare setting, the 
information exchange between the hospital and the community pharmacy can often be challenging. 
Improving information exchange regarding pharmaceutical interventions could enable a more efficient 
and safer transfer of patients between inpatient and outpatient care. An aligned classification system 
in both settings would facilitate a standardised documentation of pharmaceutical interventions. 
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Classification systems for pharmaceutical interventions 
Increasingly, hospital and community pharmacists are involved in detecting and solving DRPs on a 
regular basis. In daily life, they come across technical (e.g. illegible prescriptions) and clinical issues 
(e.g. drug-drug interaction) requiring a pharmaceutical intervention (e.g. dose adjustment). 
The use of a classification system would help in the assessment of pharmaceutical interventions and 
the collection of DRPs in a structured way, and support continuity of care through the promotion of 
mutual information [9]. Additionally, such data on pharmacists’ activities could be used for 
epidemiological studies. Such standardised documentation highlights the pharmacist's role in the safe, 
appropriate, and cost-effective use of drugs [54, 55], and increases the pharmacist’s vigilance for the 
patients’ drug-related needs [53]. 
In the literature, several classification systems have been proposed. An international review identified 
twenty different types of DRP classification system [59]. Their structure and content differ in terms of 
category size and type [59-61]. Most instruments, such as APS-Doc [62], DOCUMENT [63], and PI-Doc 
[64], were considered too time-consuming in practice. Another system, the PCNE classification system 
V6.2 [65], was originally developed for research in community pharmacy setting and has a strong focus 
on patient behaviour, therefore making it less appropriate for the hospital setting. Typical hospital 
medication errors such as application errors, incompatibilities, and incorrect transcription cannot be 
classified [9]. The large number of subcategories (n=71) renders the tool very comprehensive, but 
hinders its application in a daily routine setting. Allenet et al. validated an instrument for the 
documentation of clinical pharmacists’ interventions (SFPC system), which proved to be suitable for 
daily practice [66]. However, this simple system lacks subcategories to document detailed information, 
and the cause of the DRPs is not assessed. Most systems have not been routinely implemented in 
practice to date, as they are generally too time consuming, too comprehensive, poorly defined, or only 
partially validated [60], and none has been used in parallel in community pharmacy and hospital 
settings.  
Published classification systems underline different foci; most classification systems concentrate on 
DRPs [59] and one on the cause of DRPs [61]. A review of the application of DRP classification systems 
reported a large variability in the definition of DRPs [59]. To get around this problem, a classification 
system focusing on interventions has the advantage to enable a more objective assessment, thus 
increasing the quality and reliability of data reporting. Moreover, this is in line with the key 
characteristics of a clinical documentation that aims at recording what the healthcare provider does 
(e.g. pharmaceutical interventions), why she/he does it (cause of the intervention) and what outcomes 
are reached (outcome of the intervention) [51]. 
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Validation of a classification system is necessary, not only to ensure that one code reflects a unique 
DRP, but to guarantee that this coding is understandable to the users. Validation confirms, through the 
provision of objective evidence, that the requirements for a specific use or application are fulfilled [67]. 
The literature describes the following criteria for validating DRP classification systems [68]: 
a) appropriateness (is the classification content appropriate to the questions the application seeks to 
address?)  
b) acceptability (is the classification acceptable to the users?) 
c) feasibility (is the application easy to use?) 
d) interpretability (how well can the classification codes be interpreted?) 
e) reliability (does the classification generate results that are reproducible and internally consistent?) 
f) validity (does the classification measure what it claims to measure?) 
g) responsiveness (does the classification offer options to follow up interventions and monitor 
outcomes of interventions?) 
Hence, validated, structured, and standardised classification systems for pharmaceutical interventions, 
which fulfil both requirements of comprehensive classification and simple use in daily clinical practice, 
are rare. Furthermore, there is no national consensus in Switzerland on how to record pharmaceutical 
interventions in a standardised manner to obtain data allowing epidemiological studies for research 
and political purposes. Therefore, we recognised the need of proper instruments able to depict the 
practice in their representative setting. 
 
Depicting real-life daily practice 
It has been shown that pharmacists play an effective role in detecting, preventing and solving DRPs 
and in patient counselling on medicines to support patients to make the best use of medicines [37, 
69]. In order to investigate the extent to which this role is followed, depicting daily practice can help 
to evaluate quality of care, to uncover the gaps in the real world of pharmacy practice, and 
consequently tailor accordingly the necessary interventions. The description and assessment of 
clinical, organisational and economic impacts of pharmacy activities can help to develop them [70]. 
Several methods can be used: 
• Pharmacists’ role in detecting, preventing, and solving DRPs can be illustrated by the 
documentation of their pharmaceutical interventions (e.g. thanks to a classification system). 
Documentation is a self-reported method for collecting data, enabling to illustrate pharmacists’ 
activities in community and hospital pharmacies. It has been reported that such documentation 
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makes pharmacists more attentive regarding the patients’ drug-related needs and enhances the 
development of counseling skills and pharmaceutical care [53]. 
• As part of pharmaceutical care, patient counselling and dispensing of prescribed medicines and 
are the pharmacist’s key activities to ensure the safe and effective use of medicines [37, 69]. 
During dispensing, community pharmacists help the patient to make the best use of prescribed 
medicines by providing written and oral information responding to the patient needs [71], which 
contribute to positive treatment outcomes [72]. Patient counselling on medicines has been shown 
to be effective in improving medicines adherence [73, 74], and in identifying DRPs [75]. However, 
insufficient information about medicines can lead to patient non-adherence to the drug therapy 
and negative health outcomes. For these reasons, observation is an adequate method to describe 
the pharmacists’ role in patient counselling on prescribed medicines and to depict the current 
dispensing practice in community pharmacies. Observations give the possibility to describe 
customers’ behaviour and discover how daily pharmacy practice works [76]. It is a useful way to 
study quality of services and consistency of care. In the literature, observations described 
interactions between pharmacy staff, patients and other healthcare providers [77], questions 
pharmacy staff ask, patient counselling, and recommendation of products [78-80]. 
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Goal of the thesis 
The goal of this thesis was to create structured instruments for daily practice to improve the continuity 
of documentation and communication of pharmaceutical interventions during transitions of care. With 
a structured seamless documentation and communication (Pharmacists’ Documentation of 
Interventions in Seamless Care, PharmDISC) between inpatient and outpatient care, the information 
could be available for the healthcare providers, the pharmaceutical interventions trackable and the 
patient informed about the changes of the drug therapy, thus improving the health outcomes (Fig. 2). 
This could ensure a safe and facilitated exchange of information on medication changes, patient 
conditions, and care issues between secondary and primary healthcare providers. With better 
documentation and communication, better pharmaceutical and seamless care should be provided and 
consequently medication management and health outcomes for the patients improved.  
We identified the need for documentation in daily practice and created an innovative classification 
system suitable for both, community and hospital pharmacy practices to facilitate continuity of care 
and to increase patient safety while transferring between care settings. The aims were as follows: 
• to develop and validate a classification of pharmaceutical interventions for a cross-sectoral 
use and its proper instruments (classification systems in secondary and primary care) 
• to evaluate its feasibility in practice 
• to depict real-life daily pharmacy practice 
 
Fig. 2 Continuity of documentation: looking at the patient pathway during hospital stay, three pharmaceutical 
interventions were documented into the electronic patient file; and after discharge, two interventions initiated 
by a community pharmacist were added to the same file, using the similarly structured classification, thus 
enabling to depict real-life daily practice (represented with the magnifying glass).  
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Approach 
The goal of this thesis was to create structured instruments for daily practice to improve the continuity 
of documentation and communication of pharmaceutical interventions at transitions of care. We 
approached this goal in three main projects: 
 
Project A An intervention oriented classification system for the hospital setting: 
the GSASA system 
As a first step towards the development of a classification of pharmaceutical interventions for a cross-
sectoral use in secondary and primary care, we developed, in the first project of this thesis (Project A), 
an intervention oriented classification system for the hospital setting, the GSASA system. This project 
contains the three following studies: 
A1 Demonstrating the clinical pharmacist’s activity: validation of an intervention oriented 
classification system (publication in Int J Clin Pharm 2015;37:1162–1171 [81]) 
To develop and validate a classification system for pharmaceutical interventions and to compare 
it with the well-established Pharmaceutical Care Network Europe (PCNE) system V6.2 [65]. 
A2 Evaluation of the implementation of a classification system for pharmaceutical interventions 
(short research report [82]) 
To evaluate the implementation of this classification system in daily practice one and a half years 
after its introduction, and to analyse the pooled data retrieved from Swiss hospitals. 
A3 Classification of pharmaceutical interventions in patient care: an innovative seamless 
concept (short research report [83]) 
To develop a new seamless concept for classification of pharmaceutical interventions suitable 
for both, primary and secondary care, integrable into patient files, and supporting seamless care. 
 
 
Project B An intervention oriented classification system for the community setting: 
the PharmDISC system 
To create an aligned classification system in both hospital and community settings, the basic structure 
of the GSASA classification system should be adopted as far as possible. In the second project (Project 
B), we developed an intervention oriented classification system for the community setting, the 
PharmDISC system, based on the GSASA system for the hospital setting. An initial validation was 
conducted in an academic environment and the final validation in the daily real-life environment of 
community pharmacies. The development process of the PharmDISC system was split into two parts 
and four stages: Part 1 covered the development and piloting stages (B1), while Part 2 covered the 
evaluation and implementation stages (B2). Thereafter, a subanalysis (B3) based on the data obtained 
from the validation results (B2), allowed for characterising frequent pharmaceutical interventions 
occurring in daily practice, and identifying frequent patient-reported problems. 
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Project B comprises three studies: 
B1 Documentation of pharmaceutical care: development of an intervention oriented 
classification system (publication in Int J Clin Pharm, 2017;39(2):354-363 [84]) 
To develop an intervention oriented classification system for community pharmacies named 
PharmDISC based on the hospital system; to test it on interrater reliability, appropriateness, 
interpretability, and face and content validity; to assess pharmacists’ opinions. 
B2 Documentation of pharmaceutical care - validation of an intervention oriented classification 
system (publication in J Eval Clin Pract, submitted, under review [85]) 
 To validate the PharmDISC system in terms of interrater reliability, appropriateness, 
interpretability, acceptability, feasibility, and validity; to explore first implementation aspects. 
B3 Pharmaceutical interventions on prescribed medicines in community pharmacies: focus on 
patient problems (short research report in Int J Clin Pharm, submitted, in revision) 
 To describe pharmaceutical interventions performed by community pharmacists during the 
dispensing process of prescribed medicines and to investigate their response to patient-
reported problems. 
 
Project C Patient counselling on prescribed medicines in Swiss community pharmacies 
 
Patient-reported problems concerning prescribed medicines were frequently detected by direct 
patient-pharmacist interaction in daily practice and resulted in a pharmaceutical intervention (B3). As 
one of the last healthcare provider before the patients take their medicines, pharmacists play an 
important role in patient counselling and education on medicines and in supporting the patients to 
make the best use of medicines. Therefore, the third project (Project C) aims at investigating the role 
of the pharmacy staff in patient counselling on prescribed medicines. Firstly, we observed the 
dispensing process of prescribed medicines at the counter, focusing on counselling activities, in order 
to depict the actual practice in community pharmacies (C1). Secondly, an interview (C2) was conducted 
with one pharmacist of each participating pharmacy to assess pharmacists’ opinions on patient 
counselling at dispensing of prescribed medicines in daily community pharmacy practice, and on 
documentation and transfer of pharmaceutical interventions. 
Project C contains two studies: 
C1 Dispensing of prescribed medicines in community pharmacies - Observed counselling, 
interventions and services (publication in preparation) 
To describe the observed dispensing process of prescribed medicines at the counter in daily 
community pharmacy practice, focusing on counselling activities.  
C2 Dispensing of prescribed medicines in community pharmacies – Observation deviates from 
pharmacists’ opinions (research report) 
 To assess pharmacists’ opinions on patient counselling at dispensing of prescribed medicines in 
daily community pharmacy practice, and on documentation and transfer of pharmaceutical 
interventions  
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Abstract 
Background Clinical pharmacists are increasingly involved in detecting and solving drug-related 
problems. In order to document their performance, a convenient tool to code pharmaceutical 
interventions in daily practice is desirable. The Swiss Society of Public Health Administration and 
Hospital Pharmacists (GSASA) proposed to implement a new classification system for pharmaceutical 
interventions. 
Objectives To develop and validate a classification system for pharmaceutical interventions and to 
compare it with the well-established Pharmaceutical Care Network Europe (PCNE) system. 
Setting Rehabilitation clinic, geriatric and orthopaedic wards of a 427-bed teaching hospital. 
Methods Development of the GSASA classification started with expert panel discussions and the 
validation of the first version (GSASA V1). In order to assess appropriateness, interpretability, and 
validity, clinical pharmacists documented during a 6-week period all interventions using GSASA V1 and 
PCNE version 6.2 (V6.2). Acceptability and feasibility were tested by an 8-item questionnaire with 5-
point Likert scale (1=strongly disagree, 5=strongly agree), and interrater reliability (Fleiss-Kappa 
coefficients Κ) was determined. After revision, the second version (V2) was assessed again for 
reliability. 
Main outcome measures User's agreement/satisfaction, comprehensiveness/reliability of the 
classification system. 
Results The GSASA V1 includes 4 categories and 35 subcategories. Of 115 interventions classified with 
GSASA V1, 93 (80.9 %) could be completely classified in all categories. This explains that 3 of 6 users 
could be not satisfied with the comprehensiveness of GSASA V1 (mean user agreement 2.7 ± 0.8). The 
questionnaire showed that all users could find GSASA V1 (4.0 ± 0.0) easier to use than PCNE V6.2 (3.0 
± 0.9). Users were generally satisfied with the GSASA V1 (3.5 ± 0.8), especially with the adequate time 
expenditure (4.0 ± 0.7). Interrater reliability and acceptability of GSASA V1 were comparable to those 
of the PCNE V6.2. The agreement among the GSASA V1 users was substantial for the categories 
'problem' (Κ = 0.66), 'intervention' (Κ = 0.74), and 'outcome' (Κ = 0.63), while moderate agreement 
for the category 'cause' was obtained (Κ = 0.53). The final system GSASA V2 includes 5 categories 
(addition of 'type of problem') and 41 subcategories. Total interrater reliability was moderate (Κ = 
0.52). 
Conclusion The GSASA classification system appeared to be reliable and promising for documentation 
of pharmaceutical interventions in daily practice (practical and less time-consuming). The system is 
validated in terms of appropriateness, interpretability, validity, acceptability, feasibility, and reliability. 
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Keywords  
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Pharmaceutical interventions; Validation  
Impact of findings on practice statements  
• The new classification system GSASA V2 may serve as a helpful tool in daily practice to classify 
DRPs and clinical interventions undertaken by pharmacists. 
• Classification of DRPs together with according interventions enables demonstration of the 
performance/impact of clinical pharmacy services. 
• This classification system could be a helpful instrument to collect and quantify data on 
pharmaceutical interventions, thus enabling the merging of data for epidemiological studies. 
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Introduction 
Drug-related problems (DRPs) are common in hospitalised patients. As defined by the Pharmaceutical 
Care Network Europe (PCNE), a DRP is an event or circumstance involving drug therapy that actually, 
or potentially, interferes with the desired health outcomes [1]. A drug-related problem can be a risk to 
the patient (potential problem) or cause harm (manifest problem) as an adverse drug event (ADE) or 
an adverse drug reaction (ADR). Multiple causes for DRPs are known such as medication error, poor 
documentation, failures in communication, inappropriate processes in the health care setting or the 
patient’s behaviour. A systematic review analysing DRPs in hospitals showed that problems associated 
with pharmacotherapy lead to a prolonged hospital stay and increased healthcare costs. Medication 
errors occurred in 5.7 % of all episodes of drug administrations, and 6.1 % of hospitalised patients 
experienced an ADE or ADR [5]. 
Increasingly, clinical pharmacists are involved in detecting and solving DRPs on a regular basis. 
Utilisation of a classification system would aid in the collection of DRPs and the assessment of 
pharmaceutical interventions; support continuity of care through the promotion of mutual information 
[9]; and, additionally, such data on pharmacists’ activities could be used for epidemiological studies. In 
the literature several classification systems have been proposed. Most instruments, such as APS-Doc 
[62], DOCUMENT [63], and PI-Doc [64], were considered too time-consuming in practice. Another such 
system, the PCNE classification system [65], was originally developed for a research and community 
pharmacy setting and has a strong focus on patient behaviour, therefore making it less appropriate for 
the hospital setting. Typical hospital medication errors such as application errors, incompatibilities, 
and incorrect transcription cannot be classified [9]. The large number of subcategories (n = 71) renders 
the tool very comprehensive, but hinders its application in a daily routine setting. Allenet et al. 
validated an instrument for the documentation of clinical pharmacists’ interventions (SFPC system), 
which proved to be suitable for daily practice [66]. However, this simple system lacks subcategories to 
document detailed information, and the cause of the DRPs is not assessed. Hence, validated, 
structured, and standardised classification systems for pharmaceutical interventions, which fulfil both 
requirements of comprehensive classification and simple use in daily clinical practice, are rare. 
Validation confirms, through the provision of objective evidence, that the requirements for a specific 
use or application are fulfilled [67]. Validation of a classification system is necessary, not only to ensure 
that one code reflects a unique DRP, but to guarantee that this coding is understandable to user. The 
literature describes the following criteria for validating DRP classification systems: (1) appropriateness 
(is the classification content appropriate to the questions the application seeks to address?) (2) 
acceptability (is the classification acceptable to the users?) (3) feasibility (is the application easy to 
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use?) (4) interpretability (how well can the classification codes be interpreted?) (5) reliability (does the 
classification generate results that are reproducible and internally consistent?) (6) validity (does the 
classification measure what it claims to measure?) (7) responsiveness (does the classification offer 
options to follow up interventions and monitor outcomes of interventions?) [68]. 
Up to now, there was no national consensus in Switzerland on how to demonstrate the clinical 
pharmacist activities to obtain data allowing epidemiological studies for research and political 
purposes. The working group on clinical pharmacy of the Swiss Society of Public Health Administration 
and Hospital Pharmacists (GSASA), comprising eight French- and German-speaking clinical 
pharmacists, recognised the need for the development of a new standardised and practical tool. To 
ease the recording of interventions in inpatients during daily practice, a tool was developed, which 
seeks to combine the advantages of existing systems such as SFPC (validated, practical, and based on 
hospital setting) and PCNE (validated, logical basic structure with the categories cause and 
intervention) systems. The classification system focused on interventions to enable a more objective 
assessment, and increased quality and reliability of data recording. We used the PCNE system, which 
is validated, well-established and internationally used, as a benchmark for our new intervention 
oriented classification system [9, 60]. 
Aim of the study 
The aim of the study was to develop a classification system for drug-related problems and 
pharmaceutical interventions, and to validate this system using inpatients and against the PCNE 
classification system V6.2. 
Ethical Approval 
According to the requirements of the Swiss federal law on human research this study is exempt from 
ethical approval. 
Methods 
Overview of development process 
Figure 1 illustrates the process involved in developing the new GSASA classification system, which 
comprised four main steps. The topics were based on those of the PCNE classification system, while 
the structure followed that of the French classification system [66]. The first version (GSASA V1) of the 
classification system was developed by an expert panel of eight clinical pharmacists (GSASA working 
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group on clinical pharmacy). After validation, a second version was developed (GSASA V2) which was 
revalidated. 
We defined a ‘‘pharmaceutical intervention’’ as a recommendation initiated by a pharmacist in 
response to a DRP occurring in an individual patient in any phase of the medication process. The 
intervention aims at optimising pharmacotherapy, in terms of efficacy, safety, economic, and 
humanistic aspects [11]. 
 
Fig. 1 Process of developing the classification system 
 
Step 1: Development of classification system GSASA V1 
The GSASA working group (=expert panel) comprised four French and four German speaking clinical 
pharmacists (n = 8) from 8 different hospitals, whose professional experience in clinical pharmacy 
ranged from 3 to 14 years. Seven of them had previously used a DRP classification system. The fi 
version, developed by the aforementioned GSASA working group, was based on the PCNE classification 
system for DRPs [65] and the instrument for documentation of clinical pharmacists’ interventions of 
the French Society of Clinical Pharmacy [66]. Any discrepancies were resolved by discussion. 
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Step 2: Validation of classification system GSASA V1 
Version 1 was validated assessing appropriateness, interpretability, validity, feasibility, acceptability, 
and interrater reliability. 
Appropriateness, interpretability, and validity 
We measured appropriateness, interpretability, and validity of the classification systems by assessing 
the proportion of completely classified interventions. Classification was considered complete when all 
categories were filled out. At a 427-bed teaching hospital, six experienced clinical pharmacists used 
the GSASA V1 during a 6-week period to classify the interventions they performed themselves from 
their routine ward rounds (in geriatric ward, rehabilitation clinic, and orthopaedic ward). Additionally, 
they classified the same data with PCNE V6.2, and entered the classification codes into a Microsoft 
Excel sheet. For each DRP, only one choice per category was possible. Special attention was paid to the 
cases that could not be completely classified. 
The pharmacists received training prior to data collection. Training mainly comprised classification of 
model cases according to standardised documentation forms of PCNE and GSASA, followed by plenum 
discussions. Validated model cases in a German translation were used [4]. The collected data were 
analysed by descriptive statistics. 
Acceptability and feasibility 
In order to evaluate acceptability and feasibility of both classification systems, an 8-item questionnaire, 
which has been used in an earlier study, was completed by the six pharmacists [4, 86]. 
The extent of their agreement or disagreement was assessed by a 5-point Likert scale (1 = strongly 
disagree, 2 = dis- agree, 3 = neutral, 4 = agree, 5 = strongly agree). Time spent for classification and the 
free text comments was then evaluated. A Mann–Whitney U test was used for statistical evaluation. 
The significance level was accepted at p < 0.05. 
Interrater reliability 
Three of the six senior clinical pharmacists assessed the reliability of the classification systems. Each 
had more than 5 years of professional experience in clinical pharmacy, and had worked with DRP 
classification systems before. They classified 10 model cases using GSASA V1 and PCNE V6.2. The model 
cases consisted of five validated model cases taken from the literature [87], and five model cases 
developed for the validation of PCNE V5.0 taken from the German translation. Drug names were only 
modified to suit the Swiss market. We randomised the order of model cases and classification systems, 
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and each rater received the same instructions. For both classification systems, only one choice per 
category was possible to classify each detected problem. For the four categories of both classification 
systems (detected problem, cause, intervention, outcome of intervention) Fleiss kappa was calculated 
using a Microsoft Excel template [88]. Resulting values were interpreted according to Landis and Koch 
[89] as ‘almost perfect’ (Fleiss’ Κ 0.81–1.00), ‘substantial’ (0.61–0.80), ‘moderate’ (0.41–0.60), 
‘fair’(0.21–0.40), ‘slight’ (0.00–0.20), and ‘poor’ (<0.00). A kappa higher than 0.40 indicates that the 
system is reliable. 
Step 3: Development of classification system GSASA V2 
Revision of version 1 
The GSASA working group reviewed the results of the validation of GSASA V1. Conclusions were drawn 
and discussed until consensus was reached. 
Translation 
The GSASA working group translated the German GSASA V2 into French during an open discussion. For 
the purpose of this paper, we additionally translated version 2 into English. 
Step 4: Reliability of classification system GSASA V2 
Interrater reliability 
The GSASA working group assessed the interrater reliability of the German and French versions of 
GSASA V2 as described in step 2. They classified the same 10 model cases using the GSASA V2. 
Results 
Step 1: Development of classification system GSASA V1 
The first version included 4 main categories and a total of 35 subcategories, i.e., detected problem (3 
subcategories), cause of intervention (17 subcategories), intervention (10 subcategories), and 
outcome of intervention (5 subcategories). 
Step 2: Validation of classification system GSASA V1 
Appropriateness, interpretability, and validity 
DRPs were collected from daily work on the wards during a 6-week period. We classified 115 DRPs with 
PCNE V6.2 and GSASA V1. The proportion of the classified cases and the categories involved are shown 
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in Table 1. In both classification systems, the majority of the cases could be completely classified (PCNE 
81.7 %, GSASA 80.9 %). 
   Table 1 Proportion of classified cases per system and per category 
 
PCNE V6.2 GSASA V1 
  
n % n % 
 
All cases 115 100 115 100 
Completely* classified cases 94 81.7 93 80.9 
Per category     
Problem 106 92.2 99 86.1 
Cause 108 93.9 110 95.6 
Intervention 110 95.6 114 99.1 
Outcome 115 100 115 100 
* Classification was considered complete when all categories were  
filled out 
 
Acceptability and feasibility 
The six pharmacists completed an 8-item questionnaire on the usability of PCNE V6.2 and GSASA V1 
using a 5-point Likert scale. Data was compared using Mann–Whitney U Test. The results of the 
questionnaire were not statistically significant. Table 2 shows the differences of the results for 
acceptability and feasibility of the two classification systems (questions 1–7). 
Question 8 allowed the pharmacists to record their comments and suggestions. The subcategories 
‘untreated indications’ and ‘documentation errors’ were missing in the category ‘problem’, 
‘duplication’ and ‘insufficient effect of drug treatment/inappropriate drug’ in the category ‘cause’ and 
‘recommendations of laboratory test’ in the category ‘intervention’. 
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Interrater reliability 
Figure 2 illustrates the interrater reliability of the four classification categories, i.e., problem (GSASA 
V1 Κ = 0.66, PCNE V6.2 Κ = 0.32), cause (GSASA Κ = 0.53, PCNE Κ = 0.44), intervention (GSASA Κ = 
0.74, PCNE Κ = 0.40), and outcome (GSASA Κ = 0.63, PCNE Κ = 0.52). The three pharmacists showed 
a fair agreement for the category ‘problem’ and a moderate agreement for the other categories of the 
PCNE classification system. In comparison, GSASA V1 reached a moderate agreement for the category 
‘cause’ and a substantial agreement for the other categories. 
 
Fig. 2 Κ-Coefficients of PCNE V6.2 and GSASA V1 classification systems for the four categories, based on standard 
cases (n = 10) classified by raters (n = 3) 
 
Step 3: Development of classification system GSASA V2 
The results of the validation of GSASA V1 and the suggestions from the six users were discussed in the 
expert group, and resulted in the addition of one new category ‘type of problem’ and seven new 
subcategories, and in the modification of three subcategories. The subcategory ‘untreated indication’ 
was moved from the category ‘cause’ to ‘problem’. The major change concerned the category 
‘detected problem’. In order to precisely describe the DRPs, we included two additional subcategories 
to this category, and introduced the new category ‘type of problem’ to differentiate potential and 
manifest DRPs. Table 2 describes the English version 2 and the modifications with respect to version 1. 
The resulting classification system GSASA V2 includes 5 categories with a total of 41 subcategories as 
follows: detected problem (5 subcategories), type of problem (potential/manifest) (2 subcategories), 
cause of intervention (18 subcategories), intervention (11 subcategories), and outcome of intervention 
(5 subcategories) (see Table 3). Only one choice per category is possible. Therefore, if a detected 
PROJECT A 
AN INTERVENTION ORIENTED CLASSIFICATION SYSTEM FOR THE HOSPITAL SETTING: THE GSASA SYSTEM 
 
PhD Thesis Karen Maes 41 
 
problem involved multiple interventions, each intervention required the use of a new form or line in 
the Excel sheet. An example to illustrate this classification is given in Figure 3. 
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Fig. 3 Example of a pharmaceutical intervention classified as a drug-related problem according to classification 
system GSASA V2 
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Step 4: Reliability of classification system GSASA V2 
Interrater reliability 
The working group assessed the level of agreement of the version V2 in German and French (Table 4). 
They classified the same 10 cases used in step 2. Interrater reliability was moderate (Κ = 0.52) for all 
categories. 
Table 4 Level of agreement of the GSASA V2 among experts (n = 8), 10 standard cases 
 Kappa coefficient (agreement)  
French-speaking experts (n = 4) German-speaking experts (n = 4)  All experts (n = 8) 
Detected problem 0.58 (moderate) 0.26 (fair) 0.43 (moderate) 
Type of problem 0.48 (moderate) 0.66 (substantial) 0.57 (moderate) 
Cause of intervention 0.53 (moderate) 0.56 (moderate) 0.55 (moderate) 
Intervention 0.77 (substantial) 0.40 (moderate) 0.58 (moderate) 
Outcome of intervention 0.44 (moderate) 0.51 (moderate) 0.48 (moderate) 
Average agreement 0.56 (moderate) 0.48 (moderate) 0.52 (moderate) 
 
Discussion 
Our study showed that most (80.9 %) of the 115 pharmaceutical interventions could be documented 
with the first GSASA classification system V1 and a similar ratio of 81.7 % with the PCNE classification 
V6.2, our benchmark. Moreover, we found comparable interrater reliability and acceptability for the 
GSASA and PCNE systems. On the other hand, the comparative evaluation of the two systems revealed 
differences with respect to usability. Indeed, the category ‘intervention’ of the GSASA system allowed 
a more complete classification of the cases than the PCNE. This reveals that our system respected his 
original approach, which was focusing on recording the interventions. 
The structure of the two systems could also explain these differences. The four main categories of 
GSASA V1 corresponded with the ones of PCNE V6.2. However, PCNE V6.2 contained a twofold larger 
choice of subcategories (n = 71) than GSASA V1 (n = 35) enabling the precise classification of most 
DRPs. Consequently, users could find the PCNE instrument to be more comprehensive than the GSASA 
system, knowing that, due to the small number of raters, the comparison of both tools showed no 
statistically significant results. In contrast, the GSASA system could be easier to use and more practical 
than the PCNE system. Time is an essential element for the acceptance of a classification system. In 
routine settings, application of the GSASA system in clinical practice demonstrated this tool to be less 
time-consuming than the PCNE system. This important factor should increase the chances of a 
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successful and systematic use of the GSASA system. By addition or modification of several 
subcategories, the number of non-classifiable cases should decrease. In this way, the 
usefulness/comprehensiveness of the GSASA system could be enhanced without affecting its well-
established practical use. In summary, the validation of the two existing systems showed an acceptable 
performance in enabling documentation and a better acceptability and feasibility of the GSASA system. 
The comments of the users provided helpful input for further improvement and the development of 
the classification system GSASA V2. 
The goal of this development process was to create a classification system that permits the 
classification of DRPs detected and the recording of any pharmaceutical intervention. Van Mil et al. 
describe essential characteristics of classification systems [60]. Accurate classification of a detected 
problem should lead to only one choice per category. Therefore, the comprehensiveness of our 
instrument allows its systematic use and the consistency in the documentation of the interventions. 
Its detailed description manual, illustrated with practical examples, should enable homogenous data 
collection. In this way, the classification system would allow to collect and pool data from different 
sites, and by this generating a representative overview of clinical pharmacy activities within a given 
region. As a disadvantage, our instrument allows limited entry of details on individual cases. However, 
its open structure enables to enter additional and important information about the coded 
interventions. 
The classification GSASA V1 reached good interrater reliability. Indeed, the four classification 
categories of GSASA V1 (Κ = 0.64, which indicated a substantial agreement) was more reliable than 
the four categories of PCNE V6.2 (Κ = 0.42, moderate agreement). Interrater reliability of GSASA V2 
(Κ = 0.52) was acceptable, although the Κ-coefficients were lower than those calculated for the initial 
version. This decrease of the interrater agreement can be explained by the extension of the 
classification system from 4 to 5 categories. Additionally, the raters for the second version were more 
heterogeneous in terms of language, professional experience, and clinical background. Due to minor 
changes in GSASA V1 only interrater reliability was repeated when revalidating GSASA V2. 
Average interrater agreement for GSASA V2 was moderate (Κ = 0.52). This Kappa value was similar to 
that of the DOCUMENT [63] instrument (Κ = 0.53), a recent validated system for classifying DRPs and 
clinical interventions in community pharmacy. Similarly, the APS-Doc system obtained a substantial 
agreement for the categories and a moderate agreement for the subcategories [62]. Considering that 
(a) the pharmacists involved in our study had only little experience with the GSASA system, (b) they 
had never used a description manual to aid in DRPs classification, and (c) that Kappa value higher than 
0.40 indicates the internally acceptability and the good comprehensiveness of the classification 
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system, these results fulfil the minimum requirement for an acceptable classification system. In the 
future, the use of the descriptive manual to assist with the classification should improve the Kappa 
score. 
This study involved several limitations. As in most classification systems, subcategories are not 
mutually exclusive. The GSASA system shows similarities with the PCNE and SFPC systems, which it 
stemmed from. The validation and reliability of GSASA V1 were based on a small number of 
pharmacists (n = 6 and 3, respectively), thus we cannot exclude a selection bias. Many raters were 
involved in the different stages in the development process. Therefore, we cannot ensure the 
generalisability of the system. We limited the validation of GSASA V2 on reliability as only minor 
changes were required in the first version. We considered most results of GSASA V1 validation as 
transferable to GSASA V2. In order to enable its implementation we tested the classification system in 
a limited number of users (n = 8). All were qualified clinical pharmacists, each classifying 10 cases. On-
going projects aim to evaluate the implementation and the user’s satisfaction of GSASA V2 in daily 
practice and to analyse the pooled data retrieved from Swiss hospitals. In addition, we are currently 
adapting the system to also suit the community pharmacy setting and to support seamless 
documentation and transition from secondary to primary care. 
 
Conclusion 
The intervention oriented classification system GSASA V2 appeared to be valid and easy to use in daily 
clinical practice. The system is validated in terms of appropriateness, interpretability, validity, 
acceptability, feasibility, and reliability. The description manual assists in categorisation and hereby 
will increase the quality of data due to an appropriate use of the standardised classification system. 
Systematic use of the procedure will provide information on the performance of clinical pharmacy 
services on the whole. On-going epidemiological research aims to merge all interventions classified 
with the classification system GSASA V2 in Switzerland and to evaluate its implementation. 
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Background and Objectives 
The Swiss Society of Public Health Administration and Hospital pharmacists (GSASA) introduced in 2011 
a new GSASA classification system for pharmaceutical interventions in Swiss hospitals. The instrument 
(Fig. 1), developed and validated in a previous research, comprises five main categories (problem, type 
of problem, cause, intervention, and outcome) [81]. Our objectives were to evaluate the 
implementation of this classification system in daily practice, and to analyse the pooled data retrieved 
from Swiss hospitals. 
 
Setting and methods 
Chief hospitals pharmacists (n=47) were asked by online questionnaire (part of the Questionnaire 
Mapping clinical Pharmacy in Swiss Practice [90]) about the use and satisfaction with their classification 
system. Users of the GSASA system were asked to voluntarily provide their data containing all 
interventions classified with this system during daily work (example fig. 1). We evaluated users’ 
satisfaction about comprehensiveness, feasibility, and acceptability with a 5-point Likert scale.  
 
Fig. 1 Example of a pharmaceutical intervention classified with the GSASA classification system 
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Results 
The questionnaire was completed by 44 chief pharmacists (94%), therefrom 33 hospitals offer regularly 
clinical pharmacy services (75%) and 7 planned it (16%)[90].Figure 2 shows the types of classification 
system used in Swiss hospitals. All hospitals using the GSASA system provided regular clinical pharmacy 
services.  
        
Eleven of 12 hospitals using the GSASA system provided us all classification data thus covering an 
observation period of 121.5 months (sum of the months per hospital). In total, 9’543 interventions 
were recorded. Of all interventions, 840 (8.8%) were not fully categorised because of missing aspects 
(Fig. 3). 
Figure 4 illustrates the users’ satisfaction:  
1. Six of twelve users were not fully satisfied with the comprehensiveness of the system (mean user 
agreement 2.9±1.1). The users suggested additional subcategories (examples): 
 Problem: Problem based on electronic prescription 
 Cause: i.v. drug incompatibility, incorrect prescription 
 Intervention: Information to physician 
 Outcome: Refused by the patient 
2. Users found the system easy to use in daily work (3.8±1.0).  
3. In general, users were satisfied (3.8±0.9) with the GSASA system, especially (4.) with the adequate 
time expenditure (4.1±1.0). Ten users reported to need less than 2 minutes (83%) and 2 (17%) up to 
4 minutes to classify one intervention. 
 
7
1225
Fig. 2 How hospital pharmacists classify their 
interventions? (n=44)
No structured
classification
GSASA system
Other system
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Fig. 4 Satisfaction of the users (n=12) with the GSASA classification system 
 
Discussion and conclusion 
After one year, the GSASA classification system is already widely accepted in Swiss hospitals. This 
instrument proved to be suitable also to daily life setting. Most pharmaceutical interventions can be 
classified with adequate time effort. Overall users’ satisfaction is good. Further refinements are 
necessary to improve the precision of the system (additional subcategories, clarification of existing 
subcategories). The extent to which the system is used and the good acceptance within a short time 
after implementation are promising results to use it as basis for a further development. 
 
Appendix 
A1.1 Questionnaire Mapping clinical Pharmacy in Swiss Practice, incl. evaluation of the 
implementation of the GSASA system 
 
  
0 1 2 3 4 5 6 7 8 9 10 11 12
1. The classification system is complete
and contains all DRPs I detected
2. The classification system is easy to
use in daily practice.
3. In general I am satisfied with the
classification system
4. The expenditure of time is
appropriate
Number of clinical pharmacists
strongly disagree
disagree
neutral
agree
strongly agree
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Background 
In patient care, we defined a “pharmaceutical intervention” as a recommendation initiated by a 
pharmacist in response to a drug-related problem in an individual patient occurring in any phase of the 
medication process. 
In daily practice, classification helps to document interventions, and data provide a pool for 
epidemiological studies. Most existing instruments have not been routinely implemented in practice 
yet and none has been used in parallel in community pharmacy and hospital settings. 
In Switzerland, a classification system of pharmaceutical interventions was implemented in several 
hospitals [81, 82], while in community pharmacies no standardised classification is used. In order to 
ease seamless care and to promote mutual information, the structure of the classification system 
should be similar but provide different levels of details depending on the complexity of the 
pharmaceutical interventions, and support medication management along the patient pathway. 
Objectives 
To develop an innovative seamless concept for classification of pharmaceutical interventions suitable 
for both, primary and secondary care, integrable into patient files, and supporting seamless care 
(Fig.1).  
 
Fig. 1 Continuity of documentation: looking at the patient pathway during hospital stay, tree interventions were 
documented into the electronic patient file; and after discharge, two interventions initiated by a community 
pharmacist were added to the same file, using the similarly structured classification. 
PROJECT A 
AN INTERVENTION ORIENTED CLASSIFICATION SYSTEM FOR THE HOSPITAL SETTING: THE GSASA SYSTEM 
 
PhD Thesis Karen Maes 55 
 
Design and Methods 
Previously, we developed and validated a new classification system for the hospital setting (GSASA 
system), starting with an expert panel discussion [81]. During the adaptation of the system for the use 
in community pharmacies, further discussion rounds followed and relevant classification systems were 
retrieved by literature research. 
As a first exploratory trial to test the suitability of the GSASA system in ambulatory settings, we 
analysed protocols of medication reviews (Polymedication-Check, PMC [44]) performed by community 
pharmacists and we classified the interventions using the GSASA system. 
Results 
We identified the need for a new classification system which allows high flexibility in documenting 
pharmaceutical interventions. According to the complexity of the case, the available information, the 
type of medication review, and the need for follow-up, different levels of classification may be 
indicated. This instrument should be suitable for both, community and hospital pharmacy practices to 
facilitate continuity of care. 
During a total of 65 medication reviews, 190 pharmaceutical interventions were documented. All of 
them could be classified with the GSASA system (median of 3 per PMC). However, the system does not 
provide detailed information about certain interventions. Figure 2 illustrates the pharmaceutical 
interventions. Pharmacists intervene mainly by ‘patient counselling, training’ (69; 36.3 %), 
‘optimisation of administration’ (45; 23.7 %), ‘dose adjustment’ (13; 6.8 %) and ‘therapy monitoring’ 
(13; 6.8 %). 
 
Fig. 2 Pharmaceutical interventions (n=190) documented during 65 medication reviews 
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Conclusions and implications 
The GSASA classification system proved to be suitable also to classify interventions of medication 
reviews performed in primary care; however further refinements are necessary to improve the 
precision of the system. Thus, the development of one classification system suitable for both, primary 
and secondary care, flexible for addressing different levels of complexity, and easily integrable in daily 
practice and in electronic patient file is a promising approach. 
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PROJECT B 
An intervention oriented classification system for the community setting: 
the PharmDISC system 
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Abstract 
Background A standardised classification system of pharmaceutical interventions (PI) is currently in 
use in several Swiss hospitals, whereas none exists for community pharmacies to date. To promote 
information exchange between both settings, a compatible structure of the classification system is 
needed. 
Objective To develop an intervention oriented classification system for community pharmacies named 
PharmDISC based on the hospital system; to test it on interrater reliability, appropriateness, 
interpretability, and face and content validity; to assess pharmacists’ opinions. 
Setting Seventy-seven Swiss community pharmacies. 
Method Based on previous studies, a modified classification system was developed. Fifth-year 
pharmacy students (n=77) received a two-hour training and classified three model PIs with which 
Fleiss-Kappa coefficients Κ were calculated to determine interrater reliability. In the community 
pharmacies, each student consecutively collected 10 prescriptions that required a PI. A focus group 
interview was conducted with pharmacists (n=9). The anonymised transcript was analysed using 
thematic analysis. 
Main outcome measure Number of classified PIs, interrater reliability, pharmacists’ 
opinions/suggestions. 
Results The classification system includes 5 categories and 52 subcategories. Most of the 725 PIs 
(94.6%) were completely classified. The PharmDISC system reached an overall substantial users 
agreement (Κ=0.61). Despite some points for optimisation, the pharmacists were satisfied with the 
PharmDISC system. They recognised the importance of PI documentation and believed that this may 
allow traceability, facilitate communication within the team and other healthcare professionals, and 
increase quality of care. 
Conclusion The PharmDISC system was valid and reached substantial interrater reliability. Refinement 
based on the pharmacists’ suggestions resulted in a final version to be tested in an observational study 
with community pharmacists. 
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Key words 
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pharmacy practice, pharmaceutical care 
Impact of findings on practice statements 
• The intervention oriented classification system PharmDISC may serve as a helpful instrument 
to document pharmaceutical interventions in daily community pharmacy practice. 
• The data collected with the PharmDISC system could improve visibility of the pharmacists’ 
activities among other healthcare professionals, patients, and authorities. 
• The documentation of pharmaceutical interventions could contribute to quality management 
by enhancing traceability and information flow within teams and towards other healthcare 
professionals. 
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Introduction 
The medication process is complex and involves a variety of individuals such as patients, carers, 
prescribers, and pharmacists. It is therefore not surprising that frequent medication issues occur. A 
drug-related problem (DRP) is defined as an “event or circumstance involving drug therapy that 
actually or potentially interferes with desired health outcomes” [1]. Common DRPs observed in 
community pharmacies are drug-drug interactions, inappropriate drug choice, and missing/unclear 
information regarding the prescription [4, 6]. A Swiss study showed that in community pharmacies, 
53.4% of 329 prescriptions resulted in a DRP [4]. In daily practice, pharmacists face not only technical 
(e.g. illegible prescription) but also clinical issues (e.g. drug-drug interaction) requiring a 
pharmaceutical intervention (PI), such as changing the dosage form or adapting the dose [91]. A PI is 
defined as a recommendation initiated by a pharmacist in response to a DRP in an individual patient 
occurring in any phase of the medication process [11, 81]. A classification system is a helpful tool to 
document PIs in a structured way. Such documentation highlights the pharmacist's role in the safe, 
appropriate, and cost-effective use of drugs [54, 55], and increases the pharmacist’s vigilance for the 
patients’ drug-related needs [53]. The documentation of PIs also provides a valuable source for 
pharmaceutical care research [60, 63], improves communication between involved healthcare 
professionals [63], and facilitates political and economic discussions [55, 64]. A documentation of PIs 
is written evidence that the care was conducted in compliance with good pharmacy practice standards. 
An important part of the pharmacist’s activities is patient counselling at the time of dispensing 
medicines. Recording DRPs is an essential part of the documentation of counselling outcomes. 
Common systems and aims must be developed to enable the pharmacy profession to refine and 
enhance its counselling role [92]. 
Several DRP classification systems have been developed, either for research purposes, or for the 
application in practice. Their structure and content differs in terms of category size and type [59-61]. 
However, most existing classification systems focus mainly on DRPs, such as the Pharmaceutical Care 
Network Europe (PCNE) system [65], the third Consensus of Granada on DRPs and negatives outcomes 
associated with medication [93], and the PI-Doc® system [54]. Most systems have not been routinely 
implemented in practice to date, as they are generally too time consuming, too comprehensive, poorly 
defined, or partially validated [60].  
Solving technical issues is part of the community pharmacists’ daily work, but is often not represented 
in the classification system. Although the PI-Doc® system provides a distinct classification for some 
technical and logistical DRPs and PIs [64], they are captured in both the DRP and PI category which 
lengthens the system. Another classification system illustrates the step-wise approach of DRP 
management and separates the clinical from the technical DRPs, but was exclusive to prescriptions 
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[94]. While classification systems are mostly developed either for the clinical [62, 66] or the community 
pharmacy setting [63], no system has been developed for parallel use in both settings. In several Swiss 
hospitals, an intervention oriented classification system, the Swiss Association of Public Health 
Administration and Hospital Pharmacists (GSASA) system [81], has been implemented and is routinely 
used. However, there is no standardised classification system for community pharmacies. 
Once a PI is documented in the respective healthcare setting, the exchange of information between 
the hospital and the community pharmacy is challenging. Our aim is to enable a more efficient and 
safer transfer of patients between inpatient and outpatient care by improving the exchange of 
information regarding PIs. Implementing a compatible classification system in both settings would 
allow for standardised PI documentation and improve the medication management. To achieve this 
goal, a sound and reliable PI classification form is essential. We identified the need for a classification 
system that provides high flexibility in documenting PIs. Depending on the PI complexity, the available 
information, and the need for follow-up, different levels of classification may be required. The 
objectives of this study were to adapt the existing GSASA system [81] for the community pharmacy 
setting and to perform an initial validation. Our system, termed the Pharmacists’ Documentation of 
Interventions in Seamless Care (PharmDISC) system, is intended for the documentation of DRPs that 
result in a PI. 
 
Aim of the study 
The aim of this study was to develop and test the PharmDISC classification system on interrater 
reliability, appropriateness, interpretability, and face and content validity, and to assess pharmacists’ 
opinions on the documentation of PIs. 
 
Ethical approval 
The study was approved by the Ethics Committee of Northwest and Central Switzerland (EKNZ 2014-
102) on 30.03.2014. 
 
Methods 
PharmDISC development 
The development process of the PharmDISC system was split into two parts and four stages [95]: Part 
1 covered the development and piloting stages, while Part 2 covered the evaluation and 
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implementation stages (Table 1). This publication is focused on Part 1 of the PharmDISC development 
process exclusively. Part 2 is reported separately [85]. 
Table 1 PharmDISC development process [95]: from research to practice 
Documentation of pharmaceutical interventions 
 Part 1: Development of PharmDISC Part 2: Validation of PharmDISC 
Stage Development Piloting Evaluation Implementation 
Methods 1. Exploratory 
trial: analysis of 
medication 
review protocols 
(modification of 
GSASA system 
to PharmDISC) 
2. Expert panel 
discussion 
1. Interrater reliability 
study 
2. Appropriateness, 
interpretability and 
validity study 
3. Face and content 
validity study  
1. Interrater reliability 
study 
2. Appropriateness, 
interpretability and 
validity study 
3. Acceptability and 
feasibility study 
1.Questionnaire 
(barriers, 
facilitators) 
Outlook: quick 
classification of 
frequent 
interventions  
Output Version 1.0 Version 1.1 Version 2.0 Version 2.1  
(e-Version) 
 
Development stage  
In the initial exploratory trial, we tested the suitability of the GSASA system in a community pharmacy 
setting. We analysed protocols of medication reviews (Polymedication-Check) provided by community 
pharmacists. Three investigators independently classified all reported PIs using the GSASA system. 
Based on the outcome of this exploratory trial as well as on findings from previous studies [4], we 
modified the GSASA system [81] to generate the PharmDISC system version 1.0 that was intended for 
use in the piloting phase. Furthermore, in an expert panel discussion with five community pharmacists 
and one hospital pharmacist, experiences using the new classification system were exchanged. 
Piloting stage  
The piloting stage combined a quantitative and qualitative approach in a mixed method study. It was 
performed within an academic environment to obtain first validation results and to further develop 
the PharmDISC system in preparation of testing the final version in the daily practice in community 
pharmacies. 
1. Interrater reliability study 
A total of 77 fifth-year pharmacy students received two hours of training and instructions on the 
PharmDISC classification form. The training started with two model PIs which were classified with the 
PharmDISC system using a voting web application. Another three model PIs were classified with the 
PharmDISC system to determine interrater reliability. All model PIs were taken from the literature [87] 
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and adapted to Swiss community pharmacy practice. Fleiss-Kappa coefficients Κ were calculated for 
the categories using a Microsoft Excel template [88]. Resulting Κ-values were interpreted according to 
Landis and Koch [89] as ‘almost perfect’ (Fleiss’ Κ 0.81-1.00), ‘substantial’ (0.61-0.80), ‘moderate’ 
(0.41-0.60), ‘fair’ (0.21-0.40), ‘slight’ (0.00-0.20), and ‘poor’ (<0.00) interrater reliability. As reported 
by Ganso et al, a Κ-value greater than 0.40 suggests a reliable system necessary for a relevant 
agreement in clinical practice [87]. 
2. Appropriateness, interpretability and validity study 
This prospective observational study aimed to validate the PharmDISC system in terms of 
appropriateness, interpretability and validity, and to evaluate its suitability in community pharmacy 
practice. The study design was based on a previous study that classified DRPs with a modified PCNE 
system [4]. The main outcome measure was the proportion of completely classified PIs. The 
classification was considered complete when all categories A-E (i.e. problem, type of problem, cause, 
intervention, communication and outcome) were filled in. Beside the PI classification, we recorded 
patient and prescription characteristics. We conducted this study during 6 weeks from February to 
March 2014 in 77 community pharmacies in which the 77 fifth-year pharmacy students from the 
interrater reliability study were conducting their one-year internship.  
Each of the 77 fifth-year pharmacy students was required to consecutively collect ten prescriptions 
necessitating a PI. The role of the students was to document the PI together with the pharmacists who 
performed the PI. Prescriptions of patients aged 18 or older were eligible if they contained at least two 
prescribed drugs, thereof at least one new prescription (new drug, altered dosage form and/or 
changed dosage). Prescriptions for contraceptives, not reimbursed by the Swiss health insurance, were 
excluded. Each case was documented with a short description, a copy of the prescription, and 
classification forms for each PI. This allowed the plausibility and coherence of the documentation to 
be verified and validated by the investigator in retrospect. Each PI classification was documented on a 
separate PharmDISC classification form. Statistical analyses were performed using IBM SPSS Statistics 
for Windows, version 22 (released 2013, Armonk, NY: IBM Corp). 
3. Face and content validity 
In a next validation step, we collected suggestions from experienced community and hospital 
pharmacists to establish face validity. For content validity, the pharmacists judged the extent as to 
which the PharmDISC system covered all of the relevant issues. 
We used the focus group technique as a method to explore the pharmacists’ opinions regarding the 
importance of PI documentation and to further develop the PharmDISC system. The focus group 
consisted of nine experienced pharmacists practicing in different institutions. The participants 
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consisted of six community pharmacists (three with previous experience using a classification system), 
and three hospital pharmacists who routinely work with a classification system during ward rounds. 
Participants were specifically chosen to include practicing and experienced pharmacists directly 
involved in patient medication management. 
The focus group was moderated by the associate professor ML (male, PhD, clinical pharmacist), an 
experienced qualitative researcher [42]. At the time of this study, the moderator worked with three of 
the participants. 
To familiarize with the PharmDISC system (version 1.0), the participants were first required to 
document a model PI. This PI was subsequently discussed in the focus group at the University of Basel 
in a seminar room. As shown in the predefined focus group framework (Fig. 1), the interview was 
structured in four questions. The opening question of the importance of documentation allowed the 
participants to express two to three reasons on paper sheets, which were discussed. In question 2, the 
core content, structure and order of the PharmDISC system were discussed to assess face and content 
validity. The participants had the possibility to accept, reject or revise each item with coloured voting 
cards. Two investigators counted and recorded the votes (DS, KH). An agreement of > 50% among the 
participants was counted as approval of the item. Question 3 discussed different levels of detail of the 
PharmDISC system depending on the PI complexity. Lastly, question 4 allowed identifying barriers and 
facilitators for the implementation of a classification system in the daily community pharmacy practice. 
The focus group lasted 2 hours 40 minutes and was recorded on audio tape, transcribed and 
anonymised as written text by an investigator (KM). Notes were taken during the interview by three 
investigators (KM, DS, KH). The transcripts were qualitatively analysed using an explorative theme 
analysis guided by the predefined framework and by using the software MAXQDA, version 12 (VERBI 
GmbH, Berlin, Germany). The transcripts were not returned to the participants for proof-reading, but 
were reviewed by a second investigator. The focus group was reported according to the Consolidated 
Criteria for Reporting Qualitative Research (COREQ) checklist [96]. 
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Fig. 1 Framework for the focus group interview 
 
Results 
Development stage 
We adapted the GSASA system to allow its application in community pharmacies [81]. Figure 2 
illustrates the changes that formed the PharmDISC system version 1.0, most of which were based on 
previous studies [4, 81] and the exclusion of hospital-specific items. The modification concerning the 
quality of prescribing was adopted from the modified PCNE system [4]. Further changes originated 
from the exploratory trial using the GSASA system and from protocols of medication reviews that were 
written by community pharmacists. From a total of 65 medication reviews, 190 PIs were documented 
(median of 3 PIs per review), all of which were classified with the GSASA system. The pharmacists 
intervened mainly for ‘patient counselling/training’ (n=69, 36.3%) and ‘optimisation of administration’ 
(n=45, 23.7%). However, the system did not provide detailed information on certain interventions. 
Therefore, we added two subcategories in category D, namely ‘application instruction (training)’, and 
‘delivery of a compliance aid incl. counselling’. Moreover, the expert panel of community and hospital 
pharmacists proposed three new subcategories and some optimisation in wording to improve the 
comprehension of the classification system. The resulting PharmDISC system (version 1.0) included 5 
categories (i.e. problem, type of problem, cause, intervention and outcome) and 52 subcategories. 
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Fig. 2 The PharmDISC system (version 1.0): The changes highlighted in grey text originate from expert panel 
discussions, in grey frames from modified PCNE system [4], in black frames from exploratory trial based on 
GSASA system and protocols of medication review performed in community pharmacy, in black text from 
evaluation of GSASA system) 
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Piloting stage 
1. Interrater reliability study 
The PharmDISC system (version 1.0) reached a substantial user agreement for the categories B 
(Κ=0.70) and D (Κ=0.76), while a moderate agreement for the categories A (Κ=0.53) and C (Κ=0.45) 
was obtained. All Κ-values of the five categories were above the threshold of 0.40 and are therefore 
considered at least moderate [87]. For the category E, the used template was not able to calculate a 
Κ-value because of the high relative agreement (P=0.96), which is described as an almost perfect 
agreement. 
2. Appropriateness, interpretability and validity study 
A total of 826 PI forms were analysed of which 101 were excluded due to deficient documentation or 
did not fulfil the inclusion criteria as shown in the data management flow chart in Fig. 3. Out of the 725 
(100%) usable PI classification forms, 39 (5.4%) could not be fully classified in all classification 
categories due to missing data or manually added subcategories. Data were missing mostly for the 
category A followed by the categories C and B, while categories D and E were always completed. A 
total of 25 new subcategories were manually added by the users. Most of these were added in the 
category C (n=15) especially concerning the price and generic substitution. In the category D, the 
proposed subcategories (n=6) mainly concerned the contact with the persons involved. 
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Fig. 3 Data management flow chart 
 
Based on the results and suggestions collected in this study, we created a refined version of the 
PharmDISC system (version 1.1, supplementary Fig.). Major changes between PharmDISC version 1.0 
(Fig. 2) and version 1.1 are shown in Table 2a. 
  
Total documented PI classification forms                   
(n=826) 
Analysed PI classification forms                       
(n=725) 100% 
Fully classified PI classification 
forms (n=686) 94.6% 
Excluded because of multiple 
choices set in one or more 
categories (n=47) 
Excluded because of not fulfilled 
inclusion criteria (n=54) 
Incomplete classification (n=14) 
Manually added subcategories  
(n=25) 
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Table 2 Comparison of the PharmDISC version 1.0 and version 1.1: major changes introduced following a) the 
appropriateness, interpretability and validity study, and b) the face and content validity study 
 PharmDISC version 1.0 (Fig. 2) PharmDISC version 1.1 (suppl. Fig.) 
a) Appropriateness, interpretability and validity study 
General   Wording “only one choice” per category A, 
B, C, D, F added 
Category C  Two subcategories added: 
C5.4 Financial burden 
C7.4 Formal/regulatory reason 
C8.1 Missing/ unclear package size/ 
therapy duration 
C8.2 Missing/ unclear dosage strength/ 
galenic form  
C8.5 Missing/ unclear dosage/ application 
instruction 
Three subcategories merged into: 
C7.1 Incomplete/ unclear prescription  
 
 
 
C8.3 Illegible prescription 
C8.4 Unclear drug name, although legible 
Two subcategories merged into: 
C7.2 Illegible prescription  
 C8.6 Missing prescription of necessary 
application aid(s) / complementary 
products. 
Reworded for clarity:  
C7.3 Missing prescription of necessary 
application aid(s) 
Category D D12 information to the physician Replaced by a checkbox to indicate if the PI 
was performed by the pharmacist alone or 
in collaboration with the physician 
b) Face and content validity study 
Category C C4 Drug use  
C5 Therapy duration  
Two subcategories merged into: 
C4 Drug use 
Category D  
D12 Information to physician 
D13 Clarification in patient notes 
Reworded for clarity:  
D11 Transmission of information 
D10 Clarification/ addition of information 
 D14 Report to pharmacovigilance centre Removed 
Category E  New category (between categories D 
Intervention and F Outcome) added:  
E communication: person(s) involved 
(multiple choice possible) 
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3. Face and content validity  
Nine pharmacists joined the focus group and were asked to express their opinion on the PharmDISC 
system (version 1.0) and the PI documentation. 
Question 1: The participants recognised the importance of documenting PIs. They believed that this 
may facilitate communication within the pharmacy team and with other healthcare professionals, 
allow traceability, improve the information-flow, and increase patient safety and quality of care. Most 
participants were of the opinion that by documenting PIs, thus making the pharmacist’s performance 
quantifiable, stronger arguments can be made in political discussions. Table 3 shows a compilation of 
the major emerging themes for Question 1. 
Table 3 Statements of experienced pharmacists illustrating and emphasising the importance for documenting PIs 
in the specified major themes from the focus group interview (Question 1). 
Theme  Example 
Communication Respondent (R) 9: “I have mainly listed communication. Precisely [documentation of 
intervention can] ease communication within the team, but also with other healthcare 
professionals. And I believe it is important to document, to facilitate or even standardise 
communication that everybody knows what we are talking about. That we understand each 
other.”  
Organisation R8: “We employ about 30 people with many in and out in our pharmacy with about 60-70% 
full-time job equivalent. It takes a lot of coordination, a lot of structure and every team that 
undergoes changes also needs to know what the other team has been doing. It’s very important 
that this is documented. Not only for the team, but also for the information flow, the 
documentation transfer e.g., to the doctors, to the team of the emergency department.” 
Traceability 
 
R3: “[Documentation is important to allow] reproducibility at a later date, that the same 
mistakes are not repeated, or that we do not have to struggle with the same problems.” 
Information-flow R5: “[Documentation is important] to enable a seamless information flow between the team 
and healthcare professionals.” 
R5: “It may well be that in the future, perhaps when the patient data would somehow be 
centralised, that we could eventually have access to this information.”  
Quality 
management  
R4: “We can perform statistics that we operate for ourselves and show a certain level of 
development. We see if there are certain trends. When we record everything, we can see if our 
interventions are beneficial or not, so we can optimize our practice in the long term.”  
Drug safety R6: “[Documentation could enable to] identify common and severe problems, to implement 
actions before, during and after the prescription to ensure safe and effective use of drugs.”  
Pharmacists’ 
performance  
R2: “[Documentation of intervention is important] to map the importance of our own work.” 
Quantifiability  R5: “As part of the development of a service society, our services will be fully recognisable and 
quantifiable.“ 
R1: “It is important that we can actually show everything we do. We do so much, but we cannot 
prove it. We just do it. But when a politician asks, well, what are you going to say. We cannot 
provide any figures on our daily interventions. But we simply do it. We really should also have 
data to show which situations always need an intervention at the pharmacy, and what we 
change, and what we optimise. Providing data in black and white from research projects or 
everyday life at the pharmacy is exceptionally important.” 
Politics R1: “This is a GMP principle: ‘If something is not documented, it has never been done.‘ This is a 
basis for political discussions to present the performance of the pharmacists and change the 
field. This could determine the quality management and the frequent interventions, we could 
draw any possible consequences from it.” 
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Question 2: The interview aimed to refine and validate the PharmDISC classification system (version 
1.0) leading to the creation of a new version (version 1.1, supplementary Fig). From a total of 51 
subcategories, 47 were accepted (92.2%, mean agreement 91%), 4 needed revision (7.8%), and none 
were rejected. The major change was the addition of a category ‘communication: persons involved’ 
(Table 2b). Pharmacist R9 suggested: “An entire category is missing. Communication or a blank space 
where in which you could write ‘I have discussed with the physician or the patient’”.  
Question 3: The pharmacists suggested to differentiate between types of PIs for the classification, in 
other words to align the classification level of detail with the complexity of the PI: 
R7: “It depends on the type of intervention. I have a pharmacy software with only pharmaceutical 
records that allows to briefly document interventions such as adjustment of drug package size with a 
line or with key words. In contrast, when I need to talk to two specialists for a dose adjustment, then a 
more precise documentation is necessary. It really depends on the complexity.” 
Question 4: The pharmacists suggested factors which could enhance the implementation of the 
PharmDISC system in daily community pharmacy practice. A notable suggestion was the automatic 
integration of the PI classification form into the patient file:  
R1: “It should be integrated into the software. That when you close the prescription assessment in your 
software, the question ‘Was there an intervention?’ pops up. This appears automatically and you have 
to choose ‘yes’ or ‘no’.” 
The pharmacists further discussed the involvement of pharmacy technicians to complement the 
pharmacists. This would require the team to be trained and a descriptive manual for the PharmDISC 
system. A person in charge should be determined who, besides analysing the obtained data, has the 
ability to motivate and teach the team how to use the PharmDISC system. This approach could 
facilitate the implementation of the PharmDISC system and overcome issues such as lack of motivation 
or understanding from team members: 
R6: “Someone who is responsible and who understands the importance of it. Every week he/she 
discusses the results with the team and sometimes he/she can bring an example.” 
R8: “There are some interventions, like delivery of adherence aid, which the pharmacy technician can 
carry out, and others, depending of the intervention type intervention, have to be handed over to the 
pharmacist.” 
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Discussion 
The findings of the study confirmed that the PharmDISC system was valid and reliable. Further 
qualitative results indicated an overall favourable acceptance of the system. This positively answered 
the research question, which was to investigate whether the PharmDISC system is suitable to classify 
PIs in community pharmacies.  
The PharmDISC system (version 1.0) reached good interrater reliability. The average user agreement 
was substantial (Κ=0.61). All Κ-coefficients of the classification categories were above the threshold 
of Κ=0.40, indicating that the results were widely independent of the observers and that the categories 
were mutually exclusive. Furthermore, the PharmDISC system reached higher interrater reliability than 
both, the GSASA system (Κ=0.53) [81] and the DOCUMENT system (Κ=0.53) [63]. This shows that the 
modifications made to the GSASA system were suitable for the community pharmacy setting. The study 
showed that the majority (94.6%) of the 725 PIs were completely documented with the PharmDISC 
system which demonstrated its clarity and completeness. These results demonstrated that the 
PharmDISC system fulfilled the requirements of a valid and reliable classification system. 
To our knowledge, this is the first development of a classification system that combines a quantitative 
and qualitative approach in a mixed methods study. Integrating data from different sources is a 
challenging and labour-intensive task, but the application of diverse methods provides in-depth and 
complementary information, and can compensate for inherent weaknesses in single study designs [97, 
98]. The Medical Research Council framework [95] proposed the application of diverse methodologies 
for each stage, which was the case in our piloting stage. Both, the observational study and interrater 
reliability study provided the quantitative baseline which was used in a qualitative phase to gain the 
pharmacists’ opinion using a focus group. Although only a limited number of highly motivated and 
qualified pharmacists participated in the focus group, the findings highlight the factors which positively 
influenced the PI documentation, while limited insight in possible opposing factors was addressed. 
The focus group confirmed the need for a classification system which is compatible with the electronic 
patient file by pointing out the importance of PI traceability. Similar observations in a survey with 
community pharmacies in the United States were made, in which the advantages of a computerised 
system compared with paper charts were highlighted [99]. Pharmacists wished to distinguish the type 
of intervention depending of the PI complexity. This could be solved by separating technical and clinical 
PIs. Technical PIs such (e.g. generic substitution) are routine and non-complex PIs that require little 
time expenditure as opposed to clinical PIs (e.g. dose adjustment). We also discovered that 
pharmacists are highly motivated to document PIs, as it provides a tangible proof of their work, 
improves the communication within the team and with other healthcare professionals, and maintains 
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quality management. They also mentioned that issues with the quality of PI documentation (e.g. 
repeated mistakes) could be improved by the analysis of frequent PIs. Conclusions of such analyses 
could be included in team training and learning. The increased visibility and transparency of PI-related 
activities by the pharmacist could provide strong arguments when negotiating a remuneration-based 
service for PI documentation, which is currently in effect in Australia with the DOCUMENT system [63]. 
Points for optimisation of the PharmDISC system were discovered in this study. The community 
pharmacists frequently misinterpreted the subcategory ‘information to the physician’ as the PI. 
Therefore, a clear distinction between the PI itself and the communication was needed. 
Communication was also a predominant topic discussed in the focus group, finally leading to the 
creation of a category ‘communication: person involved’ (e.g. introduction of a drug is correctly 
classified as ‘therapy started’ and not as ‘information to the physician’ although this PI needs 
communication with the physician, which is additionally documented in category ‘communication’). In 
Switzerland, the pharmacist is required to inform the prescriber in the case of any change in the 
prescribed medicines. In Germany, the validation study of the PI-Doc® system showed that the 
prescriber was contacted in 60.5% of the cases [54]. It could be more convenient to refer all patient to 
the prescriber once DRPs are detected. It seems that Swiss community pharmacists in most cases 
decide to initiate the intervention themselves, but in collaboration with the prescriber. With respect 
to the practice of pharmaceutical care, pharmacists should take responsibility for the patient’s drug-
related needs together with other healthcare professionals [100]. 
In this piloting stage of the project (Part 1), we refined and validated the PharmDISC system within an 
academic environment, where the PI documentation was performed by trained pharmacy students. 
The pharmacists understood the importance of PI documentation. The next step is to validate the 
herein established PharmDISC system (version 1.1) in real-life daily practice in community pharmacies. 
Therefore, Part 2 of the PharmDISC development process highlights the evaluation stage by performing 
an observational study with practicing community pharmacists, and enabling discussions of 
implementation aspects. 
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Conclusion 
The hospital-specific GSASA classification system for PIs was modified into the PharmDISC system for 
the application in community pharmacies. The PharmDISC system proved to be valid and reached 
substantial interrater reliability. Almost all PIs could be classified using the PharmDISC system. The 
system was refined based on the results from the piloting stage and the pharmacists’ suggestions, 
resulting in a final version which will be tested in an observational study with community pharmacists. 
As stated by the pharmacists, PI documentation should enhance traceability and information flow 
within team and with other healthcare professionals, improving so the visibility of pharmacists’ 
activities. Documentation can also have a teaching and learning effect and therefore increase quality 
and performance.  
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Supplementary Fig.: The PharmDISC system (version 1.1) 
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Abstract 
Rationale, aims and objectives During the dispensing process, pharmacists may come across technical 
and clinical issues requiring a pharmaceutical intervention (PI). An intervention oriented classification 
system is a helpful tool to document these PIs in a structured manner. Therefore, we developed the 
PharmDISC classification system (Pharmacists’ Documentation of Interventions in Seamless Care). The 
aim of this study was to evaluate the PharmDISC system in the daily practice environment (in terms of 
interrater reliability, appropriateness, interpretability, acceptability, feasibility, and validity); to assess 
its user satisfaction, the descriptive manual, and the online training; and to explore first 
implementation aspects. 
Method Twenty-one pharmacists from different community pharmacies each classified 30 
prescriptions requiring a PI with the PharmDISC system on five selected days within five-weeks. 
Interrater reliability was determined using model PIs and Fleiss’s kappa coefficients (Κ) were 
calculated. User satisfaction was assessed by questionnaire with a 4-point Likert scale. The main 
outcome measures were: interrater reliability (Κ); appropriateness, interpretability, validity (ratio of 
completely classified PIs/all PIs); feasibility, and acceptability (user satisfaction and suggestions). 
Results The PharmDISC system reached an average substantial agreement (Κ=0.66). Of documented 
519 PIs, 430 (82.9%) were completely classified. Most users found the system comprehensive [median 
user agreement 3 (2/3.25 quartiles)] and practical [3(2.75/3)]. The PharmDISC system raised the 
awareness regarding drug-related problems for most users (n=16). To facilitate its implementation, an 
electronic version that automatically connects to the prescription together with a task manager for PIs 
needing follow-up was suggested. Barriers could be time expenditure and lack of understanding the 
benefits. 
Conclusion Substantial interrater reliability and acceptable user satisfaction indicate that the 
PharmDISC system is a valid system to document PIs in daily community pharmacy practice. 
Key words 
Evaluation; healthcare; patient-centered care; medical error 
  
PROJECT B 
AN INTERVENTION ORIENTED CLASSIFICATION SYSTEM FOR THE COMMUNITY SETTING: THE PHARMDISC SYSTEM 
 
PhD Thesis Karen Maes 79 
 
Introduction 
The daily practice of pharmacists comprises a wide variety of interventions regarding drug-related 
problems (DRPs). The classification and documentation of pharmaceutical interventions (PIs) increases 
the pharmacists’ attention to the drug-related needs of patients, enhances counselling skills and 
improves pharmaceutical care [53]. It also highlights the pharmacists’ role in ensuring the safe use of 
medicines [54, 55]. Indeed, a prerequisite for high-quality pharmaceutical care is an effective 
documentation allowing the evaluation of the PI outcome [56]. In other terms, the documentation of 
care represents the evidence of practice [57]. It is therefore essential to be recorded in a standardised 
and structured manner.  
Once PIs are documented in the respective healthcare setting, the information exchange between the 
hospital and the community pharmacy and vice versa can often be challenging. Improving information 
exchange regarding PIs could enable a more efficient and safer transfer of patients between inpatient 
and outpatient care. An aligned classification system in both settings would facilitate a standardized 
documentation of PIs. Most existing classification systems focus on DRP enabling documentation of all 
DRPs (potential and manifest). However, in daily practice and especially in seamless care, only those 
DRPs become relevant that were also addressed through PIs. Therefore, we identified the need for a 
PI classification system in community pharmacies and created the Pharmacists’ Documentation of 
Interventions in Seamless Care (PharmDISC) system, adapted to an existing system used in Swiss 
hospitals [81]. This system allows a comprehensive classification of prescription-focused as well as 
patient-centered PIs. The PharmDISC system is intervention oriented and contains 6 categories 
(problem, type of problem, cause, intervention, communication, and outcome) and 53 subcategories 
for classification. The development process of the PharmDISC system was split into two parts and four 
stages following an established development framework (Table 1) [95]. Part 1 covered the 
development and the piloting stage and was reported separately [84]. In this piloting stage of the 
project, the PharmDISC system was refined and validated within an academic environment, where the 
PI documentation was performed by trained pharmacy students (n=77). To assess face and content 
validity, a focus group interview was performed and revealed that the pharmacists (n=9) understood 
the importance of PI documentation. The next step was to validate and evaluate the herein established 
PharmDISC system (version 1.1) in real-life daily practice in community pharmacies.[84] Hence, this 
publication is focused on Part 2 that includes the evaluation stage and implementation aspects. The 
validation of a classification system is necessary to confirm “through the provision of objective 
evidence, that the requirements for a specific intended use or application have been fulfilled” [101]. 
For evaluating patient-based outcome measures, Fitzpatrick et al. defined eight criteria to consider: 
appropriateness, reliability, validity, responsiveness, precision, interpretability, acceptability, and 
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feasibility. These measures are originally defined for the validation of DRP classification [68, 102], but 
they are without restriction applicable to a PI classification as well. 
Table 1 PharmDISC development process [95]: from research to practice 
Documentation of pharmaceutical interventions 
 Part 1: Development of PharmDISC Part 2: Validation of PharmDISC 
Stage Development Piloting Evaluation Implementation 
Methods 1. Exploratory 
trial: analysis of 
medication 
review protocols 
(modification of 
GSASA system 
to PharmDISC) 
2. Expert panel 
discussion 
1. Interrater reliability 
study 
2. Appropriateness, 
interpretability and 
validity study 
3. Face and content 
validity study  
1. Interrater reliability 
study 
2. Appropriateness, 
interpretability and 
validity study 
3. Acceptability and 
feasibility study 
1.Questionnaire 
(barriers, 
facilitators) 
Outlook: quick 
classification of 
frequent 
interventions  
Output Version 1.0 Version 1.1 Version 2.0 Version 2.1  
(e-Version) 
 
The aim of this study was to validate the PharmDISC system in the daily practice environment (in terms 
of interrater reliability, appropriateness, interpretability, acceptability, feasibility, and validity); to 
assess its user satisfaction, the descriptive manual, and the online training; and to explore first 
implementation aspects. 
 
Methods 
Setting 
A prospective observational study was conducted in Swiss community pharmacies to evaluate the 
practicability of the PharmDISC system (version 1.1) in daily practice and to validate it. This study was 
approved by the ethics committee of the Northwest and Central Switzerland (EKNZ:2014-102). The 
study coordination center was located at the University of Basel in the German-speaking part of 
Switzerland which collaborated with the community pharmacy of the Department of Ambulatory Care 
& Community Medicine, Lausanne, in the French-speaking part of Switzerland. All documents and 
study materials were available in German and French. The translation of the German PharmDISC 
system to the French version was based on a previous study [81]. All community pharmacists of the 
expert list for the state exams of the Universities of Basel and Lausanne/Geneva were contacted by e-
mail and asked to participate in the study. The aim was to recruit twenty pharmacists using 
convenience sampling. 
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Training 
The study participants completed an online training prior to PI documentation. The training consisted 
of two videos that were available from the online study platform. The first video was a fifteen-minute 
Microsoft Power Point Presentation narrated by a trainer that described the study procedure and 
material, and provided instructions for the correct use of the PharmDISC system. The second three-
minute video presented a role play demonstration of the documentation of a PI. The two model PIs 
[87], showed in the videos, were modified to suit the community pharmacy setting. The study 
documents were also available on the online study platform. 
Study 
The validation of the PharmDISC system (version 1.1) was performed in a stepwise approach: 
1. Interrater reliability  
To describe the extent of independent agreement between raters, interrater reliability was 
determined using three model PIs [87]. After online training, the model PIs were classified by each 
pharmacist prior to real-world data collection. Fleiss’s kappa coefficients (Κ) were calculated using a 
Microsoft Office Excel template [88]. Resulting Κ-values were interpreted according to Landis and Koch 
[89]as almost perfect (Κ=0.81-1.00), substantial (0.61-0.80), moderate (0.41-0.60), fair (0.21-0.40), 
slight (0.00-0.20), and poor (<0.00) agreement. A Κ-value greater than 0.40 suggests a reliable system 
necessary for a relevant agreement in clinical practice [87]. 
2. Appropriateness, interpretability and validity  
We measured appropriateness, interpretability, and validity of the PharmDISC system by assessing the 
ratio of completely classified PIs to all PIs. In addition, we collected users’ suggestions for optimization 
and comments on classification difficulties. Classification was considered completed when all six 
categories were filled in. Each participating pharmacist consecutively collected 30 prescriptions 
requiring a PI on five selected days within five weeks from March to April 2015. The dates chosen were 
communicated to the study center and each PI was classified on the same day as the prescription was 
collected. There were no inclusion criteria for the prescriptions. Each PI was documented with a short 
description, the anonymized prescription copy, a three-month medication history and the PI 
classification form. We developed a descriptive manual which defined the PharmDISC system with 
examples reflecting the community pharmacy practice (Table 4). This supported the users in the PI 
classification, thus increasing consistency and comprehensibility. All PI classification forms were 
validated and statistically analyzed using IBM SPSS Statistics for Windows, version 22 (released 2013, 
Armonk, NY:IBM Corp). 
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3. Acceptability and feasibility  
Feasibility and acceptability were evaluated with a 47-item online user satisfaction questionnaire 
(FlexiForm® version 2.6.9, University of Basel, Switzerland), which was split into four sections. In 
section 1 (18 questions), pharmacists expressed their opinion on the PharmDISC system. Most 
questions of section 1 were adapted from AbuRuz et al. [81, 86]. In section 2 (10 questions), the users 
evaluated the online training, in section 3 (6 questions) the descriptive manual, and in section 4 (13 
questions) the overall project. Most questions in sections 2-4 were adapted from the literature [103-
105]. Table 2 illustrates the evaluation framework, based on the four steps proposed by Kirkpatrick 
[106]: reaction (35 questions), learning (3), behavior (8) and results (1). The extent of the agreement 
was assessed by 4-point Likert scale (1=strongly disagree, 4=strongly agree). An option answer ‘no 
comment’ was also available. 
Table 2 Description of the evaluation steps, adapted from Kirkpatrick et al. [106] 
Step Description  example of a question/statement 
Step 1 
Reaction 
Evaluates the feelings of the participants, 
how well they liked and accepted the 
project/training. 
“The topics of the online training 
were relevant.” 
Step 2 
Learning 
Determines how much was learned. “After the online training I felt 
confident to use the PharmDISC 
system.” 
Step 3 
Behavior 
Evaluates if participants change their 
behavior after the project/training. 
 
“Classifying PIs in this study 
motivated me to document PIs in the 
future.” 
Step 4 Results Evaluates if the project/training had any 
influence on the results (e.g. increase in 
quality and/or quantity of production). 
“I intervene now more in the 
dispensing process of medicines 
than before the study.” 
 
In view of a future implementation of the PharmDISC system in community pharmacies, we surveyed 
the pharmacists about potential barriers and facilitators that influence implementation. We also 
obtained feedback from the pharmacists on the usefulness of the online training and the descriptive 
manual. The answers and comments were collected and qualitatively analyzed  
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Results 
We approached 57 community pharmacists (33 German-speaking and 24 French-speaking). Twenty-
one pharmacists (11 German-speaking and 10 French-speaking), all working in separate pharmacies, 
participated in the study (participation rate 36.8%). Their professional experience ranged from 3.0 to 
20.8 years. Twelve pharmacies were located in urban areas (57.1%) and nine in the rural areas (42.9%). 
Seventeen were independent pharmacies (80.9%) while four belonged to a pharmacy chain (19.1%). 
1. Interrater reliability  
Nineteen pharmacists classified three model PIs to assess the level of user-agreement for each 
category of the PharmDISC system (version 1.1) [Fig.1]. Two pharmacists did not participate in this part 
of the study due to time constraints. An overall substantial agreement (average Κ=0.66) was achieved 
for the classification categories A-E. Category E (Κ= 0.29) was the only category reaching a Κ-value less 
than 0.40. For the last category F ‘outcome’, the calculation template was not able to calculate a Κ-
coefficient because of the high relative agreement (P=1.00), describing an almost perfect agreement. 
 
Fig. 1 User-agreement based on three model PIs rated by 19 users for each classification category of the 
PhamDISC system expressed as Κ-coefficients. A Κ-value greater than 0.40 is considered necessary for a valid 
classification system. 
 
2. Appropriateness, interpretability, and validity  
To evaluate appropriateness, interpretability, and validity, the pharmacists classified prescriptions 
requiring a PI on five days within five weeks. Table 3 illustrates a typical PI performed in community 
pharmacy. A total of 535 PIs from 365 prescriptions were documented by 21 pharmacists. Sixteen PIs 
were excluded because they were either not drug-related or data validation was not possible. Of 519 
analyzed PIs, 430 (82.9%) were completely classified in all categories (Table 4). In 89 cases (17.1%), the 
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instructions for the completion of the PI classification form were not respected (i.e. categories with no 
data and/or statement for optimization such as new subcategories). Categories with no data (n=64, 
12.3%) were observed in the categories A (n=26), B (n=25), and other categories (n=13). 
The pharmacists proposed 19 new subcategories to address classification difficulties they encountered 
and provided 16 statements for optimization in a free text box. The proposed subcategories were 
mainly related to technical issues (prescription error [n=9], technical/formal problems [n=8], financial 
burden for the healthcare system [n=2]) for which the classification in category A was challenging. 
 
Table 3 Illustration of a typical PI classified in this study in a community pharmacy with the PharmDISC system 
The pharmaceutical intervention The classification PharmDISC 
Category                  Subcategory 
A mother visited the pharmacy with a prescription 
for her 18-month old daughter. One measuring 
spoon (=5 mL) Dextromethorphan syrup was 
prescribed 2 to 3 times daily. 
A Problem  
 
A3 safety of treatment  
B Type of 
problem 
B2 potential, 
preventive  
During the dispensing process, the pharmacist 
noticed that the dose of Dextromethorphan is too 
high for this age (<2 years old).  
C Cause of the 
Intervention  
C3.2 Overdose  
 
The pharmacist adjusted the dose according to the 
Swiss drug formulary to a half measuring spoon 
(=2.5 mL) twice daily in the morning and the 
evening. 
D Intervention D1 Dose adjustment  
 
The mother accepted the dose adjustment and 
thanked. 
E Communication 
F Outcome of 
intervention  
E4 Patient/relatives  
F1 Accepted and 
implemented 
.
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Table 4: Descriptive manual of the PharmDISC system for the documentation of PIs with examples, and with frequencies [n=430 PIs] (bolded text added to version 2.0, italicised 
text modified to version 2.0) 
Code Category Code Subcategory Subcategory description Example Frequency n (%) 
 
 
A Problem 
(1 choice)  
A1 Treatment effectiveness Any problem or circumstance which may modify the 
effectiveness of a medication (type of problem: potential), 
or any signs or symptoms (type of problem: manifest) 
suggesting lacking or unsatisfactory effectiveness 
No effect of the quinolone therapy due 
to formation of non-absorbable 
complexes with multivalent cations 
(e.g., Ca2+, Mg2+) 
172 (40.0%) 
A2 Untreated indication Preventive, therapeutic, or concomitant medication not 
prescribed for a valid indication 
No laxative prescribed together with 
opioid therapy 
8 (1.9%) 
A3 Safety of treatment Any problem or circumstance which may expose the patient 
to an increased risk for an adverse drug event (type of 
problem: potential) or any signs or symptoms (type of 
problem: manifest) suggesting a lacking or unsatisfactory 
medication safety 
Risk of torsades de pointes due to 
combination of amiodarone and 
clarithromycin 
98 (22.8%) 
A4 Treatment costs Any issue associated with the cost of a drug treatment 
(e.g., high price, reimbursement, cost-effectiveness, 
patient’s economic situation, generic substitution) 
Switch original product to generic 
(generic substitution) because of 
lower treatment costs 
53 (12.3%) 
A5 Patient dissatisfaction / 
problems 
Any complaint or concern regarding drug therapy expressed by 
the patient or the caregivers/relatives 
Patient complains about high number of 
prescribed drugs, about swallowing 
difficulties, lack of information, etc. 
99 (23.0%) 
  A6 Technical / formal problem Any problem regarding the pharmacy logistics, the prescription 
quality or other technical and formal problem 
The pharmacy does not have the 
prescribed drug in stock. 
The drug dosage was missing on the 
prescription. 
- 
B         Type of problem 
           (1 choice)   
B1 Manifest, reactive Patient shows signs or symptoms of an adverse drug event, 
therapy failure or non-treatment. Problem is present  
reactive, corrective intervention 
Occurrence of vaginal mycosis after 
antibiotic therapy 
192 (44.7%) 
 B2 Potential, preventive  Patient is at risk for an adverse event but does not present signs 
or symptoms of adverse clinical outcomes.  
Problem is in the future  preventive intervention 
Loss of cardio protective effect of 
acetylsalicylic acid (ASS) in combination 
with ibuprofen causes an increased risk 
for myocardial infarction 
238 (55.3%) 
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Code Category Code Subcategory Subcategory description Example Frequency 
C Cause of 
 intervention 
                (  h ) 
 
Therapy choice 
 
67 (15.6%) 
 Clinical cause C1.1 No concordance with 
guidelines, only suboptimal 
therapy possible 
Drug selection does not comply with treatment guidelines. Contrary to the guidelines, ASS is not 
prescribed in a patient after myocardial 
infarction. 
13 (3.0%) 
C1.2 Contraindication Patient has a contraindication to the therapy due to his medical 
conditions. 
Metformin contraindicated in patient 
with renal failure. (Creatinine clearance 
<30 ml/min). 
3 (0.7%) 
C1.3 Interaction Combination of a drug with another drug or with food 
representing a potential or manifest negative outcome. 
Calcium in combination with 
levothyroxine 
25 (5.8%) 
C1.4 Drug not indicated Drug use without an indication. PPI continued although anticoagulation 
therapy was stopped. 
4 (0.9%) 
 C1.5 Duplication Inappropriate use of two drugs from the same therapeutic 
class. 
Combination of ACE inhibitor and 
angiotensin receptor blocker. 
Original and generic drug concomitantly 
prescribed. 
11 (2.6%) 
 C1.6 Adverse effect Response to a drug that is noxious and unintended and occurs 
at doses normally used in man for the prophylaxis, diagnosis or 
therapy of disease, or for modification of physiological function. 
Symptoms of myalgia under statin 
therapy.  
8 (1.9%) 
C1.7 Missing patient documentation Lack of patient information in case notes / laboratory results. Allergies not reported in patient cases. 3 (0.7%) 
Drug choice 20 (4.7%) 
C2.1 Inappropriate dosage form / 
administration route 
Wrong drug administration route or method, or wrong form, or 
incompatibility. 
Sustained release tablets crushed for the 
administration through feeding tube. 
20 (4.7%) 
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Code Category Code Subcategory Subcategory description Example Frequency 
 Dose choice 40 (9.3%) 
 C3.1 Underdose Prescribed dose too low Pantoprazole 20 mg in acute duodenal 
ulcer. 
19 (4.4%) 
C3.2 Overdose Prescribed dose too high Prescribed dose of acetaminophen 
exceeds maximal daily dose. 
20 (4.6%) 
C3.3 Inappropriate monitoring Inappropriate process of observing, recording and detecting the 
effects or safety of a therapy, incl. therapeutic drug monitoring 
(TDM). 
No thyroid hormones control in 
substituted hypothyroidism. 
0 (0.0%) 
C3.4 Dose not adjusted to organ 
function (e.g., renal/liver 
failure, age) 
Dose adjustment required due to organ impairment (renal/liver 
failure, etc.) or advanced age. 
High dose allopurinol (300 mg/d) was 
prescribed daily in renal impairment. 
1 (0.2%) 
 Drug use 50 (11.6%) 
 C4.1 Inappropriate timing or 
frequency of administration 
Wrong timing of drug intake regarding circadian rhythm or food 
intake, or no respect of the dosing interval. 
Bisphosphonate intake with breakfast; 
Nitrate-free period for nitroglycerin patch 
is too short. 
16 (3.7%) 
 C4.2 Inappropriate application Misapplication / incorrect use of drug, e.g., with an application 
aid. 
Application of an asthma inhaler without 
prior shaking the aerosol. 
18 (4.2%) 
 C4.3 Inappropriate therapy duration Duration of therapy too long or too short Too long application of a cortisone cream 
after healing. 
Too short treatment with amorolfine 
(Loceryl) for nail mycosis. 
16 (3.7%) 
 Patient 114 (26.5%) 
  C5.1 Insufficient adherence Patient does not take his medication as prescribed. Patient forgot to intake a prescribed drug. 9 (2.1%) 
  C5.2 Insufficient knowledge Patient lacks information about their medication or disease. Patient does not know how to use an 
asthma device. 
30 (7.0%) 
  C5.3 Concerns about the treatment Patient is concerned about his/her treatment.  Patient is concerned about the number of 
prescribed drugs. 
26 (6.0%) 
  C5.4 Financial burden (Patient / 
public health) 
The costs of treatment are a financial burden for the patient or 
the public health. 
The original product is substituted by a 
generic drug. 
49 (11.4%) 
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Code Category C
 
Subcategory Subcategory description Example Frequency 
 Technical cause  
Logistics 
 
  61 (14.2%) 
  C6.1 Prescribed drug not available Drug not in stock, drug shortage or any other logistic problems 
in drug provision. 
Drug is currently undeliverable and is not 
in stock at the wholesaler. 
53 (12.3%) 
  C6.2 Error in medication process Any error appearing during drug prescription, transcription, 
distribution or administration. 
Erroneous delivery of an incorrect dosage 
strength or wrong package size. 
8 (1.9%) 
 Prescription quality 78 (18.1%) 
  C7.1 Incomplete / unclear 
prescription 
Missing or unclear information on the medical prescription. The dosage is not specified on the 
prescription. 
59 (13.7%) 
  C7.2 Illegible prescription The writing on the prescription is illegible. The drug name is illegible. 4 (0.9%) 
  C7.3 Missing prescription of 
necessary application aid(s) 
The necessary tools for the correct drug application are not 
prescribed. 
Missing spacer for a steroid-containing 
metered dose inhaler 
4 (0.9%) 
  C7.4 Formal / regulatory reason Formal or regulatory errors concerning prescription. Oxycodone was not prescribed on a 
special prescription for narcotic 
substances; 
forged prescription 
11 (2.6%) 
D Intervention 
(1 choice) 
D1 Substitution Replace a drug by another for the same therapeutic indication. Switch from esomeprazole to 
pantoprazole. 
132 (30.7%) 
  D2 Dose adjustment Adjust drug dose or therapy duration regarding medical and 
personal conditions. 
Adjust acetaminophen dose relative to 
the body weight of an infant. 
57 (13.3%) 
  D3 Adjustment of package size / 
quantity 
Adjust package size or the number of package. Delivery of two packages of antibiotic 
suspension in order to ensure a sufficient 
therapy duration 
30 (7.0%) 
  D4 Optimisation of administration 
/ route 
Change the treatment plan to suit patient or to optimise drug 
response, regarding e.g., meal interval, posture, fasting intake, 
swallowing difficulties.  
Find an appropriate drug administration route. 
Recommend bisphosphonate intake on 
empty stomach and in upright position. 
Switch intravenous antibiotic therapy to 
oral therapy. 
47 (10.9%) 
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Code Category Code Subcategory Subcategory description Example Frequency 
  D5 Therapy stopped / no delivery Withdraw a drug without substitution by another drug; or drug 
is not delivered. 
Stop proton pump inhibitor (PPI), which 
was prescribed without indication/risk 
factors. 
15 (3.5%) 
  D6 Therapy started / continued Introduce a drug to the treatment plan. Start laxative therapy with concurrent 
opioid analgesics. 
26 (6.0%) 
  D7 In-depth counselling of patient Comprehensively advise the patient about his/her medications 
or diseases. 
Counsel patient on drug indication to 
increase the acceptance of a regular 
application. 
39 (9.1%) 
  D8 Application instruction 
(training) 
Train and educate patient on the correct use of prescribed 
medicines. 
Instruct on the use of an asthma device 
following misapplication. 
14 (3.3%) 
  D9 Delivery of adherence aid incl. 
counselling 
Deliver an adherence aid and advise patient to improve 
adherence/compliance. 
Instruct and deliver a weekly pill 
dispenser following adherence problems.  
2 (0.5%) 
  D10 Clarification / addition of 
information 
Clarify, complete or correct information in patient notes. Add new diagnosed penicillin allergy in 
patient notes. 
48 (11.2%) 
  D11 Transmission of information Report/communicate information to the patient or other health 
personnel regarding medications or diseases. 
Communicate an adverse drug reaction in 
a report to the physician. 
16 (3.7%) 
  D12 Proposition of therapy 
monitoring 
Initiate the observation, record, or detection of the effects of a 
drug administered to an individual, by indication of safety or 
efficacy, incl. TDM. 
Recommend regular blood pressure 
measurement; increased blood glucose 
measurements by patient after dose 
adjustment of insulin. 
4 (0.9%) 
E  
 
Communication: 
involved person  
E1 Nobody Pharmacist intervenes in an independent manner without 
consultation. 
Complete the patient case record with 
the information on drug allergy. 
59 (13.7%) 
          Except pharmacist 
 (Multiple choice  
possible) 
 
E2 Physician Communication with physician. Pharmacist consults the 
physician to intervene.  
Recommend the physician to start a 
therapy with a PPI, to reduce the 
gastrointestinal bleeding risk under 
anticoagulation treatment. 
138 (32.1%) 
E3 Caregiver / home care Communication with caregiver/home care. Pharmacist involved 
the nursing staff, care giver or home care in an intervention. 
Remind the caregiver to administer 
levothyroxine under fasting conditions. 
14 (3.3%) 
E4 Patient / relative Communication with patient/relative. Pharmacist involved the 
patient or relative in an intervention. 
The patient agreed to switch the original 
product to generic drug. 
294 (68.4%) 
PROJECT B 
AN INTERVENTION ORIENTED CLASSIFICATION SYSTEM FOR THE COMMUNITY SETTING: THE PHARMDISC SYSTEM 
 
PhD Thesis Karen Maes 90 
 
Code Category Code Subcategory Subcategory description Example  
F Outcome of 
Intervention 
(1 choice) 
F1 Accepted and 
implemented 
Recommendation of intervention approved by the person 
involved and implemented. 
Drug without indication is stopped (e.g., 
discontinuation of PPI after a treatment 
with NSAID). 
381 (88.6%) 
  F2 Partially accepted or 
accepted without 
implementation 
Recommendation of intervention partially approved by the 
person involved but not implemented or not possible to 
implement. 
Discontinuation of a PPI without 
indication: physician approved the 
recommendation with good cause, but 
he/she does not have plausible 
explication for PPI therapy (e.g., reflux) or 
physician accepted the recommendation 
but not the patient. 
12 (2.8%) 
  F3 Not accepted The person involved does not agree with the recommendation. Drug without indication is 
continued without clarification. 
16 (3.7%) 
  F4 Not known Outcome of intervention not known. No feedback after written 
recommendation. 
14 (3.3%) 
  F5 Not applicable Intervention needing no approval or implementation. Information given to the physician. 7 (1.6%) 
  Short case description / 
comments 
- - Free text comments or place for a description of the case. Dextromethorphan dose too high 
(5ml, 2-3 times/day) for an 18-
month child, dose reduction to 
twice daily in the morning and the 
evening a half measuring spoon 
(=2.5 mL). Accepted. 
- 
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3. Acceptability and feasibility  
Acceptability and feasibility were evaluated with a 47-item questionnaire on user satisfaction. Eighteen 
pharmacists (return rate 85.7%) expressed their opinion on the PharmDISC system and this study. 
Three pharmacists did not respond due to time constraints and holidays. The results of the four 
sections of the questionnaire are provided below. 
Section 1, evaluation of the PharmDISC system: Most users found the PharmDISC system 
comprehensive [median user agreement 3(2/3.25 quartiles)], practical [3(2.75/3)] and were in general 
satisfied [3(2/3)] (Fig. 2). Time expenditure was considered adequate [3(2.75/4)]. Most pharmacists 
showed willingness to use the system once integrated in pharmacy software [4(3/4)]. 
Fig. 2 Pharmacists’ satisfaction with the PharmDISC system, n=18; all questions belonged to Step 1 “Reaction” 
 
Within the questionnaire, pharmacists proposed optimisations that triggered a few changes to the 
PharmDISC system as illustrated in Table 2. The version 2.0 comprised 6 categories and 54 
subcategories (Fig. 3). 
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1) The PharmDISC system is complete and allows the
classification of all DRPs I identified
2) The PharmDISC system is easy to use and practical
in daily life
3) Overall I am satisfied with the PharmDISC system
4) The time needed for the classification with the
PharmDISC intervention sheet is adequate
5) The PharmDISC system would be an adequate basis
for documenting pharmaceutical interventions
6) The PharmDISC classification system is useful for
my work
7) I would use the PharmDISC system in future in my
daily work if it were integrated in pharmacy software
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Fig. 3 The PI classification form of the PharmDISC system (version 2.0) 
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Section 2, evaluation of the online training: The pharmacists were very satisfied with the online training 
[4(3.5/4)] (Fig. 4). One pharmacist suggested that it would have been helpful to have a printed version 
of the online training. 
Fig. 4 Pharmacists’ satisfaction with the online training, n=18; all questions belonging to Step 1 “Reaction”, 
except questions 4-5 to Step 2 “Learning”. 
 
Section 3, evaluation of the descriptive manual: According to the pharmacists’ opinion, the descriptions 
and examples of the descriptive manual (Table 4) were helpful [4(3/4)] and relevant [4(3/4)]. The 
pharmacists were overall satisfied with the manual [4(3/4)] and its length was generally considered 
adequate [4(3/4)], while some wished for more examples. 
Section 4, evaluation of the overall project: All participants recognized the importance of PI 
documentation [4(4/4)]. Classifying PIs motivated the pharmacists to document PIs in the future 
[3(3/4)]. They believed that they did not intervene more during the dispensing process than prior to 
the study [2(2/2.5)]. However, through documenting their PIs, sixteen pharmacists agreed that they 
became more aware of what they were accomplishing in daily practice [3(3/4)]. 
To facilitate the implementation of the PharmDISC system, the pharmacists wished for an electronic 
version with additional functionalities such as an automatic connection to the prescription, a task 
manager for PIs needing follow-up and a section for comments. Barriers for implementation 
mentioned by the pharmacists were time expenditure, lack of understanding of the benefits and 
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1) The topics of the online training were relevant
2) The length of the online training was adequate
3) The tempo of the online training was adequate
4) I understood how to use the PharmDISC system
5) After the online training I felt confident to use
the PharmDISC system
6) The online training was easy to use
7) The online training was more practical than
frontal teaching
8) Overall I was satisfied with the online training
number of pharmacists
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missing persistent motivation of the whole pharmacy team to systematically document all PIs. A 
pharmacist commented: “Pharmacy staff perform lots of interventions without realizing it. A raised 
awareness of the intervention undertaken in daily practice and a change in behavior/habits is needed.” 
 
Discussion 
The two-phase development process of our intervention oriented classification system (named 
PharmDISC) followed a translational approach by adapting the existing hospital-specific PI system to 
the requirements of community pharmacies.[81, 84] In this second development phase, we validated 
the PharmDISC system by means of interrater reliability, appropriateness, interpretability, 
acceptability, feasibility, and validity and explored first implementation aspects. 
With the PharmDISC system version 1.1, we demonstrated favorable interrater reliability for all but 
one classification categories (average Κ=0.66), that was on average higher than previously obtained 
with version 1.0 (average Κ=0.61) [84]. This improvement was likely due to refinements in the updated 
version as well as the introduction of the descriptive manual that may have facilitated PI classification. 
For the DOCUMENT system, a recently validated system for DRPs and clinical interventions in 
community pharmacies [63], a moderate level of agreement (Κ=0.53) was found while the PharmDISC 
system reached a substantial agreement. 
The validation study showed that the PharmDISC system was suitable to document PIs in community 
pharmacies, with 82.9% of PIs completely classified in all categories. Throughout the validation phase, 
the participating pharmacists provided valuable comments that were evaluated in terms of frequency 
and relevance. Selected comments led to further modifications of the PharmDISC system (e.g. 
rewording of category E Communication to increase clarity because of the low Κ-value). Other 
comments related to classification issues, where the PIs were nonetheless correctly classified, were 
disregarded. 
One strength of this study is that because the validation was performed in two regions of Switzerland 
with different languages and cultures, we expect that the PharmDISC system would be suitable for 
other countries. Moreover, different methods for the validation were used, according to the validation 
criteria proposed by Fitzpatrick [68]. The main limitation was the inclusion of highly motivated and 
qualified pharmacists to participate in the study. To foster its generalizability, the PharmDISC system 
should be further tested in studies enrolling a broader range of community pharmacists. The ongoing 
studies using the PharmDISC system by other research groups are consequently very welcomed. 
Furthermore, the pharmacists stopped documentation after 30 PIs instead of documenting all 
interventions triggered by 30 prescriptions as required in the study protocol, suggesting that this 
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instruction was not clear enough. In addition, we were not able to ensure that the collection of 
prescriptions was done consecutively, and there might have been a selection bias.  
Although all validation results of the PharmDISC system fulfilled the requirement for an acceptable 
classification system, its implementation into the daily routine of a community pharmacy remains a 
challenge. However, we expect that the PharmDISC system is viable for future implementation for 
several reasons: 
a) In contrast to the classification of manifest or potential DRPs, which require an interpretation by the 
practitioner, the PharmDISC system is focused on the documentation of actual PIs allowing for an 
objective assessment. 
b) The PharmDISC system offers a flexible and comprehensive classification system for PIs of varying 
complexity that, consequently, is able to capture both prescription-focused as well as patient-centered 
PIs. Cipolle et al. proposed both focus points to be accounted for in medication management services; 
the prescription-focused approach is linked to the dispensing process, while the patient-centered 
approach is based on pharmaceutical care practice [107]. In the PharmDISC system, the complex and 
time-consuming patient-centered aspects are related to clinical issues, while the less complex PIs are 
related to technical issues. 
c) The descriptive manual, rated as helpful and relevant, provided clear definitions of PIs which should 
have aided in uniformly classifying PIs, another requirement for classification systems [61]. 
d) The pharmacists noted that with increasing familiarity with the PharmDISC system over the course 
of the study, the faster and more comprehensive their PI classification became. 
e) Little time was necessary for the pharmacists to get accustomed with the PharmDISC system. This 
correlated with the pharmacists’ positive opinion on the use of the PharmDISC system. Furthermore, 
most pharmacists were willing to use the system, but only once integrated into the pharmacy software. 
This determined the need for a computerized classification system. 
f) The online training was appreciated by the pharmacists. It is therefore important to offer online 
training to any future user of the PharmDISC system. 
g) The documentation of PIs may raise the awareness for DRPs and consequently increase the 
intervention rate and patient safety. It has been reported that PI documentation makes pharmacists 
more attentive regarding the patients’ drug-related needs and enhances the development of 
counseling skills and pharmaceutical care [53]. 
With respect to seamless care, an electronic PI classification in hospitals (e.g. for Switzerland with the 
GSASA system [81]) and in community pharmacies (with the PharmDISC system) could in future 
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facilitate the exchange of information between both settings. Such an exchange is known to ensure 
continuity of care, communication between healthcare professionals, safe transfer of information and 
patient safety [108, 109]. A Belgian study showed that their newly developed discharge medication 
plan was rated as valuable for the continuity of care by community pharmacists, however, they 
requested additional information such as medication modifications [110]. This is covered with the 
PharmDISC system as such additional information is included. 
Next steps towards implementation will include further descriptive analyses on the nature of common 
PIs with the aim to develop an electronic quick classification with a variety of prefilled classification 
forms. This could save time and improve the quality of PI documentation, which would further facilitate 
the implementation in community pharmacies. Quick classification combined with the descriptive 
manual and the online training would optimally facilitate the implementation. Currently, the 
PharmDISC system is used in several studies in Switzerland and in Belgian to further test its 
practicability in different situations, which may lead to modifications of the PharmDISC system specific 
to the setting. 
 
Conclusions 
Substantial interrater reliability and high rating of acceptability and feasibility indicates that the new 
PharmDISC system is a valid system for PI documentation in community pharmacy practice. The 
pharmacists were satisfied with the system and considered it helpful, easy to use, and practical for 
daily work. They appraised the fact that by using an intervention oriented classification system, their 
awareness of DRPs and consequently the intervention rate increased. 
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Abstract 
Background: During dispensing of prescribed medicines, pharmacists frequently encounter technical 
and clinical problems that require a pharmaceutical intervention (PI). 
Objective: To describe the PIs during dispensing of prescribed medicines in community pharmacies, 
and to investigate patient-reported problems with the prescribed medicines. 
Method: Twenty-one pharmacists each collected 30 prescriptions requiring a PI on five selected days 
within a five-week period. All PIs were classified using the PharmDISC system. 
Results: Of all 430 PIs, 242 PIs (56.3%) had a clinical cause and 188 PIs (43.7%) a technical cause. 
Patient-reported problems (n=99, 23.0%) were common. Pharmacists mainly intervened to substitute 
a drug (n=132, 30.7%), adjust a dose (n=57, 13.3%), and clarify/complete information (n=48, 11.2%). 
In 138 (32.1%) cases, the pharmacists contacted the prescriber whereas in 292 cases (67.9%), only the 
pharmacist was involved (alone n=59, with the patient n=222, with the caregiver n=11). A total of 243 
PIs (56.5%) resulted in a change of the prescription. The implementation rate of PIs reached 88.6%. 
Conclusion: During dispensing, pharmacists performed individualised PIs to solve or prevent drug-
related problems concerning prescribed medicines. The high frequency of PIs following patient-
reported problems highlight the importance of direct patient-pharmacist interaction when dispensing 
prescribed medicines. 
Impact of findings on practice statements 
• Pharmacists, as one of the last healthcare professionals interacting with patients prior to 
medication, add a relevant contribution in improving treatment outcomes by intervening in 
DRPs, particularly during the dispensing of prescribed medicines. 
• Direct contact between pharmacists and patients during dispensing is essential to reveal the 
patient’s problems, concerns or dissatisfaction with prescribed medicines. 
Key words 
Pharmaceutical intervention; drug-related problem; community pharmacy practice; pharmaceutical 
care; classification system 
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Introduction 
During the dispensing of prescribed medicines, community pharmacists frequently encounter 
technical and clinical issues resulting in a pharmaceutical intervention (PI). A PI is defined as a 
recommendation initiated by a pharmacist in response to a drug-related problem (DRP) in an individual 
patient occurring in any phase of the medication process [81]. In a medicines optimisation approach, 
the ultimate goal of pharmacists is to improve treatment outcomes. This is achieved by the exploring 
the patients’ experience, to choosing evidence based medicines and ensuring that the overall therapy 
is as safe as possible [111]. The pharmacist’s professional knowledge is essential to perform PIs aimed 
to improve pharmacotherapy and facilitate the collaboration with the patient and/or with other 
healthcare professionals [112]. The PI documentation could highlight the pharmacists’ activities that 
include proactively identifying, solving, and preventing DRPs during dispensing in community 
pharmacies [113, 114]. 
In prior research, we identified the need for a classification system for community pharmacies focusing 
on PIs. We subsequently developed and validated the Pharmacists’ Documentation of Interventions in 
Seamless Care (PharmDISC) system [85]. While the frequency and nature of DRPs detected in 
pharmacy practice have been exhaustively described [6], little is known on how community 
pharmacists handle these DRPs and how they intervene for patient-reported problems. Therefore, we 
performed a subanalysis with data from the PharmDISC validation study [85]; the documented PIs from 
that study allowed reliable and consistent analyses. 
 
Aim of the study 
The aim of this study was to describe PIs performed by community pharmacists during the dispensing 
of prescribed medicines and to investigate their response to patient-reported problems. 
 
Ethical approval 
This study was approved by the ethics committee of the Northwest and Central Switzerland 
(EKNZ:2014-102). 
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Method 
A prospective observational study was conducted in Swiss community pharmacies. The study design 
has been described previously [85]. Each pharmacist consecutively collected 30 prescriptions requiring 
a PI on five selected days within five weeks in March and April 2015. The PIs were classified with the 
PharmDISC system [85], allowing information to be recorded with respect to the problem, type of 
problem, cause, intervention, persons involved, and outcome. In addition to the PharmDISC 
documentation (PI classification form), a short description, an anonymised prescription copy, and a 
three-month medication history were collected. All documentation was checked for consistency and 
plausibility for each PI. A descriptive manual and an online training were available for the participants 
[85]. The data were analysed using IBM SPSS Statistics for Windows, Version 22 (Armonk, NY:IBM 
Corp). 
Results 
Twenty-one (11 German-speaking and 10 French-speaking) pharmacists participated in the study. Of 
the 519 PIs documented with the PharmDISC system, 430 (82.9%) were completely classified in all 
categories. Eighty-nine PI classification forms did not fulfil all requirements for a complete classification 
and were therefore excluded from the analysis. 
The patients for which a PI was documented were mostly female (n=233, 63.8%) regular customers 
(n=269, 81.1%) with a mean age of 55.9±23.5 years. The number of medicines per prescription ranged 
from 1 to 21 (mean 3.4±3.3). The 430 eligible PIs originated from 365 prescriptions (mean 1.2±0.48 PIs 
per prescription, range 1-4). Of these, 313 (85.8%) PIs were ambulatory, 45 (12.3%) based on a hospital 
discharge and 7 (1.9%) unknown. 
The problems triggering PIs comprised treatment effectiveness (n=172, 40.0%), patient-reported 
problems (n=99, 23.0%), safety of treatment (n=98, 22.8%), treatment cost (n=53, 12.3%) and 
untreated indication (n=8, 1.9%). The cause of the PI was clinical for 242 PIs (56.3%) and technical for 
188 PIs (43.7%). The pharmacists mainly intervened to substitute a drug (n=132, 30.7%), adjust a dose 
(n=57, 13.3%), and clarify/complete information (n=48, 11.2%) [Table 1].  
Pharmacist-prescriber interaction was necessary in 138 (32.1%) cases, whereas the pharmacist alone 
was involved in 292 (67.9%) of PIs (alone n=59, with the patient n=222, with the caregiver n=11). 
Overall, 243 PIs (56.5%) resulted in a change of the prescription. PIs were in 88.6% cases approved by 
the involved person and consequently implemented. 
The number of medicines per prescription increased with the age (correlation r=0.233, p<0.001) and 
also with the number of PIs per prescription (r=0.236, p<0.001).
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Table 1 Most frequent pharmaceutical interventions (n=430) on prescribed medicines in community pharmacies and their clinical or technical cause  
 Intervention n (%) Cause n (%) Problem n (%) Outcome n (%) Example 
 
 
 
 
Clinical 
n=242 
 
Substitution  
 
34 
(14.0) 
Inappropriate 
dosage form/admin 
8 
(23.5) 
Patient dissatis-
faction/ problem 
8 
(100.0) 
Accepted and 
implemented 
8 
(100.0) 
Patient preferred to take ibuprofen tablets instead of pellets. 
Pharmacist substituted the dosage form. 
Concerns about 
treatment 
9 
(26.5) 
Patient dissatis-
faction/ problem 
7 
(77.8) 
Accepted and 
implemented 
7 
(100.0) 
A patient with generalised itching did not tolerate the newly 
prescribed dimetindene gel, the pharmacist proposed 
dimetindene drops. 
 
Dose adjustment 
 
47 
(19.4) 
Underdose 17 
(36.2) 
Treatment 
effectiveness 
13 
(76.5) 
Accepted and 
implemented 
12 
(92.3) 
The pharmacist detected a lower prescribed dose of lamotrigine 
than in prior prescription. The physician readapted the dose 
based on pharmacist’s recommendation. 
Overdose 10 
(21.3) 
Safety of treatment 8 
(80.0) 
Accepted and 
implemented 
7 
(87.5) 
Dextromethorphan dose was too high (12.5mg, 2-3 times/day) for 
an 18-month child. The pharmacist reduced the dose (6.25mg) to 
twice daily in the morning and the evening. 
In-depth counselling 
patient 
36 
(14.9) 
Insufficient 
knowledge (patient) 
15 
(41.7) 
Patient dissatis-
faction/ problem 
8 
(53.3) 
Accepted and 
implemented 
6 
(75.0) 
Patient supposed that acetaminophen causes his stomach trouble 
and wanted acetylsalicylic acid instead. The pharmacist clarified 
the confusion. 
 
 
 
 
Technical 
n=188 
 
 
Substitution 
 
 
98 
(52.1) 
Financial burden 44 
(44.9) 
Treatment costs 43 
(97.7) 
Accepted and 
implemented 
40 
(93.0) 
The patient agreed to switch the original product to generic 
escitalopram to safe costs. 
 
Prescribed drug not 
available  
46 
(46.9) 
Treatment 
effectiveness 
35 
(76.1) 
Accepted and 
implemented 
34 
(97.1) 
Drug is currently undeliverable and not in stock at the wholesaler, 
but the pharmacist proposed an alternative. 
Patient dissatis-
faction/ problem 
11 
(23.9) 
Accepted and 
implemented 
11 
(100.0) 
The pharmacy does not have the prescribed drug in stock, but the 
pharmacist proposed an alternative dosage form. 
Optimisation of 
admin./route 
12 
(6.4) 
Incomplete/unclear 
prescription 
8 
(66.6) 
Treatment 
effectiveness 
7 
(87.5) 
Accepted and 
implemented 
7 
(100.0) 
Correct timing of magnesium administration was not specified. 
Due to drug-drug interaction, magnesium should be taken at 
lunch time, and the levothyroxine 30 minutes before breakfast. 
Clarification/ 
addition of info 
33 
(17.6) 
Incomplete/unclear 
prescription 
24 
(72.7) 
Treatment 
effectiveness 
14 
(58.3) 
Accepted and 
implemented 
11 
(78.6) 
The dose of the combination product valsartan + 
hydrochlorothiazide was not specified on the prescription. The 
pharmacist clarified the correct dose with the prescriber. 
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Patient-reported problems 
Patient-reported problems resulted in a PI in 99 cases (23.0%). Of these, 76 PIs had a clinical cause (Fig. 
1) while 23 PIs had a technical cause. In 15 (15.2%) cases, the contact with the prescriber was necessary 
whereas 61 (84.8%) of PIs only involved the pharmacist (alone n=15, with the patient n=68, with the 
caregiver n=1). The PIs resulted in 66 cases (66.7%) to a change of the prescription, and of these, 52 
cases (78.8%) were solved without the prescriber. 
 
Fig. 1 Patient-reported problems with clinical causes and corresponding pharmaceutical interventions (n=76). 
The size of the circle represents its frequency. 
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Discussion 
This subanalysis demonstrated that community pharmacists applied a medicines optimisation 
approach for a broad range of PIs which was facilitate by direct patient interaction. The PIs were mostly 
accepted by the involved person and implemented in practice. Individual assessment of each PI, the 
pharmacist’s professional expertise, and the collaboration between the patient, caregiver or physician 
were needed to fully address the patients’ needs. This ensured a safe and appropriate use of medicines 
- all while controlling treatment costs. 
Almost a quarter of the PIs were related to patients who reported problems with their prescribed 
medicines at the time of dispensing. It is known that after the prescription is handed over by the 
prescriber, problems for the patients may still remain. The prescriber possibly provides insufficient 
information that does not meet the patient’s needs. A Canadian study has previously revealed the 
discrepancies between the patient’s need for information on prescribed medicines and the 
information provided by pharmacists and physicians [115]. Direct contact between the healthcare 
professional and the patient is essential to detect these problems. By addressing these problems, 
adherence to medical treatment and consequently patient outcomes could be improved. Indeed, 
Horne et al reported that the patient’s beliefs and concerns are related to adherence, meaning that 
lower concerns correlated with higher adherence [116]. 
Another possible reason for remaining patient-related problems is that some concerns regarding 
therapy or the need for supplementary information may arise at a time after the consultation with the 
prescriber has taken place. The same Canadian study revealed that patients found it more convenient 
to receive information and counselling from the pharmacists rather than from the physician. This is 
likely a consequence of easy accessibility of the pharmacists and the challenge to contact the physician 
who often has time constraints [115]. Our findings confirm that patient-reported problems with 
prescribed medicines can frequently be addressed by community pharmacists. As one of the last 
healthcare professionals before patients take their medicines, pharmacists provide a relevant 
contribution in improving treatment outcomes by intervening in DRPs during the dispensing of 
prescribed medicines. 
As this study collected data in two regions of Switzerland with different languages and cultures, the 
results provide a robust assessment that can likely be transferred to other regions. The main limitation 
was the inclusion of highly motivated and qualified pharmacists who participated in the study. We 
were not able to ensure the consecutive collection of prescriptions, which might have caused a 
selection bias. This would explain the high frequency of PIs compared to another observational study 
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that was conducted in Swiss community pharmacies which recorded all 38’663 patient visits with 
prescriptions during four weeks, revealing mean intervention rates of 1.90% related to 736 technical 
and of 0.77% related to 257 clinical DRPs [94]. 
 
Conclusion 
By intervening during the dispensing of prescribed medicines, community pharmacists contribute to 
the safe, appropriate and cost-effective use of drugs. They have the opportunity to support the patient 
to make the best use of prescribed medicines by performing individualised PIs. The high number of PIs 
following patient-reported problems highlights the importance of a direct patient-pharmacist contact 
when dispensing prescribed medicines. 
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Abstract 
Background As part of pharmaceutical care, dispensing of prescribed medicines and patient 
counselling are the pharmacist’s key activities to ensure the safe and effective use of medicines. To 
our knowledge, the dispensing process of prescribed medicines including all activities from the 
prescription reception to the medicines distribution has not been described in Swiss community 
pharmacies yet. 
Objective To describe the observed dispensing process of prescribed medicines at the counter in daily 
community pharmacy practice, focusing on counselling activities. 
Setting and Method: Community pharmacies in Basel, Switzerland, were randomly invited for study 
participation. One master student in pharmacy performed non-participant observations during one 
day at each included community pharmacy. At dispensing, patient characteristics, counselling content, 
and additional activities were documented on a structured checklist with predefined themes. 
Pharmaceutical interventions were documented and classified systematically. All data were analysed 
with descriptive statistical methods. 
Main outcome measures: Number and nature of counselled themes, interventions and additional 
activities. Factors influencing counselling provision. 
Results: In March and April 2016, 18 of 49 invited community pharmacies participated in the study. A 
total of 556 prescription encounters (PE) were analysed (269 first prescriptions; 287 refill 
prescriptions). Patients mostly collected their medicines personally (n=451, 81%), were regular 
customers (n=523, 94.1%) and on average 53.8±23.4 years old. Counselling was provided to 367 
(66.0%) customers on 2.9 ±3.1 themes per PE (first 4.9±3.0; refill 1.0±1.7, p<0.001). The PE lasted on 
average 4.5±3.0 minutes (first 5.2±3.1; refill 3.9±2.7, p<0.001). Pharmacy staff mainly counselled on 
administration (first 465; refill 73), dose (188; 46), and use (152; 36) and provided an individualised 
label (189; 55). However, 148 patients (26.6%) refused counselling. Significantly more counselling was 
provided by pharmacists vs other staff members, with a first prescription vs refill, prescription 
requiring a pharmaceutical intervention, prescription filled by carers vs patient, to new vs regular 
customer and to customer who did not vs did refused counselling. During 144 PEs (101 first PEs; 41 
refill PEs, p<0.001), 203 interventions were documented (intervention rate 25.9%), such as drug 
substitution (n=89), clarification of information (n=64) and adjustment of package size/quantity 
(n=39). Pharmacists proposed few additional activities (e.g. 3 follow up offers), while no cognitive 
pharmaceutical service was performed. 
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Conclusions: The observation of the dispensing process of prescribed medicines allowed to depict the 
community pharmacy practice in the customers’ perspective (at the counter) and to identify factors 
influencing counselling provision at patient, prescription and pharmacy level. Counselling was not 
equally provided, indicating that pharmacy staff counsels at different degrees during PEs. A more 
transparent practice and patient-centered counselling is necessary to better meet the patients’ needs 
on information. While pharmacists intervened frequently, only few additional activities and no further 
services were offered. 
 
Key words 
Community pharmacy practice, dispensing, counselling, pharmaceutical intervention, pharmaceutical 
care, observation 
Impact of findings on practice statements/practice implications 
• Pharmacists, as one of the last healthcare professionals interacting with patients prior to 
medication, help the patient to make the best use of prescribed medicines by providing 
counselling and intervening in drug-related problems during the dispensing of prescribed 
medicines. 
• We suggest more transparency trough better communication of the pharmaceutical activities 
performed in the back office and a more patient-centered counselling to meet patients’ needs. 
• Factors influencing counselling provision are indicators to help in prioritising prescriptions 
needing in-depth counselling. 
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Introduction 
Pharmaceutical care has been defined as “the pharmacist’s contribution to the care of individuals in 
order to optimize medicines use and improve health outcomes provided” [46]. As part of 
pharmaceutical care, dispensing of prescribed medicines and patient counselling are the pharmacist’s 
key activities to ensure the safe and effective use of medicines [37, 69]. Dispensing includes all 
activities between the reception of the prescription and the distribution of medicines to the patient 
with the provision of information [69]. During dispensing, community pharmacists help the patient to 
make the best use of prescribed medicines by providing written and oral information responding to 
the patient needs [71], which contribute to positive treatment outcomes [72]. Patients have the 
opportunity to receive counselling and education about their health problems and medicines in several 
care situations, especially in community pharmacies at the time of dispensing prescribed medicines 
[72]. Patient counselling about their medicines (e.g. administration, risk and benefit) has been shown 
to be effective in improving medicines adherence [73, 74], and in identifying drug-related problems 
(DRPs) [75]. In contrast, insufficient information about medicines can lead to patient non-adherence 
to the drug therapy and negative health outcomes. 
The joint International Pharmaceutical Federation and World Health Organization (FIP/WHO) 
guidelines on Good Pharmacy Practice (GPP) describes the pharmacists’ function of dispensing 
medicines concerning counselling as “providing advice to ensure that the patient receives and 
understands sufficient written and oral information to derive maximum benefit for the treatment”[37]. 
Prescription dispensing at the community pharmacy is an important contact point for patient 
counselling [75]. Patients regularly pick up their prescribed medicines in community pharmacies [117], 
hence pharmacy staff is usually one of last healthcare providers, who interacts with patients prior to 
medication and who has the possibility to inform and counsel them [118, 119]. The joint FIP/WHO GPP 
suggests also minimum national standards that should be established for this function. 
In Switzerland, the Swiss Association of Pharmacists published recommendations for pharmaceutical 
counselling [120]. Additionally, a service–based remuneration system for community pharmacies is 
established since 2001 [121]; some cognitive pharmaceutical services are reimbursed by the health 
insurance (Table 1) [50, 122]. The counselling provided during dispensing of prescribed medicines is 
remunerated by the ‘Drug check’ and ‘Delivery check’. Moreover, in Switzerland, prescribers can issue 
refill prescriptions for up to 12 months for patients with an ongoing long-term therapy. 
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Table 1 A selection of remunerated cognitive pharmaceutical services in Swiss community pharmacies, adapted 
from Hersberger et al. [50] 
Pharmacy services Description Fee (EUR) 
Drug check fixed fee for checking each dispensed item on dosage, limitations, interactions, risk factors, 
contraindications, misuse and eventual possibility of repeat dispensing, and for patient 
counselling, eventual contact with prescriber, choice of optimized package size, and immediate 
provision 
4.00 
Delivery check fixed fee for checking medication history for interactions and accumulation, including self-
medication 
3.00 
Generic substitution Pharmacists have been allowed to substitute generic drugs for originals with the patient’s 
agreement and when the doctor does not oppose it. 
40% of the 
difference to 
the original 
Polymedication 
check 
Medication review to support adherence for patient on more than four drugs taken over more 
than three months. If patient agrees, but independently from the prescriber. 
45.00 
Adherence fee For preparation of a weekly pill organizer/blister pack for an outpatient with chronic condition 
and taking at least 3 different drugs 
20.00/week 
 
Literature on counselling in community pharmacies describes the communication patient-provider 
about the medicines use [123, 124] and compare the counselling practice to the guidelines [117, 125]. 
A Swiss study described counselling by community pharmacy staff at patient contacts, with focus on 
adherence [126]. To our knowledge, the dispensing process of prescribed medicines including all 
activities from the prescription presentation to the medicines distribution has not been described in 
Swiss community pharmacies yet. For this reason, our study aimed at observing what activities a 
prescription triggered at the time of dispensing. 
 
Aim 
To describe the observed dispensing process of prescribed medicines at the counter in daily 
community pharmacy practice, focusing on counselling activities. 
 
Ethical Approval 
The study was approved by the Ethics Committee of Northwest and Central Switzerland (EKNZ BASEC 
UBE-req. 16/00011) on 25.01.2016. 
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Methods 
We conducted a non-participant observation study in community pharmacies to illustrate the 
observed dispensing process of prescribed medicines. The main outcome measures were the number 
and type of themes counselled, the factors influencing counselling provision, and number, frequency, 
and type of pharmaceutical interventions, and additional activities. 
Data collection 
Community pharmacies in Basel, Switzerland, were randomly invited for study participation according 
to a prior study [126]. One master student in pharmacy performed non-participant observations during 
one day at each included community pharmacy from March to April 2016. After a quick briefing on the 
study, the pharmacy staff were neither actively involved in the study process nor disturbed in their 
practice. At dispensing of prescribed medicines, counselling content (information exchanged over the 
counter between customer and pharmacy staff), patient characteristics (age, sex, customer status), 
and additional activities (offer of a further activity) were documented on a structured checklist with 
predefined themes for each prescription encounter (PE). A PE lasted from the customer’s greetings to 
closing salutations; thereupon, the next customer (patient or carer) was observed. Each customer 
filling a prescription in the community pharmacy was included in the study. Customers were excluded 
if ordered medicines were picked up without counselling or if only over-the-counter (OTC) products 
were requested. Customers were not informed about the study to avoid any influence on the 
counselling activities. 
The checklist was modified from a previous study [127] and enabled ad hoc coding of nine categories 
and 61 predefined themes: pharmacy staff involved (n=1 theme), patient (n=4), prescription (n=7), 
counselling (n=34), intervention (n=2), physician contact (n=2), situation (n=6), and additional activities 
(n=5). The category counselling included 34 counselling themes that were considered as best practice 
and was based on the ‘Drug check’ of the Swiss service–based remuneration system [121]. Other 
counselling themes originated from the literature [117, 128, 129], the requirement of the Omnibus 
Budget Reconciliation Act (OBRA, 1990) [130], the recommendations for internal audits of the Swiss 
Pharmacists’ Association [131], and from expert discussions with five community pharmacists. The 
checklist enabled to distinguish between the active and passive involvement of the pharmacy staff and 
the customer during the PEs. After piloting, the checklist was refined. A copy of the prescription and a 
list of repeat medicines were additionally collected and used to test the documentation of the 
observed PEs on consistency and plausibility. Observation time and characteristics of the pharmacies 
and their staff were recorded. 
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The pharmaceutical interventions were systematically documented with the PharmDISC system, which 
records information about the problem, type of problem, cause, intervention, person involved and the 
outcome of the intervention [85]. 
At the end of the observation day, a semi-structured interview concerning the pharmacists’ opinion on 
the counselling, triggers, facilitators and barriers was conducted at each community pharmacy with 
one pharmacist per pharmacy. The results of the interviews are reported separately. 
Data analysis 
All coded data were quantified and analysed descriptively using IBM SPSS Statistics for Windows, 
Version 24 (IBM Corp., Armonk, NY). For the determination of factors influencing counselling provision, 
counselling theme ratios (sum of each counselling theme counseled by the pharmacy staff divided by 
all medicines dispensed on one prescription) were calculated. A mean counselling theme ratio of 100% 
represents the maximum of all possible counselling themes counselled for each dispensed medicine. 
A single factor variance–analysis, Chi-Quadrat, Spearman and Mann-Whitney U tests were used to 
compare variables. A p-value <0.05 was considered statistically significant.  
 
Results 
Of a total of 49 invited community pharmacies, 18 participated in the study. Reasons for participation 
refusal were no interest (n=7), lack of personal resources (n=4) or time (n=4), holidays (n=2), not 
enough prescriptions (n=1), or unknown (n=13). All pharmacies were located in the urban area of Basel. 
Thirteen were independent pharmacies (72.2%), while five belonged to a pharmacy chain (27.8%). 
They were on average open during 10.25±1.5 hours and were observed during 8±0.6 hours (78.0% 
observed time) per day and pharmacy. The mean number of working staff per pharmacy at the 
observation day was 5.8±2.6 (1.7±0.9 pharmacists, 2.8±1.7 pharmacy technicians, 1.0±0.3 
apprendices, and 0.2±0.7 pharmacists in training). 
During the total observation time of 145.5 hours (18 observation days), 571 PEs (mean 31.2±6.4 per 
pharmacy, range 22-45) were documented. Fifteen PEs had to be excluded because no medicines were 
dispensed (n=9, e.g. drug not in stock), spoken language was foreign (n=3), ordered medicines were 
picked-up (n=1), physician ordered medication (n=1), no document about the dispensed medicines 
was available (n=1). A total of 556 PEs (269 first PEs and 287 refill PEs) constituted the sample for 
statistical analysis (each PE involved one customer). 
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Table 2 illustrates patient, prescription, and pharmacy characteristics. The number of medicines per 
prescription varied from 1 to 25, resulting in an average of 3.2 ±3.2. 
Table 2 Patient, prescription, and pharmacy staff characteristics 
Prescription encounter All  
(n=556) 
First 
(n=269) 
Refill 
(n=287) 
Patient    
Female n (%) 337 (60.6) 162 (60.2) 175 (61.0) 
Mean age (years) ± SD 53.8 ± 23.4 45.6 ± 23.9 61.4 ± 20.2 
Regular customer n (%) 523 (94.1) 242 (90.0) 281 (97.9) 
Carer filled a prescription for a patient n 
(%) 
105 (18.9) 62 (23.0) 43 (15.0) 
Prescription    
Ambulatory n (%) 468 (84.2) 212 (78.8) 256 (89.2) 
Hospital discharge n (%) 88 (15.8) 57 (21.2) 31 (10.8) 
Pharmacy staff    
Pharmacist n (%) 149 (26.8) 70 (26.0) 79 (27.5) 
Pharmacy technician n (%) 267 (48.0) 124 (46.1) 143 (49.8) 
Apprentice n (%) 86 (15.5) 45 (16.7) 41 (14.3) 
Pharmacist in training n (%) 13 (2.3) 8 (3.0) 5 (1.7) 
Druggist n (%) 8 (1.4) 1 (0.4) 7 (2.4) 
Combination of pharmacy staff n (%) 33 (5.9) 21 (7.8) 12 (4.2) 
 
Counselling 
The PEs lasted on average 4.5±3.0 minutes (first 5.2±3.1; refill 3.9±2.7, p<0.001), ranging from 1.0 to 
23.0 minutes. In 106 PEs (19.1%), pharmacy staff offered counselling by asking if the patient already 
knew the medicines or if they have any questions (general questions that were intended to verify 
patient knowledge). Within the 556 PEs, counselling was provided to 367 (66.0%) customers (first 249 
and refill 118, p<0.001). Of these 367 customers, 68 (12.2%) received counselling on one theme (out 
of the 34 counselling themes), 52 (9.4%) on two themes, 132 (36.0%) on three to five themes, and 115 
(20.7%) on five to thirteen themes (Fig. 1). Pharmacy staff did not provide any counselling in 169 refill 
PEs and in 20 first PEs. On average, customers were counselled on 2.9 ±3.1 themes per PE (first 4.9±3.0; 
refill 1.0±1.7, p<0.001). Customers who refused counselling (148 PEs [26.6%]; 51 first PEs vs 97 refill 
PEs, p<0.001) were significantly more often approached for counselling at first PEs than refill PEs 
(3.7±2.9 theme vs. 1.7±1.9, p<0.001). 
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Fig 1 Number of themes counselled by the pharmacy staff per PE during first (n=269) and refill PEs (n=287). 
 
Table 3 illustrates the number of the counselling themes and their initiator. Pharmacy staff mainly 
counselled on administration (in first PEs 465 times and in refill PEs 73 times), dose (188; 46), and use 
(152; 36) and provided a label (189; 55). Of the 34 counselling themes, 8 were never addressed. 
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Table 3 Number of counselling themes and their initiators. Bold p-value (p<0.05) are considered as statistically significant 
  
 
 
Counselling themes (n=34) 
 
First prescription encounters (n=269) Refill prescription encounters (n=287)  
P–Value (first 
vs refill PE of 
themes 
counseled by 
pharmacy staff) 
Theme 
counseled  
(pharmacy 
staff) 
n  (%) 
Theme 
discussed 
(pharmacy or 
customer) 
n  (%) 
Pharmacy 
staff as 
Initiator 
 
n  (%) 
Customer 
as initiator  
 
 
n  (%) 
Initiator 
not 
known  
 
n  (%) 
Theme 
counseled  
(pharmacy 
staff) 
n  (%) 
Theme 
discussed 
(any 
person) 
n  (%) 
Pharmacy 
staff as 
Initiator 
 
n  (%) 
Customer 
as initiator  
 
 
n  (%) 
Initiator 
not 
known  
 
n  (%) 
Anamnesis (total) 
1. Medicines 
2. Diseases  
3. Allergy 
4. Pregnancy/lactation  
5. Familiar 
6. Lifestyle  
7. Clinical parameter 
100  (37.2) 
34  (12.6) 
9  (3.3) 
34  (12.6) 
8  (3.0) 
0  (0) 
0  (0) 
15  (5.6) 
101  (37.5) 
35  (13.0) 
9  (3.3) 
34  (12.6) 
8 (3.0) 
0  (0) 
0  (0) 
15  (5.6) 
99.  (98.0) 
33  (94.3) 
9  (100) 
34  (100) 
8  (100) 
0  (0) 
0  (0) 
15  (100) 
1  (1.0) 
1   (2.9) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
1  (1.0) 
1  (2.9) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
8  (2.8) 
3  (1.0) 
0  (0) 
3  (1.0) 
0  (0) 
0  (0) 
0  (0) 
2  (0.7) 
9  (3.1) 
4  (1.4) 
0  (0) 
3  (1.0) 
0  (0) 
0  (0) 
0  (0) 
2  (0.7) 
8  (88.9) 
3  (75.0) 
0  (0) 
3  (100) 
0  (0) 
0  (0) 
0  (0) 
2  (100) 
1  (11.1) 
1  (25.0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
 
<0.001 
0.001 
<0.001 
0.003 
- 
- 
0.001 
8. Dose 188 (69.9) 191 (71.0) 180 (94.2) 8  (4.2) 3  (1.6) 46  (16.0) 50  (17.4) 46  (92.0) 4  (8.0) 0  (0) <0.001 
Drug use (total) 
9. Use  
10. Duration of use (single 
application) 
11. Instruction/training of use 
152  (56.5) 
129 (48.0) 
14  (5.2) 
9  (3.3) 
153  (56.9) 
130 (48.3) 
14  (5.2) 
9  (3.3) 
143  (93.5) 
121 (93.1) 
13  (92.9) 
9  (100) 
9  (5.9) 
8  (6.2) 
1  (7.1) 
0  (0) 
1  (0.6) 
1  (0.8) 
0  (0) 
0  (0) 
36  (12.5) 
34  (11.8) 
1  (0.3) 
1  (0.3) 
38  (13.2) 
36  (12.5) 
1  (0.3) 
1  (0.3) 
36  (94.7) 
34  (94.4) 
1  (100) 
1  (100) 
2  (5.7) 
2  (5.6) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
 
<0.001 
<0.001 
0.009 
Drug administration (total) 
12. Frequency of administration 
13. Therapy duration 
14. Timing of administration 
15. Modality of administration 
465  (172.9) 
159 (59.1) 
90  (33.5) 
120 (44.6) 
96  (35.7) 
475  (176.6) 
163 (60.6) 
91  (33.8) 
125 (46.5) 
97  (36.1) 
437  (92.0) 
154 (94.5) 
85  (93.4) 
111 (88.8) 
87  (89.7) 
26  (5.5) 
6  (3.7) 
4  (4.4) 
6  (4.8) 
10  (10.3) 
13 (2.7) 
3  (1.8) 
2  (2.2) 
8  (6.4) 
0  (0) 
73  (25.4) 
34  (11.8) 
13  (4.5) 
20  (7.0) 
6  (2.1) 
80  (27.9) 
37  (12.9) 
13  (4.5) 
24  (8.4) 
6  (2.1) 
69  (86.3) 
33  (89.2) 
11  (84.6) 
19  (79.2) 
6  (100) 
8  (10.0) 
3  (8.1) 
1  (7.7) 
4  (16.7) 
0  (0) 
3  (3.7) 
1  (2.7) 
1  (7.7) 
1  (4.2) 
0  (0) 
 
<0.001 
<0.001 
<0.001 
<0.001 
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Counselling themes (n=34) 
First prescription encounters (n=269) Refill prescription encounters (n=287)  
P–Value 
(first vs refill PE 
of themes 
counseled by 
pharmacy staff) 
Theme 
counseled  
(pharmacy 
staff) 
n  (%) 
Theme 
discussed 
(pharmacy or 
customer) 
n  (%) 
Pharmacy 
staff as 
Initiator 
 
n  (%) 
Customer 
as 
initiator  
 
n  (%) 
Initiator 
not 
known  
 
n  (%) 
 Theme 
counseled  
(pharmacy 
staff) 
n  (%) 
Theme 
discussed 
(any 
person) 
n  (%) 
Pharmacy 
staff as 
Initiator 
 
n  (%) 
Customer 
as 
initiator  
 
n  (%) 
Initiator 
not 
known  
 
n  (%) 
Written information 
16. Label 
17. Flyer 
18. Schedule 
19. Document 
 
189 (70.3) 
8  (3.0) 
0  (0) 
0  (0) 
 
189 (70.3) 
8  (3.0) 
0  (0) 
0  (0) 
 
188 (99.5) 
8  (100) 
0  (0) 
0  (0) 
 
1  (0.5) 
0  (0) 
0  (0)  
0  (0) 
 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
 
55  (19.2) 
0  (0) 
0  (0) 
0  (0) 
 
55  (19.2) 
0  (0) 
0  (0) 
0  (0) 
 
55  (100) 
0  (0) 
0  (0) 
0  (0) 
 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
 
<0.001 
0.003 
- 
- 
20. Indication 
21. Effect  
22. Mechanism of action 
23. Benefit/purpose of therapy 
108 (40.1) 
51  (19.0) 
1  (0.4) 
3  (1.1) 
111 (41.3) 
52  (19.3) 
1  (0.4) 
4  (1.5) 
98  (88.3) 
49  (94.2) 
1  (100) 
3  (75) 
11  (9.9) 
3  (5.8) 
0  (0) 
1  (25.0) 
2  (1.8) 
0  (0) 
0  (0) 
0  (0) 
21  (7.3) 
7  (2.4) 
0  (0) 
8  (2.8) 
25  (8.7) 
7  (2.4) 
0  (0) 
9  (3.1) 
20  (80) 
6  (85.7) 
0  (0) 
7  (77.8) 
5  (20) 
1  (14.3) 
0  (0) 
2  (22.2) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
<0.001 
<0.001 
0.480 
0.226 
24. Adverse effect 
25. Red flag 
26. Drug-drug interaction 
27. Contraindication 
18  (6.7) 
3  (1.1) 
17  (6.3) 
1  (0.4) 
18 ( 6.7) 
3  (1.1) 
18  (6.7) 
1  (0.4) 
16  (88.9) 
3  (100) 
13  (72.2) 
1  (100) 
1  (5.6) 
0  (0) 
5  (27.8) 
0  (0) 
1  (5.6) 
0  (0) 
0  (0) 
0  (0) 
6  (2.1) 
0  (0) 
4  (1.4) 
0  (0) 
7  (2.4) 
0  (0) 
4  (1.4) 
0  (0) 
6  (85.7) 
0  (0) 
4  (100) 
0  (0) 
1  (14.3) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0.011 
0.110 
0.003 
0.480 
Appropriate action in case of: 
28. Missed dose 
29. Underdose 
30. Overdose 
 
0  (0) 
0  (0) 
0  (0) 
 
0  (0) 
0  (0) 
0  (0) 
 
0  (0) 
0  (0) 
0  (0) 
 
0  (0) 
0  (0) 
0  (0) 
 
0  (0) 
0  (0) 
0  (0) 
 
0  (0) 
0  (0) 
0  (0) 
 
0  (0) 
0  (0) 
0  (0) 
 
0  (0) 
0  (0) 
0  (0) 
 
0  (0) 
0  (0) 
0  (0) 
 
0  (0) 
0  (0) 
0  (0) 
 
- 
- 
- 
31. Storage 
32. Information transfer  
5  (1.9) 
0  (0) 
5  (1.9) 
0  (0) 
5  (100) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0.025 
- 
33. Adherence 
34. Self-/monitoring 
12  (4.5) 
0  (0) 
12  (4.5) 
0  (0) 
12  (100) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
23  (8.0) 
1  (0.3) 
23  (8.0) 
1  (0.3) 
22  (95.7) 
1  (100) 
1  (4.3) 
0  (0) 
0  (0) 
0  (0) 
0.116 
1.000 
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Patient involvement 
The customer was actively involved in 193 (34.7%) of PEs by providing information (149, 77.2%), asking 
questions (25 PEs, 13.0%) or a combination of both (19, 9.8%). During first PEs, the customer was more 
often actively involved than during refill PEs (48.7% vs. 21.6%, p<0.001). Table 4 illustrates the 
questions customers ask during first PEs. At refill PEs, customers asked five questions concerning 
therapy duration, indication, effect, benefit/purpose of therapy and adherence. 
Table 4 Questions customers ask during first PEs, n=46 questions 
 n % 
Questions on 46 100.0 
 Modality of administration 9 19.6 
 Drug use 7 15.2 
 Timing of administration 6 13.0 
 Indication 6 13.0 
 Dose 4 8.7 
 Drug-drug interaction 4 8.7 
 Therapy duration 3 6.5 
 Effect 2 4.3 
 Frequency of administration  2 4.3 
 Adverse effect 1 2.2 
 Duration of use 1 2.2 
 Written information (label) 1 2.2 
 
Factors influencing counselling provision 
Patient level 
New compared to regular customer received more counselling from the pharmacy staff (mean 
counselling theme ratio 11.9% vs. 5.0%, p<0.001) [Table 5]. Carers who filled the prescription for a 
patient vs patients who filled the prescription themselves were more counselled by the pharmacy staff 
(6.7% vs. 5.1%, p<0.05). Customers who did not vs did refuse counselling received also more 
counselling (6.2% vs. 3.5%, p<0.001). 
Prescription level 
The type of prescription also influenced the rate of counselling. Significantly more counselling was 
provided with a first compared with a refill prescription (mean theme counselling ratio 9.6% vs. 1.5%, 
p<0.001), and with prescription requiring a pharmaceutical intervention vs. no intervention (7.9% vs. 
4.6%, p<0.001). 
Pharmacy level 
Pharmacists provided information on significantly more themes per PE than pharmacy technicians (3.5 
vs. 2.6 themes, p<0.05), druggists (3.5 vs. 1.9, p<0.05), and apprentices (3.5 vs. 2.3, p<0.05). However, 
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no significant difference between pharmacists and pharmacists in training (3.5 vs. 3.2, p=0.849) and 
between pharmacists and a combination of a pharmacist and another staff member (3.5 vs. 4.2, 
p=0.194) was reported. 
Table 5 Mean counselling theme ratios of factors influencing counselling provision. Bold p-value are statistically 
significant. 
Variable 1 Mean 
counselling 
theme ratio [%] 
average ± SD 
Variable 2 Mean 
counselling 
theme ratio [%] 
average ± SD 
P–value 
 
Patient 
Regular customer  [n=523] 5.0 ± 6.1 New customer  [n=33] 11.9 ± 6.3 <0.001 
Female patient  [n=337] 5.2 ± 6.1 Male patient [N=219] 5.8 ± 6.5 0.436 
Counselling not refused  [n=408] 6.2 ± 6.7 Counseling refused  [n=148] 3.5 ± 4.6 0.001 
Prescription filled by the patient  [n=451] 5.1 ± 6.2 Prescription filled by the carer  [n=105] 6.7 ± 6.7 0.026 
Prescription 
First prescription [n=269] 9.6 ± 6.2 Refill prescription  [n=287] 1.5 ± 3.1 <0.001 
Ambulatory prescription  [n=468] 5.3 ± 6.2 Discharge prescription [n=83] 6.7 ± 6.7 0.088 
Prescription with interventions  [n=144] 7.9 ± 6.6 No intervention  [n=412] 4.6 ± 6.0 <0.001 
Hand written prescription  [n=247] 7.5 ± 6.7 Printed prescription  [n=117] 7.0 ± 6.3 0.599 
All medicines directly dispensed  [n=495] 5.7 ± 6.4 Some medicines picked up later   [n=61] 3.2 ± 4.6 0.004 
> 1 medicine dispensed  [n=290] 5.7 ± 5.9 1 medicine dispensed [n=266] 5.2 ± 6.7 0.027 
>1 medicine on prescription  [n=353] 5.0 ± 5.8 1 medicine on prescription  [n=182] 6.5 ± 7.2 0.129 
Pharmacy staff: counselling provided by  
a pharmacist  [n=149] 6.3 ± 6.6 a pharmacy technician [n=267] 5.0 ± 6.1 0.018 
  a druggist  [n=8] 2.4 ± 6.8 0.019 
  an apprentice [n=86] 4.6 ± 5.4 0.045 
  a combination of a pharmacist and a 
other staff member  [n=33] 
7.6 ± 7.8 0.476 
  a pharmacist in training  [n=13] 6.7 ± 5.7 0.651 
Situation  
Stress factor by waiting customers [n=89] 6.5 ± 6.6 No waiting customer  [n=467] 5.3 ± 6.2 0.059 
Silent environment  [n=500] 5.4 ± 6.4 Loud environment  [n=56] 5.6 ± 5.9 0.582 
No disruption during counselling [n=550] 5.5 ± 6.3 Disruption during counselling  [n=6] 3.9 ± 4.8 0.610 
No communication problem  [n=548] 5.4 ± 6.3 Communication problem  [n=8] 6.9 ± 6.5 0.525 
 
The detection of factors influencing counselling provision, allowed illustrating visual patterns of 
counselling (Fig. 2). 
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Fig. 2 Patterns of counselling: frequency of counselling themes as a function of the factors influencing counselling provision. These factors were selected in terms of 
significance. The size of the circle represents its frequency with respect to the factors influencing counselling provision. 
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Pharmaceutical interventions 
During all 18 observation days, 203 pharmaceutical interventions were documented at 144 PEs (103 
first PEs vs. 41 refill PEs, p<0.001; intervention rate 25.9%), with an average per prescription of 1.4±0.7 
(range 1-4). Pharmacists mainly intervened by substituting a drug (89, 43.8%), clarifying information 
(64, 31.5%), and by adjusting the package size/quantity (39, 19.2%). Table 6 illustrates the most 
frequent pharmaceutical interventions. The cause of the PI was technical for 180 pharmaceutical 
interventions (88.7%) and clinical for 23 pharmaceutical interventions (11.3%). Pharmacist-prescriber 
interaction was necessary for 11 pharmaceutical interventions (5.4%), whereas the pharmacist alone 
involved in 192 (94.6%) pharmaceutical interventions (alone n=65, with the patient n=127). 
 
Table 6 The most frequently observed pharmaceutical interventions, their cause, type of problem and problem 
(documented with the PharmDISC system) 
Intervention Cause of intervention Type of problem Problem n (%) 
Total interventions    203 (100.0) 
 Technical   180 (88.7) 
Clarification/addition of 
information 
Incomplete/unclear prescription Manifest, reactive Technical/formal problem 55 (27.1) 
Substitution (generic) Financial burden Manifest, reactive Treatment costs 49 (24.1) 
Substitution Prescribed drug not available Manifest, reactive Technical/formal problem 31 (15.3) 
Adjustment of package 
size/quantity 
Financial burden Manifest, reactive Treatment costs 18 (8.9) 
Adjustment of package 
size/quantity 
Financial burden Manifest, reactive Patient dissatisfaction/ 
problems 
9  (4.4) 
 Clinical   23 (11.3) 
Adjustment of package 
size/quantity 
Concerns about the treatment Manifest, reactive Patient dissatisfaction/ 
problems 
3 (1.5) 
Substitution No concordance with guidelines, 
only suboptimal therapy possible 
Potential, 
preventive 
Safety of treatment 2 (1) 
Substitution Concerns about the treatment Manifest, reactive Patient dissatisfaction/ 
problems 
2 (1) 
Therapy stopped/no 
delivery 
Interaction Potential, 
preventive 
Safety of treatment 2 (1) 
In–depth counseling of 
patient 
Interaction Potential, 
preventive 
Safety of treatment 2 (1) 
 
The number of pharmaceutical interventions per PE increased with the number of counselled themes 
per PE (correlation r=0.270, p<0.001) and the number of dispensed medicines per PE (r=0.236, 
p<0.001). The number of pharmaceutical interventions per PE did not increase with the patient age 
(r=–0.018, p=0.687) and the work experience of the pharmacy staff (r=0.032, p=0.470). 
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Additional activities 
Of all PEs, 10 PEs resulted in a phone call with the physician (4 first and 6 refill PEs), 5 in a referral to 
the physician (4 first and 1 refill PEs), 1 refill PE in refusal of dispensing, and 1 first PE in a consultation 
in a private room. The pharmacists reconstituted seven suspension, and offered three follow up. At 11 
PEs (11 first, 0 refill, p<0.001), counselling on non-pharmacological measures (e.g. balanced nutrition) 
was provided. 
 
Discussion  
This observation study allowed depicting the dispensing process of prescribed medicines in Swiss 
community pharmacies in the manner how the patients received counselling at the counter. 
Counselling 
When counselling was provided, moderate to good practice of counselling was observed, indicating 
that the pharmacy staff assumed in certain cases the responsibility to ensure that the patient received 
sufficient oral and written information on prescribed medicines to make the best use of them [37]. 
Counselling was given to 66.0% of the customers receiving prescribed medicines, which is slightly more 
than in a previous observation study (57.3%) performed in 2010 [126]. A review of worldwide 
counselling practices on prescribed medicines reported counselling rates from 12 to 100%, when 
observation methods were used [124]. This indicates a variation in frequency of pharmaceutical care 
provision. The customers were counselled on one to thirteen different themes (out of the 34 
predefined counselling themes) per PE. Written information as an individualised label to reinforce 
verbal communication was provided in 43% of the cases. 
Although a quarter of customers refused counselling, one-third of the customers did not received any 
counselling. Possibly, our study design did not take into account the long-term relationship between 
the pharmacy staff and the patient as a regular customer, which lead to substandard scores because 
they know each other. This is in line with what we observed; new customers received more counselling 
that regular customers. We could not assess what happened before the observed PE and which 
information was already exchanged during prior PEs. However, this study depicted how the patient 
received the counselling at the counter; we observed that pharmacists were involved by direct patient 
contact in only a quarter of all PEs. Pharmacists’ activities such as drug interaction-check and 
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investigation of the medication history that have been done in the back office are neither visible nor 
communicated to the customer. Pharmacy staff should be more transparent about their activities 
through openness and better communication with the customer in daily practice. 
The counselling was more based on product-centered (e.g. dose, use, and administration) than patient-
centered information (e.g. adherence, therapy benefit, and adverse effect), similarly to other studies 
[124, 126, 132]. In reference to Figure 2, the counselling patterns illustrates well the gaps in patient-
centered counselling. Especially for patients refilling prescribed medicines, low counselling ratios were 
observed. Not addressing the patient-centered counselling themes to the customers showed that the 
pharmacists missed the opportunity to improve patients’ adherence to their drug therapy [133]. It is 
known that patients often stop taking their newly prescribed medicines in the first six month of therapy 
(medication non-persistence), because of concerns about medication (e.g. adverse effect), the lack of 
perceived need for it (e.g. poor understanding of medicines/disease) and medication affordability [134, 
135]. Therefore, remunerated cognitive pharmaceutical services (e.g. ‘Polymedication check’, 
‘Adherence fee’) were introduced in Switzerland since 2010 [50], but during the observation, none of 
these services were performed. 
Patient involvement 
We showed that the pharmacy staff was mostly the initiator of the discussion, confirming the findings 
of another study [117]. A systematic review revealed a mainly passive role of the patient in 
conversations with healthcare providers [136], even though some guidelines encourage an interactive 
communication [72]. This is in line with what we observed; customers asked only few questions. 
However, these questions give the opportunity to the pharmacy staff to tailor information on patients’ 
needs [133]. Lack of privacy at the counter [137], lack of interest in pharmacy counselling [138-140], 
and patients’ underestimation of pharmacists’ role in healthcare are possible reasons for patients’ 
difficulties in asking questions [132, 141, 142]. Nevertheless, the patients’ initiative would be 
important, knowing that the outcome of a dialogue depends on the person who initiates the discussion 
[76]. Indeed, in patient-centered care, the patient always comes first and its needs should drive the PE 
[107]. Therefore, the patient should be encouraged in PEs to be more active in the discussion. 
Furthermore, we observed that sometimes pharmacy staff offered counselling by asking only general 
questions (e.g. do you know this medicine already?), limiting the counselling provision and the patient 
involvement, and consequently not taking into account the patients’ needs. It has been shown that 
the counselling provided to the patients did not completely meet their need for information [143]. A 
study exploring advice-giving behaviour in British community pharmacies reported that the counselling 
was mostly based on product use and that the customers wished information about the drug 
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effectiveness while the pharmacists provided information on drug safety. The authors proposed a 
protocol to guide pharmacy staff that includes the customer perspective [132]. To meet patient needs, 
the pharmacists should better listen to the patients’ problems and provide individualised counselling 
and information [144]. 
Factors influencing counselling provision 
Counselling was not equally provided, indicating that pharmacy staff use different degrees of 
counselling at PEs. If extended counselling at each first and refill PE is not possible in daily practice, 
pharmacy staff should target counselling for specific situations. However, it is important to notice that 
each PE offers the pharmacists the opportunity to interact with the patient and hence to detect DRPs 
and patients’ concerns. The study findings highlight some factors influencing counselling provision at 
patient, prescription and pharmacy level. These indicators could help in prioritising prescriptions 
needing in-depth counselling. 
Patient level 
• New customers were more likely to receive counselling from the pharmacy staff than regular 
customers. The counselling patterns revealed that the pharmacy staff performed more likely 
an anamnesis (medicine, diseases, and allergy) with the new customers, while the counselling 
patterns of the other factors influencing counselling provision were comparable (Fig. 2). 
Similarly to a review [124], the pharmacy staff mainly provided information on administration, 
dose and use, what also the counselling patterns demonstrates. 
• Customers who did not refuse counselling received more counselling. Refusing counselling did 
not mean that the patient did not receive any counselling, but such refusing is known as an 
important barrier for the provision of counselling [126]. Lack of the patients’ interest is a 
common phenomenon during counseling in community pharmacy [138, 139], up to 41–63% 
patients decline a counseling offer [140, 146], leading to low counseling ratios [140]. 
• Carers who filled a prescription for a patient received more information on the prescribed 
medicines than the patients themselves. Possibly the carer was not present at the consultation 
with the prescriber and did not receive information on the patient’s drug therapy. 
Prescription level 
• Customers with a first prescription received more counselling than the customers with a refill 
prescription. In a first PE, it is important to ensure that the patient receives the knowledge for 
using their medicines correctly [126]. Correct drug use is ensured by counseling on therapy 
duration treatment, dosage, and optimal timing of drug intake [147]. At refill PE, pharmacists 
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could suppose that patients with chronic medication were already informed about their use 
[148]. They could be also regular customers that need less clarification. Previous studies 
showed that pharmacy staff classified the communication with patients to be more difficult 
during refill PE than during first PE [149, 150]. It has been shown that patients’ expectations 
towards the counselling are different in first and refill PEs. More interest during first PE may 
facilitate an extensive counselling [140]. This is in line with our findings: during first PEs, 
patients showed more interest in counseling than during refill PEs because two third of the 
counselling refusals were observed during refill PEs.  
• Prescriptions that resulted in a pharmaceutical intervention required more counselling than 
prescriptions without any intervention. These prescriptions involved mandatorily the 
pharmacist, who is known to give more counselling than other pharmacy staff member and 
hence, the PE required more counselling to inform the patient about the DRP. 
Pharmacist level 
• Pharmacists provided more counselling to customers than the other pharmacy staff members. 
Other studies reported this factor [126, 148, 151]. A reason could be that pharmacists have a 
larger knowledge about drug therapy. The practice of dispensing prescribed medicines should 
be homogenised in the pharmacy staff, for example by training and using a protocol to guide 
pharmacy staff [132]. 
Lack of counselling provision might reflect insufficient knowledge or skills of the pharmacy staff. 
Counselling quality can be improved by developing counselling skills through education (e.g. role-play 
with standardised patients [152]), patient-centered communication (concordance of provided care 
with patients’ preferences and needs) [153, 154] and the application of established guidelines on Good 
Pharmacy Practice [37]. 
Pharmaceutical interventions 
Our findings confirm that the community pharmacists were effective in detecting, preventing, and 
solving DRPs [6, 133]. By intervening during dispensing, pharmacists contributed to the safe, 
appropriate, and cost-effective use of drugs. Individual judgement and professional knowledge of the 
pharmacists and the collaboration with the patient, carer or prescriber was needed to respond 
satisfactorily to the patient needs. We assessed a comparable rate of pharmaceutical interventions 
(25.9%) to a German study describing DRPs at time of dispensing prescribed medicines which reported 
an intervention rate of 18.0% [6]. 
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Additional activities  
Pharmacy staff proposed only few additional activities during PE, missing the opportunity to offer 
additional care and ensure continuity of care to optimise patient therapy and health outcomes. 
Nevertheless, each refill prescription is an opportunity for the pharmacists to offer follow-up and 
further cognitive pharmaceutical services. Although these services are remunerated in Switzerland 
[50], none of the pharmacists proposed to the customer a medication review (e.g. ‘Polymedication 
check’) and an adherence aid (e.g. ‘Adherence fee’). However, they performed often ‘Generic 
substitution’ for newly prescribed medicines. This limited observed provision of pharmaceutical care 
in community pharmacies confirms the results of other studies [146, 151, 155] and indicates that the 
implementation of these cognitive pharmaceutical services is still challenging. 
Strengths and limitations 
Our approach to describe the dispensing process of prescribed medicines at the counter was non-
participant observation, which is a useful way to study quality of services and consistency of care [156]. 
In the literature, observations allowed to describe customers’ behaviour and practice from real daily 
life [157], thus avoiding the biases of self-report methods [147]. Our observation method was based 
on ad hoc taking notes of exchanged information and transcribing into quantitative information. The 
documentation of the observed PEs has been tested on consistency and plausibility. The data was 
collected in eighteen randomly selected pharmacies, while the study was restricted to one region in 
Switzerland. The principal limitation was the presence of an observer which could positively influence 
the counselling performance of the pharmacy staff by triggering them to be more aware of their way 
of approaching customers (the Hawthorne effect) [158]. In order to minimise this effect, our observer 
became accustomed with the pharmacy staff prior data collection to make them feel at ease. 
Moreover, the observation lasted a whole working day, which allowed observing the normal practice 
over time. Simulated client methods such as mystery shopping could minimise observation bias, but 
present limitations of their own. The extracted information corresponds to a small part (snapshot) of 
healthcare practice only and is therefore hard to generalise to other health situations [159]. The 
observations were not recorded and not reviewed by a second investigator, which might have limited 
the reliability of the results. 
Outlook Ongoing research will analyse the pharmacists’ interviews and investigate their opinion on 
counselling. In a future similar observation study, we could ask patients’ opinion on what they expect 
of counselling after having filled a prescription that has been observed. We could also develop 
instruments to assess the patients’ needs and consequently tailor the counselling.  
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Conclusion 
The observation of the dispensing process of prescribed medicines allowed to depict the community 
pharmacy practice from the customers’ perspective (at the counter) and to identify factors influencing 
counselling provision at patient, prescription and pharmacy level. Significantly more counselling was 
provided by pharmacists, to customers with a first prescription, with a prescription requiring a 
pharmaceutical intervention, to carers who filled the prescription for a patient, to new customers, and 
to customers who did not refuse counselling. Counselling was not equally provided, indicating that 
pharmacy staff counsels at different degrees during PEs. A more transparent practice and patient-
centered counselling is necessary to better meet the patients’ needs on information. While 
pharmacists intervened frequently, only few additional activities and no further service (e.g. adherence 
support) were offered. 
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Background and Objectives 
Counselling of patients on prescribed medicines is a key competency element to ensure a rational use 
of medicines. International good pharmacy practice guidelines [37] describe how pharmacists should 
counsel the patients about their medicines, offer additional activities where needed, and intervene at 
drug-related problems. In Switzerland, these services are reimbursed by a fee at the dispensing of 
prescribed medicines [50]. However, international literature shows that daily practice often differs 
from theory [126, 155, 160]. To our knowledge, the dispensing process of prescribed medicines 
including all activities from the prescription presentation to the medicines distribution has not been 
described in Swiss community pharmacies yet. This study aimed at illustrating the observed process of 
dispensing prescribed medicines in daily community pharmacy practice. This analysis focuses on 
pharmacists’ opinions. 
 
Setting and Method 
Community pharmacies in Basel, Switzerland, were randomly invited for study participation. One 
master student in pharmacy performed non-participant observations during one day at each included 
community pharmacy (C1). At dispensing of prescribed medicines, patient data, content of counselling, 
and provision of additional activities (e.g. follow-up offer) were documented on a structured checklist 
with predefined themes. The pharmaceutical interventions were documented systematically with the 
PharmDISC system [85]. A 20-item semi-structured interview on the pharmacists’ opinions on the 
counselling (triggers, facilitators and barriers), and on the documentation and transfer of 
pharmaceutical interventions was conducted at each community pharmacy with a pharmacist. We 
evaluated pharmacists’ agreement with 4-point Likert scale (1=not true, 4=true). 
 
Results 
In March and April 2016, 18 of 49 invited community pharmacies participated in the study. They were 
mostly female (55.6%), manager of the pharmacy (n=9, 50%), deputy pharmacists (n=5, 27.8%), or 
owner (n=4, 22.2%). Their professional experience in community pharmacy ranged from 3 to 36 years. 
Seven of them had one specialization (Foederatio Pharmaceutica Helvetiae [FPH] title) and one 
pharmacist had two. A total of 556 encounters were analysed (first prescription: 269; refill prescription: 
287). 
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Counselling on prescribed medicines 
Counselling was provided to 367 (66.0%) of all customers (n=556 patients or carers) with an average 
of 2.9±3.1 themes per prescription encounter. A total of 148 customers refused counselling. The most 
counselled themes at first and refill prescription dispensing were: administration (first 476; refill 80), 
dose (191; 50), and use (153; 38). For the interviewed pharmacists (n=18), most important counselling 
themes to be discussed at first prescription dispensing were indication (n=11), administration (n=9), 
and anamnesis (n=8); for refill prescription dispensing: adherence (n=9), therapy benefits (n=9), and 
adverse effects (n=7) [Fig. 1]. 
 
Fig. 1 The most important counselling themes for the pharmacists (n=18), during first (n=46 answers) and refill 
(n=37 answers) prescription encounters. 
 
The counselling content of themes observed (Fig. 2, observation) and reported by the pharmacists (Fig. 
3, interview) are illustrated and compared as follow: 
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Most pharmacists (n=13) felt that it was their obligation to ask questions about patients’ health during 
the dispensing of prescription medicines and named trigger factors, but one third reported difficulties 
with asking questions. Pharmacists reported triggers, facilitators, and barriers for patient counselling 
on prescribed medicines (Table 1). 
Table 1 Triggers, facilitators, and barriers for patient counselling that pharmacists (n=18) expressed 
Triggers (n=45) n  Facilitators (n=34) n  Barriers (n=35) n 
Patient’s knowledge gap 8  Interest of patient 11  Counselling refusal by 
patient 
13 
Patient’s 
motivation/interest  
6  Open-minded patient 4  Communication 
problems/language 
7 
Drug-drug interaction 5  Medical data available 4  Lack of time, stress 4 
Polypharmacy, 
polymorbidity 
4  Patient and provider 
speak same language/ 
suitable communication 
4  Medical data 
unavailable 
3 
Special patient 
population 
4  Relationship 3  Mental ability of the 
patient 
2 
Adverse drug reactions 3  Patient understands 
necessity 
2  Unclear indication and 
patients’ need 
1 
First prescription 3  Pharmacist’s experience  2  Patient not present 1 
Adherence  3  Patient needs are clearly 
expressed 
1  Patients who are not 
aware of competency of 
pharmacy staff 
1 
Concerns of the patient  2  Privacy (e.g. in private 
room) 
1  Lack of knowledge 
(pharmacist) 
1 
Special medicine  2  Pharmacist has enough 
time 
1  Pharmacist 
incompetency 
1 
Others 5  Fully staffed 1  Difficult economic 
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Documentation of pharmaceutical interventions 
All 18 pharmacists confirmed that they documented their pharmaceutical interventions. Six 
pharmacists (33.3%) affirmed to always document them, seven often (38.9%), four sometimes (22.2%) 
and one rarely (5.6%). Most of the pharmacists (n=17, 94.4%) stated to electronically document them, 
nine (50.0%) to additionally write notes on the prescription and four pharmacists (22.2%) to have an 
additional system for documentation. Other documentation methods were used: a pharmacy noticed 
important changes on the medication list of the adherence aid and another pharmacy printed out all 
faxes and e–mails sent to the physician for collecting them in a folder. One pharmacy wrote in a “book 
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for pharmacists” all special events, mainly pharmaceutical interventions, so that the pharmacist 
overtaking the service can easily update him–/herself. Lastly, one pharmacy had an nonconformance 
document for each essential intervention, including the questions “What happened?”, “When?”, 
“How?”, “Which decision was made?”, and “Who does what until when?”. Additionally, the document 
included a classification system (type of problem, category, and result) which had to be ticked. This 
document had to be filled out by hand and was collected in a folder. Some comments about the 
intervention were manually added in the electronic medical patient data. 
Sixteen pharmacists found important and two quite important that the pharmaceutical interventions 
could be documented (mean user agreement 3.9 ± 0.3) (Fig. 4). Three agreed and thirteen quite agreed 
on the importance of the transfer of the performed interventions to other healthcare providers 
(3.1±0.7). Pharmacists suggested possible reasons for no transfer: minor relevance of some 
pharmaceutical interventions (e.g. substitution, n=15), overwork (e.g. too time-consuming, too much 
data, and difficult access to physician, n=9), no feedback of the physician (n=3) or unfriendly/negative 
feedback (n=2), unease (uncertainty, feeling of disturbance, n=2), and no patient wish (n=1). 
Fig. 4 Pharmacists’ agreement on the importance of the documentation and the transfer of pharmaceutical 
interventions. 
All 18 pharmacists reacted positively to the idea of having an intervention history (created from the 
data collected with a documentation system) for each patient (good n=9, great n=2, useful n=2, other 
positive comments n=5). Additionally, they expressed their overall opinion by making a comparison 
with the current situation (n=3) or by mentioning advantages of a consistent documentation of 
pharmaceutical interventions for each patient (n=3). Seven pharmacists added requests for the 
documentation system (with the option ‘intervention history’); for example, the system should be 
simple, practicable and fast in use, and its use should be optional. 
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Figure 5 illustrates the new possibilities that the implementation of such documentation system would 
offer to the pharmacist’s profession. However, two pharmacists warned that such system could be 
time-consuming by involving lots of computer work. 
 
Fig. 5 Pharmacists’ statements on new possibilities for the implementation of a documentation system for the 
pharmacists (n=32 statements). 
The idea of a pop–up window, which appears automatically at the end of the prescription control and 
asks if an pharmaceutical intervention was performed, was accepted by nine of pharmacists (50.0%), 
while six (33.3%) found that it would disturb them. Eight pharmacists (44.4%) mentioned the risk that 
the pop–up window could be ignored over time. 
Figure 6 illustrates the pharmacists’ statements on facilitators for the implementation of a 
documentation system. Most pharmacists wished a short and practical training, online or on site, with 
case studies and simple instructions. 
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Fig. 6 Pharmacists’ statements on facilitators for the implementation of a documentation system [n=28 
statements] 
 
Conclusions 
A discrepancy in counselling content by observation compared to pharmacists’ opinions was revealed. 
Observations showed a focus on product-centered themes (e.g. dose, administration), whereas 
pharmacists highlighted the importance of patient-centered content (e.g. benefit, adherence). This 
might indicate that pharmacists are aware but limited by barriers to practice according to good 
pharmacy practice guidelines.  
The majority of the pharmacists recognised the importance of the documentation of the 
pharmaceutical interventions. The diverse documentation methods reported by the pharmacists in 
their own pharmacy showed that no standardised documentation is currently used. Pharmacists found 
important to transfer the performed pharmaceutical interventions to other healthcare providers, but 
some barriers (e.g. minor relevance of some pharmaceutical interventions, too time-consuming) could 
hinder it. A simple and fast in use computerised documentation system, with an additional intervention 
history option, could be a promising approach according to the positive reactions and the needs of the 
pharmacists. As stated by the pharmacists, its implementation should increase the appreciation and 
visibility of pharmacists’ work, facilitate data handling by saving time and costs, ensure seamless care 
by improving collaboration among healthcare providers, and ultimately improve the therapy 
outcomes. 
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GENERAL DISCUSSION AND CONCLUSIONS 
 
The goal of this thesis was to create structured instruments for daily practice to improve the continuity 
of documentation and communication of pharmaceutical interventions during transitions of care. We 
approached this goal by developing and validating classification systems of pharmaceutical 
interventions for the hospital setting, the GSASA system, and for the community setting, the 
PharmDISC system, and evaluating their feasibility in practice (Fig. 1). We also depicted pharmacists’ 
activities in real-life daily practice through the documentation of pharmaceutical interventions and the 
observation of patient counselling on prescribed medicines at dispensing. 
The initial detected need for documentation was substantiated by the use of the classification systems 
in practice and/or research by hospital and community pharmacists, and the pharmacist-reported 
motivation to document pharmaceutical interventions in daily practice all along the projects. Thanks 
to an addition of a comment section to the classification systems, our classification systems became 
consequently structured documentation systems. Thus, by creating structured instruments, this thesis 
contributed to the improvement of the documentation of pharmaceutical interventions in practice 
and research. 
Fig. 1 Continuity of documentation: looking at the patient pathway during hospital stay, three pharmaceutical 
interventions could be documented with the GSASA system; and after discharge, two interventions initiated by 
a community pharmacist with the PharmDISC system, using the similarly structured and compatible classification. 
The documentation of these pharmaceutical interventions and the observation of patient counselling at 
dispensing enabled to depict pharmacists’ activities in the routine practice.  
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The GSASA system  
In Project A, we developed together with the GSASA working group in clinical pharmacy an 
intervention oriented classification system for hospital setting, the GSASA system. We validated the 
GSASA system (A1), evaluated its implementation in practice (A2), and developed a new seamless 
concept of classification of pharmaceutical interventions in patient care (A3). 
The GSASA system was developed based on the PCNE system V6.2 [65] and the SFPC system [66] and 
is composed of five main categories (i.e. problem, type of problem, cause of intervention, intervention, 
and outcome of intervention) [81]. The GSASA system appeared to be valid and easy to use in daily 
clinical practice. The system is validated in terms of appropriateness, interpretability, validity, 
acceptability, feasibility, and reliability. Study A1 showed that most of the 115 pharmaceutical 
interventions (n=93, 80.9 %) could be documented with the GSASA system and a similar ratio of 81.7% 
(n=94) with the PCNE system V6.2 [65], our benchmark. Comparable interrater reliability and 
acceptability for the GSASA and PCNE systems were also found. The comparative evaluation of the two 
systems revealed differences with respect to usability. Indeed, the category ‘intervention’ of the 
GSASA system allowed a more complete classification of the cases than the PCNE system. This reveals 
that our system respected its original approach, which focused on recording the interventions. The 
GSASA system is currently used in practice and in research. The current status and a selection of works 
is presented below. 
Since the GSASA introduced the classification system to standardise the documentation of 
pharmaceutical interventions, the GSASA system has been implemented in daily practice. Twelve Swiss 
hospitals are using it to record all pharmaceutical interventions during ward rounds or any other 
activities/requests (A2) [82]. This substantiates that there was a real need for documentation of 
pharmaceutical interventions and indicates that the pharmacists are convinced of the beneficial use 
of the GSASA classification in the pharmacy practice. The obtained data on pharmacists’ activities is 
used for epidemiological studies and described in the hospital annual report. This enabled 
demonstration of the performance/impact of clinical pharmacy services, which as a matter of fact 
facilitated political and economic discussions to obtain, for example, new job vacancies for clinical 
pharmacists. Moreover, the GSASA system as Microsoft Word or Excel file and the descriptive manual 
are available on the GSASA website in three languages (French, German, and Italian) [161]. The 
descriptive manual assists in categorisation and hereby will increase the quality of data due to an 
appropriate use of the standardised classification system. Some hospitals completed the Excel file by 
adding, for example, a section for comments (unstructured notes), the ward specialisation, and the 
pharmacist’s initials. 
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On the research side, a recent randomised controlled study used the GSASA system to classify the 
addressed DRPs and describe the pharmacists’ interventions during medication reviews on medicines 
use in patients on polypharmacy (Polymedication-check, PMC) in Swiss community pharmacies [44]. 
The authors adapted the system to the study setting: by dividing the subcategory ‘insufficient 
knowledge of the patient’ of the category ‘cause’ into three subcategories focusing on patients’ 
information needs about a) safe and effective use of his medicines, b) potential adverse drug reactions, 
and c) lifestyle, nutrition, or empowerment in general; moreover the subcategory ‘more cost-effective 
therapy available’ was added to the category ‘cause’ as the generic substitution might be likely to be 
triggered throughout a PMC. In an ongoing study in a Swiss hospital, systematic medication reviews 
were performed with inpatients to detect potential and manifest DRPs. They were classified and 
evaluated by hospital pharmacists with the GSASA system in combination with the German version of 
the CLinical Economic and Organisational (CLEO) instrument [162] to validate a trigger tool for 
pharmacists’ interventions (DART) [45]. 
These applications show that the GSASA system is usable in different settings and for various 
situations. However, in order to use it in the community setting, the GSASA system had to be slightly 
adapted. This confirms our seamless concept that the classification of pharmaceutical interventions 
should allow high flexibility in documenting pharmaceutical interventions (A3). According to the 
complexity of the case, the available information, the type of medication review, and the need for 
follow-up, different levels of classification may be indicated. This innovative classification system 
should be suitable for both, community and hospital pharmacy practices to facilitate continuity of care. 
Therefore, the basic structure of the GSASA classification system, currently used in hospitals, was 
adopted as far as possible to develop a similar classification system for the community pharmacies, 
the PharmDISC system. 
 
The PharmDISC system  
Project B succeeded in a two-phase development process of the PharmDISC system which followed a 
translational approach by adapting the existing hospital-specific system to the requirements of 
community pharmacies. The development process was split into two parts and four stages: Part 1 
covered the development and piloting stages (B1), while Part 2 covered the evaluation and 
implementation stages (B2). 
In Part 1 (B1), the PharmDISC system (version 1.0) reached higher interrater reliability (Κ=0.61) than 
the GSASA system (Κ=0.53) [81], revealing that the modifications made to the GSASA system were 
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suitable for the community pharmacy setting. All Κ-coefficients of the classification categories were 
above the threshold of Κ=0.40, indicating that the results were widely independent of the observers 
and that the categories were mutually exclusive. The study showed that the majority of the 725 
pharmaceutical interventions (n=686, 94.6%) were completely documented with the PharmDISC 
system which demonstrated its clarity and completeness. To our knowledge, this is the first 
development of a classification system that combines a quantitative and a qualitative approach in a 
mixed methods study. Both, the observational study and interrater reliability study provided the 
quantitative baseline, which was used in a qualitative phase to gain the pharmacists’ opinions using a 
focus group. The focus group participants confirmed the need for a classification system which is 
compatible with the electronic patient file by pointing out the importance of traceability of 
pharmaceutical interventions. Pharmacists wished to distinguish the type of intervention depending 
on the complexity. This could be solved by separating technical and clinical pharmaceutical 
interventions. Technical pharmaceutical interventions (e.g. generic substitution) are routine and non-
complex pharmaceutical interventions that require little time expenditure as opposed to clinical 
pharmaceutical interventions (e.g. dose adjustment). The pharmacists were highly motivated to 
document pharmaceutical interventions, as it provides a tangible proof of their work, improves the 
communication within the team and with other healthcare professionals, and maintains quality 
management. Points for the optimisation of the PharmDISC system (e.g. addition of the category 
‘communication’) were discussed and resulted in a new version. 
In Part 2 (B2), the validation study showed that the PharmDISC system was suitable to document 
pharmaceutical interventions in community pharmacies, with 82.9% (n=430) of pharmaceutical 
interventions (n=535) completely classified in all categories. With the PharmDISC system version 1.1, 
we could demonstrate favourable interrater reliability for all but one classification categories (average 
Κ=0.66), which was on average higher than previously obtained with version 1.0 (average Κ=0.61). 
This improvement was likely due to refinements in the updated version as well as the introduction of 
the descriptive manual that may have facilitated the classification of pharmaceutical interventions. 
Although all validation results of the PharmDISC system fulfilled the requirement for an acceptable 
classification system [68], its implementation into daily routine of a community pharmacy remains a 
challenge for information technology, as several different pharmacy software programs co-exist in 
Switzerland. In practice, the PharmDISC system has not been implemented in pharmacy software yet. 
However, an implementation is discussed as a standard for the Swiss electronic patient file, which is 
part of the “eHealth 2020” project of the federal health authorities. However, we expect the 
PharmDISC system to be is viable for future implementation for several reasons: 
 
GENERAL DISCUSSION AND CONCLUSIONS 
 
PhD Thesis Karen Maes 140 
 
• In contrast to the classification of DRPs, which require an interpretation by the practitioner, 
the PharmDISC system focuses on the documentation of actual pharmaceutical interventions 
allowing for an objective assessment.  
• The PharmDISC system offers a flexible and comprehensive classification system for 
pharmaceutical interventions of varying complexity that, consequently, is able to capture both 
prescription-focused as well as patient-centered pharmaceutical interventions.  
• The descriptive manual, rated as helpful and relevant, provides clear definitions of 
pharmaceutical interventions which should aid in uniformly classifying pharmaceutical 
interventions, another requirement for classification systems [61]. 
• The pharmacists noted that with increasing familiarity with the PharmDISC system over the 
course of the study, the faster and more comprehensive their classification of pharmaceutical 
interventions became. 
• Little time was necessary for the pharmacists to get accustomed with the PharmDISC system. 
This correlated with the pharmacists’ positive opinions on the use of the PharmDISC system. 
Furthermore, most pharmacists were willing to use the system, but only once integrated into 
the pharmacy software. This underlined the need for a computerised classification system. 
• The online training was highly appreciated by the pharmacists. It is therefore important to 
offer online training to future users of the PharmDISC system. 
• The documentation of pharmaceutical interventions may raise the awareness for DRPs and 
subsequently increase the intervention rate and patient safety. It has been reported that 
documentation of pharmaceutical interventions makes pharmacists more attentive regarding 
the patients’ drug-related needs and enhances the development of counseling skills and 
pharmaceutical care [53]. 
On the research side, the PharmDISC system is currently used in several unpublished studies in 
Switzerland. A recent Swiss study aimed at assessing the impact of a medication review focusing on 
anticoagulation therapy in ambulatory anticoagulated patients; and for that purpose applied the 
PharmDISC system to classify the interventions performed by the pharmacists [163]. As a seamless 
care example, a future Swiss prospective randomised controlled trial will apply the PharmDISC system 
in both hospital and community settings to document the pharmaceutical interventions performed at 
dispensing of hospital discharge prescriptions of the surgery and internal medicine wards. The aim is 
to demonstrate that the pharmaceutical interventions in community pharmacies can be reduced 
following a prior optimisation of the discharge prescriptions in hospital, and as a consequence the 
workload of the community pharmacists decreases. A first explorative trial of this future study aimed 
at illustrating this workload; a community pharmacist already recorded, during medication 
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reconciliation of hospital discharge prescriptions, pharmaceutical interventions with the PharmDISC 
system. Internationally, an ongoing research project (SIMENON study) of the University of Leuven in 
collaboration with the Universities of Ghent and Brussel and the Belgian National Pharmacists’ 
Association on the medication use review in community pharmacies intended to use a Dutch version 
of the PharmDISC system. 
All these current projects/applications show that the PharmDISC system, used in different settings and 
situations, has already become a well-accepted classification system in research, thus an 
implementation of it in practice is highly promising. In comparision, the PCNE system launched its 
seventh version V7.0 in 2016, referring to its importance in research. In order to be in line with current 
practice, the PCNE system V7.0 underwent corresponding modifications. Indeed, a review on the 
application of worldwide classification systems reported that three-quarters of the 268 published 
studies (n=202) using classification systems adapted an already existing one (46%, n=123) or developed 
one of their own (29.5%, n=79), while 25% (n=67) used an unmodified one [59]. The most used 
classification system unmodified was that of Cipolle et al [164], while the most frequently modified 
was that of Strand et al [55]. Of 21 published studies, the PCNE system was used unmodified in 9 
studies, while 12 studies applied it in a modified version. 
 
Depicting real-life daily practice  
The subanalysis of the documented pharmaceutical interventions (data from Study A2) demonstrated 
that community pharmacists applied a medicines optimisation approach for a broad range of 
pharmaceutical interventions which was facilitated by direct patient-pharmacist interaction (A3). The 
pharmaceutical interventions, were mostly accepted by the involved person and implemented in 
practice. Individual assessment of each pharmaceutical intervention, the pharmacist’s professional 
expertise, and the collaboration between the patient, caregiver or physician were needed to fully 
address the patients’ needs. This ensured a safe and appropriate use of medicines - all while controlling 
treatment costs. Almost a quarter of the pharmaceutical interventions were related to patients who 
reported problems with their prescribed medicines at the time of dispensing. Our study findings 
revealed that patient-reported problems with prescribed medicines can frequently be addressed by 
community pharmacists [75]. As one of the last healthcare professionals before patients take their 
medicines, pharmacists provide a relevant contribution in improving treatment outcomes by 
intervening in DRPs, particularly during the dispensing of prescribed medicines [37, 75]. 
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Pharmacists play also an important role in patient counselling on medicines by supporting the patients 
to make the best use of medicines. Moreover, patient counselling has been shown to be effective in 
identifying DRPs [75]. Therefore, in Project C, in order to investigate this role, patient counselling was 
depicted in respect to the non-participation observation method. The observation study allowed to 
describe the observed dispensing process of prescribed medicines at the counter in Swiss community 
pharmacies (C1). Counselling was given to 66.0% (n=367) of all 556 customers receiving prescribed 
medicines and moderate to good practice of counselling was observed. This indicates that the 
pharmacy staff assumed in certain cases the responsibility to ensure that the patient received 
sufficient oral and written information on prescribed medicines to make the best use of them [37]. 
Although a quarter of customers refused counselling, one-third of the customers, nevertheless, did not 
received any counselling. Our study design could not assess what happened before the observed 
prescription encounter and which information was already exchanged during prior prescription 
encounters. However, this study illustrated how the patient received the counselling at the counter; 
we observed that pharmacists were only involved by direct patient contact in a quarter of all 
prescription encounters. Pharmacists’ activities such as drug interaction-check and investigation of the 
medication history that have been done in the back office are neither visible nor communicated to the 
customer. Pharmacy staff should be more transparent about their activities through openness and 
better communication with the consumer in daily practice. 
Counselling was not equally provided, indicating that pharmacy staff use different degrees of 
counselling during prescription encounters. If extended counselling at each first and refill PE is not 
possible in daily practice, pharmacy staff should target counselling for specific situations. The study 
findings revealed factors influencing counselling provision at patient, prescription and pharmacy level. 
These indicators could help in prioritising prescriptions needing in-depth counselling. Significantly 
more counselling was provided by pharmacists, to customers with a first prescription, with a 
prescription requiring a pharmaceutical intervention, to carers who filled the prescription for a patient, 
to new customers, and to customers who did not refuse counselling. Furthermore, pharmacists 
intervened in 25.9 % of all prescription encounters, thus contributing to the safe, appropriate, and 
cost-effective use of drugs, while only few additional activities were offered. However, remunerated 
cognitive pharmaceutical services (e.g. ‘Polymedication check’, ‘Adherence fee’) were introduced in 
Switzerland since 2010 [50], but during the observation, none of these services were performed. 
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The interviews with the pharmacists of the observation study (C2) revealed a discrepancy in 
counselling content by observation compared to pharmacists’ opinions was revealed. Observations 
showed a focus on product-centered themes (e.g. dose, administration), whereas pharmacists 
highlighted the importance of patient-centered content (e.g. benefit, adherence). This might indicate 
that pharmacists are aware but limited by barriers to practice according to good pharmacy practice 
guidelines. 
The results of the interviews additionally showed that pharmacists occasionally documented their 
pharmaceutical interventions, however almost always not in a standardised way. Pharmacists found 
important to transfer the performed pharmaceutical interventions to other healthcare providers, but 
some barriers (e.g. too time-consuming, overwork) could hinder it. Therefore, a simple and fast in use 
computerised documentation system, with an additional intervention history option, could be a 
promising approach according to the positive reactions and the needs of the pharmacists. As stated by 
the pharmacists, its implementation should increase the appreciation and visibility of pharmacists’ 
work, facilitate data handling by saving time and costs, facilitate seamless care by improving 
collaboration among healthcare providers, and ultimately improve the therapy outcomes.  
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Strengths and limitations 
 
The main strength of Project A and Project B is the application of diverse methods at each 
development stage of the classification systems, which provides in-depth and complementary 
information, and can compensate for inherent weaknesses in single study designs [97, 98]. The 
PharmDISC system was developed combining a quantitative and a qualitative approach in a mixed 
methods study. Different methods for the validation of the GSASA and PharmDISC systems were used, 
according to the validation criteria proposed by Fitzpatrick [64]. Moreover, as the validation was 
performed in two regions of Switzerland with different languages and cultural backgrounds, we expect 
the PharmDISC system to be suitable also for other countries. The same can be assumed for the GSASA 
system which is implemented in twelve hospitals all over Switzerland. 
A limitation presents the inclusion of highly motivated and qualified pharmacists into the studies. As 
the validation and reliability of the GSASA system were based on a small number of pharmacists, a 
selection bias cannot be excluded (A1). Many raters were involved in the different stages in the 
development process, and consequently, we cannot ensure the generalisability. The participants of 
the focus group were a limited number of highly motivated and qualified pharmacists. These findings 
highlight the factors which positively influenced the documentation of pharmaceutical interventions, 
yet might have reduced statements on possible opposing factors (B1). We also invited highly motivated 
and qualified pharmacists to participate in Study B2. In order to be able to generalise our findings, the 
PharmDISC system should be tested in a future study without pre-selected community pharmacies. 
As a self-reported data method, pharmaceutical interventions were documented with the 
classification form, short description, prescription copy, and medication history. Although, the 
documented data was tested on consistency and plausibility, self-reported data also has limitations. In 
Study B2, we were not able to ensure that the collection of prescriptions was done consecutively, and 
there might have been a selection bias. 
In contrast, in Project C, our approach to describe the observed process of prescribed medicines 
dispensing at the counter was non-participant observation. This allowed to describe customers’ 
behavior and practice from real daily life [157], thus avoiding the biases of self-report methods [147]. 
However, the main limitation of the observation was the presence of an observer which could 
positively influence the counselling performance of the pharmacy staff by triggering them to be more 
aware of their way of approaching customers (the Hawthorne effect) [158]. Simulated client methods 
such as mystery shopping could minimise observation bias, but present limitations of their own. The 
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extracted information corresponds to a small part (snapshot) of healthcare practice only and is 
therefore hard to generalise to other health situations [159]. 
Finally, the classification and documentation of DRPs and interventions are a very up-to-date topic, 
entailing a fast update of the literature. Our findings were compared with international publications 
until November 2016. 
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Conclusions 
This thesis adds some findings to the topic field of classification and documentation of pharmaceutical 
interventions. The following conclusions can be drawn: 
The GSASA system 
• The GSASA classification system appeared to be reliable and promising for the documentation 
of pharmaceutical interventions in daily practice (practical and less time-consuming). Its 
validation was successful in terms of appropriateness, interpretability, validity, acceptability, 
feasibility, and reliability (A1). 
• After 18 months of introduction (2013), the GSASA classification system is already widely 
accepted in Swiss hospitals, suggesting to be suitable also to daily life settings. Most 
pharmaceutical interventions can be classified with adequate time effort and overall users’ 
satisfaction is good. The extent to which the system is used and the good acceptance within a 
short time after implementation are promising results to use it as basis for a further 
development (A2). 
• The GSASA classification system was tested in primary care and proved to be suitable also to 
classify interventions of medication reviews performed by community pharmacists in primary 
care; however, further refinements were necessary to improve the precision of the system. 
Thus, the development of one classification system suitable for both, primary and secondary 
care, flexible for addressing different levels of complexity, and easily integrable in daily 
practice and in electronic patient file was recognised as a promising approach (A3). 
The PharmDISC system 
• In a focus group interview, pharmacists recognised the importance of the documentation of 
pharmaceutical interventions and were convinced that this may allow traceability, facilitate 
communication within the team and other healthcare professionals, and eventually would 
increase quality of care (B1). 
• Substantial interrater reliability and high rating of acceptability and feasibility indicates that 
the new PharmDISC system is a valid system for the documentation of pharmaceutical 
interventions in daily practice of community pharmacies. The pharmacists were satisfied with 
the system and considered it helpful, easy to use, and practical for daily work. They appraised 
the fact that by using an intervention oriented classification system, their awareness of DRPs 
and concurrently the intervention rate increased (B2). 
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• The developed descriptive manual of the PharmDISC system and the online training were 
helpful elements for an accurate use of the PharmDISC system and are promising utilities to 
enhance its implementation (B2). 
Depicting real-life daily practice 
• The high number of pharmaceutical interventions following DRPs and patient-reported 
problems highlights the importance of a direct patient-pharmacist interaction when 
dispensing prescribed medicines (B3). 
• The observation of the dispensing process of prescribed medicines allowed to depict the 
community pharmacy practice from the customers’ perspective (at the counter). However, 
counselling was not equally provided, indicating that prescription encounters need different 
degrees of counselling. A more transparent practice and patient-centered counselling is 
necessary to better meet the patients’ needs on information. While pharmacists intervened 
frequently, only few additional activities and no further services were offered (C1). 
• Factors influencing counselling provision were identified at patient, prescription and pharmacy 
level. Significantly more counselling was provided by pharmacists, to customers with a first 
prescription, to customers with a prescription requiring a pharmaceutical intervention, to 
carers who filled the prescription for a patient, to new customers, and to customers who did 
not refuse counselling (C1). 
• A discrepancy in counselling content by observation compared to pharmacists’ opinions was 
revealed. Observations show a focus on product-centered themes (e.g. drug administration, 
dose), whereas pharmacists’ interviews highlight the importance of patient-centered themes 
(e.g. benefit, adherence). This might indicate that pharmacists are aware but hindered by 
barriers to practice according to good pharmacy practice guidelines (C2). 
• Pharmacists recognised the importance of the documentation of pharmaceutical interventions 
and their transfer to others healthcare providers, but reported also possible reasons of non-
transfer (e.g. minor relevant of pharmaceutical interventions, overwork) (C2). 
• A simple and fast in use computerised documentation system, with an additional intervention 
history option, could be a promising approach according to the positive reactions and the 
needs of the pharmacists. As stated by the pharmacists, its implementation should increase 
the appreciation and visibility of pharmacists’ work, facilitate data handling by saving time and 
costs, ensure seamless care by improving collaboration among healthcare providers, and 
ultimately improve the therapy outcomes (C2).   
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Outlook 
In this thesis, we developed two valid classification systems of pharmaceutical interventions for 
hospitals, the GSASA system, and for the community setting, the PharmDISC system. A paper-based 
form of the systems was used in the research projects. To assure and maintain the sustainability of the 
systems in practice, a computerised version should be developed together with pharmacy software 
suppliers, and notably be continuously improved through research. Indeed, the integration of the 
classification system in pharmacy software can facilitate the provision of pharmaceutical care and 
support seamless care at transitions of care [51]. Once the pharmaceutical interventions are 
documented in their representative setting, the information exchange should be assured. The link 
between the GSASA and the PharmDISC systems allowing the transfer of pharmaceutical interventions 
has not been established to date, thus remaining a challenge of information technology [Fig. 2, red 
arrow]. 
 
Fig. 2 Continuity of documentation: looking at the patient pathway during hospital stay, the five pharmaceutical 
interventions could be documented in their respective setting, but could not be exchanged between hospital and 
community setting yet. 
 
To accomplish this task of linking, a handover can be a helpful document to ensure continuity of care, 
communication between healthcare professionals, safe transfer of information and patient safety, and 
transfer of responsibilities (follow-up, e.g. medication review) [108, 109]. It should contain all key 
information, such as medication modification, patient conditions, and care issues, that healthcare 
professionals should have access to when a patient arrives in their healthcare setting [109]. A Belgian 
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study has shown that its developed discharge medication plan was defined as valuable for the 
continuity of care by the community pharmacists and that they requested additional information such 
as medication modifications [110]. As both contain the information ‘medication modification’, the next 
step in the development process could be to connect the GSASA system with the PharmDISC system 
by exchanging the information regarding pharmaceutical interventions. This information could be 
extracted from the respective classification systems and combined in a handover document. 
According to the conclusions and the experiences of this thesis, the recommendation for future 
research are as follows:  
The GSASA system  
• Re-evaluation of the implementation of the GSASA system including users’ satisfaction, and 
collection of all documented pharmaceutical interventions from the hospitals using the GSASA 
system. Since the descriptive manual is available for the users, the quality of data should be 
increased thanks to appropriate utilisation of the standardised classification system. 
• Adaptation of the version of the GSASA system to the current practice and setting by 
o further refinements to improve the precision of the system (e.g. addition of 
subcategories, clarification of existing subcategories) 
• Integration of the GSASA system into patient file of the hospital software 
• Creation of an electronic national database in which all the pharmacists could key in their 
pharmaceutical interventions 
The PharmDISC system  
• Implementation of the PharmDISC system in community pharmacies: 
o Development of a catalogue of case studies. In combination with the descriptive 
manual and the online training, this could be helpful material for the correct 
application of the PharmDISC system and facilitate its implementation. 
o Collaboration with IT specialists to integrate the PharmDISC system (ePharmDISC) in 
pharmacy software. 
 Development of an electronic quick classification with a variety of prefilled 
classification forms, based on frequent pharmaceutical interventions. This 
could save time and improve the quality of documentation. 
 Creation of an intervention history option by extracting the documented 
pharmaceutical interventions from the patient file 
o Validation of the ePharmDISC system in a feasibility study 
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• Modification of the PharmDISC system specific to particular settings/situations and current 
practice. 
 
Depicting real-life daily practice 
• Investigation of the patients’ opinions on counselling in community pharmacies and patients’ 
information needs about prescribed medicine in order to ameliorate the pharmacy practice. 
• Acquisition of more knowledge about barriers and facilitators for patient-centered 
counselling. 
• Development of instruments to assess the patients’ needs and consequently to tailor 
accordingly the counselling. 
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online voting (Movo.ch) 
Case 1 
• Ms. K., 77 years old, 165cm, 66kg, is treated in the accident surgery due to a lower leg fracture. 
• The patient has got postoperatively a bad Creatinin-Clearance. 
• Because of her condition after a myocardial infarct, she receives like prestationary Aldactone® 
50mg Drageés 2-0-0. 
• You notice that Aldactone® is contraindicated at bad kidney function. You recommend to 
pause with the Aldactone® to the physician.  
• The physician agrees, however he will go on with 25mg. 
 
Case 2: 
• Ms. A, 81 years, 167cm, 59kg, enters the pharmacy.  
• Because of her depression she gets Cipralex® (Escitalopram) 20mg tablets 0-0-1.  
• Since a while she complains about sleeping problems. 
• You ask Ms. A why the drug is prescribed in the evening. 
• No plausible reason is found for the vespertine intake. 
• Therefore you propose a morning intake.  
• Ms. A agrees. 
A2.1.5 Three model pharmaceutical interventions, adapted from Ganso et al 
Case 12: 
• Mr. E suffers from a herniated disk. 
• Because of his strong aches he gets Oxycontin® (Oxycondon) 20mg controlled-release tablets 
1-0-1. Mr. E gets strict bed rest for 6 weeks. 
• You fear an obstipation. Therefore you propose a laxative to the physician. 
• The physician agrees. 
Case 14:  
• Mr. K, 61 years, 175cm, 74kg, is treated in the general surgery because of his esophagus 
carcinoma. 
• Furthermore he is suffering from Coronary Heart Disease and receives per stomach tube 
Corvaton® (Molsidomin) 2mg tablets ½-0-0.  
• During this therapy he sustains repeated angina pectoris attacks. 
• You propose to the physician to increase the dosage to Corvaton® 4mg tablets 1-0-1. The 
current blood pressure is stable. 
• The physician agrees. 
Case 21: 
• Ms. L, 61 years, 167cm, 64kg, enters the pharmacy with her permanent prescription. Ms. L 
suffers from Hypertonia. 
• For that the patient gets for a long time Reniten® (Enalapril) 10mg tablets 1-0-0 as well as 
Esidrex® (Hydrochlorothiazid) 25mg tablets 1-0-0. Her blood pressure is in the normal range.  
• The patient moans about the huge daily intake of tablets.  
• You propose to change to the combination remedy Co-Reniten® to reduce the amount of 
tablets to be taken.  
• The patient agrees. 
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